Mixed-methods evaluation of a nurse-pharmacist managed pain clinic by Hadi, Muhammad Abdul
Mixed-methods evaluation of a nurse-pharmacist managed 
pain clinic 
 
 
 
 
 
Muhammad Abdul Hadi 
 
 
 
 
Submitted in accordance with the requirements for the degree of 
Doctor of Philosophy 
 
 
 
The University of Leeds 
School of Healthcare 
 
 
 
March 2014 
- ii - 
The candidate confirms that the work submitted is his own, except where work 
which has formed part of jointly-authored publications has been included. The 
contribution of the candidate and the other authors to this work has been 
explicitly indicated below. The candidate confirms that appropriate credit has 
been given within the thesis where reference has been made to the work of 
others. To date, the following   papers have been published. 
Peer-reviewed publications 
 HADI, M.A., ALLDRED, D.P., BRIGGS, M., MUNYOMBWE, T.,CLOSS, 
S.J. 2014. Effectiveness of pharmacist-led medication review in chronic 
pain management: Systematic Review and Meta-Analysis.  The Clinical 
Journal of Pain DOI: 10.1097/AJP.0000000000000063 
 HADI, M.A., ALLDRED, D.P., BRIGGS, M., CLOSS, S.J. 2014. Mixed-
methods research in Pharmacy Practice: Recommendations for quality 
reporting (Part 2). International Journal of Pharmacy Practice, 22, 96-100  
 HADI, M.A., ALLDRED, D.P., BRIGGS, M., MARCZEWSKI, K., CLOSS, 
S.J. 2013. Mixed-methods evaluation of nurse-pharmacist managed pain 
clinic: Design, rationale and limitations. Canadian Pharmacists Journal, 
46,1-5. 
 
 HADI, M.A., ALLDRED, D.P., BRIGGS, M., CLOSS, S.J. 2013. Mixed-
methods research in pharmacy practice: Basics and beyond (Part 1). 
International Journal of Pharmacy Practice, 21,341-345 
 HADI, M.A., ALLDRED, D.P., BRIGGS, M., CLOSS, S.J. 2012. 
Effectiveness of pharmacist-led medication reviews in improving patient 
outcomes in chronic pain: A Systematic review protocol. Canadian 
Pharmacists Journal, 145, 264-267 
 HADI, M.A., ALLDRED, D.P., BRIGGS, M., CLOSS, S.J. 2012.  A 
combined nurse-pharmacist led pain clinic: joint venture of public-private 
sector. International Journal of Clinical Pharmacy, 34; 1-3  
 
 
 
- iii - 
Conference abstracts 
 HADI, M.A., ALLDRED, D.P., BRIGGS, M., Marczewski, K., CLOSS, S.J. 
2014. Clinical and sociodemographic characteristics of patients referred 
to a community-based pain clinic. The British Pain Society’s Annual 
Scientific Meeting; April 29- May 1; Manchester Central, Manchester, 
United Kingdom [Accepted] 
 HADI, M.A., ALLDRED, D.P., BRIGGS, M., Marczewski, K., CLOSS, S.J. 
2014. An analysis of the nature of recommendations made at a nurse-
pharmacist managed pain clinic. Health Services Research and 
Pharmacy Practice Conference;  April 3-4; University of Aberdeen, 
Aberdeen, United Kingdom [Accepted] 
 HADI, M.A., ALLDRED, D.P., BRIGGS, M., CLOSS, S.J. 2013. 
Systematic review of pharmacist-led medication review in chronic pain 
management: Preliminary findings. Health Services Research and 
Pharmacy Practice Conference;  May 9-10; University of Central 
Lancashire, Preston, United Kingdom 
 
Other publications 
 HADI, M.A., ALLDRED, D.P., BRIGGS, M., CLOSS, S.J. 2012.  A model 
for a pain management clinic led by the combined efforts of a pharmacist 
and a nurse. The Translator, 6, 3. 
 HADI, M.A., ALLDRED, D.P., BRIGGS, M., CLOSS, S.J. 2012.  Is 
pharmacist-led medication review effective for chronic pain management 
among adult patients? A systematic review. 
PROSPERO:CRD42012001957. Available from 
http://www.crd.york.ac.uk/PROSPERO/full_doc.asp?ID=CRD420120019
57 
 
The author of this thesis was the first and corresponding author for all the 
publications. He drafted the papers, revised as per supervisors’ feedback, 
formatted according to the journal style, submitted to the respective journals, 
and answered the quires raised by the editorial office, reviewers and the 
production office.  
- iv - 
This copy has been supplied on the understanding that it is copyright material 
and that no quotation from the thesis may be published without proper 
acknowledgement. 
 
The right of Muhammad Abdul Hadi to be identified as Author of this work has 
been asserted by him in accordance with the Copyright, Designs and Patents 
Act 1988. 
 
© 2014 The University of Leeds and Muhammad Abdul Hadi 
- v - 
Acknowledgements 
First and foremost, I would like to thank ALLAH ALMIGHTY for blessing me with 
health and wisdom, without which none of this would have been possible.  
I do not have words to thank my supervisors Prof. José Closs, Prof. 
Michelle Briggs and Dr. David Alldred for their encouragement, help, guidance 
and immense support throughout these years. It was a great learning 
experience which I enjoyed a lot. I also received excellent support from Kathryn 
Marczewski, Clinical Nurse Specialist at the pain clinic – thanks Kath for 
everything. I am also thankful to Dr. David Clarke, then the postgraduate 
research tutor of the School of Healthcare, for encouraging me to apply for the 
scholarship and School of Healthcare for awarding me with the scholarship. I 
would also like to thank all the staff members at the School’s research and 
innovation office especially Ruth Allcroft and Helen Simpson for providing 
excellent logistical support.  
I am grateful to my parents Dr. Jawed Batish and Samina Firdous for all 
the sacrifices that they made so that we get the best. You guys are indeed the 
greatest blessing of ALLAH and a source of inspiration.  I would like to thank my 
better half, Saleha Mazhar, for her kind understanding, support and most 
importantly accepting my lack of concentration during our conversations. I hope 
that it will get better once I am done with my PhD. Thank you very much for 
hanging in there. My daughters, my two little angels, Ayma and Zahra - seeing 
you has been a source of happiness and relief. I would like to thank my brother 
Muhammad Saadi and my sister Sundas Muddasar for their moral support. I am 
also grateful to my friends Long Chiau Ming, Jaqui Long, Rebecca Dickinson, 
Alexia Burton, Mohammad, Tahir Khan and Emily for their friendship and 
support. 
Last but not least, I would like to express my gratitude to all the patients who 
participated in this study. 
- vi - 
Abstract 
Background: Under-treatment of chronic pain within the community is a global 
problem. There is a growing interest to evaluate the role of nurses and 
pharmacists in chronic pain management with an aim to improve access to and 
quality of pain services.  
Aim: The research presented in this thesis had two aims: first, to evaluate the 
effectiveness of pharmacist-led medication review in chronic pain management; 
second, to evaluate the impact of a community based nurse-pharmacist 
managed pain clinic. 
Methods: A systematic review and meta-analysis was conducted to evaluate 
the effectiveness of pharmacist-led medication review in chronic pain 
management. For the second aim, a mixed-methods study consisting of a 
quasi-experimental design and a qualitative descriptive design was undertaken. 
Pain intensity was the primary outcome. The secondary outcomes included: 
physical functioning; emotional functioning; quality of life; chronic pain grade 
and patient satisfaction. Patient satisfaction was evaluated using face-to-face, 
semi-structured qualitative interviews. 
Results: Of the 578 papers screened, five RCTs were included in the 
systematic review and three in the meta-analysis. Compared to the control, the 
meta-analysis found that patients in the intervention group had: a statistically 
significant reduction in pain intensity of  0.8 point (95% CI -1.28 to -0.36) and  
0.7 point (95% CI -1.19 to -0.20) at 3-months and 6-months respectively; and  
4.84 point (95% CI, -7.38 to -2.29) at 3-months and -3.82 point (95% CI, -6.49 
to -1.14) at 6-months improvement in physical functioning. 
 Seventy nine patients with a mean age of 46.5 years (SD ±14.4) took part in 
the quasi-experimental study. Thirty-six and 9 patients completed discharge and 
3-month follow-up assessments respectively. Compared to baseline, statistically 
significant reductions were noted for two of the four outcome measures: pain 
intensity (P=0.02), and interference of pain with physical functioning (P=0.02) 
on discharge from the service. The majority of the patients were, in general, 
satisfied with the service. Four contributing factors to patient satisfaction were 
- vii - 
identified: ample consultation time; in-depth specialised knowledge; listening 
and understanding to patients’ needs; and a holistic approach.  
Conclusion: Community-based pain clinics managed by a nurse and 
pharmacist have the potential to improve chronic pain management in the 
community by providing timely access to a specialised pain service, ensuring 
safe and effective use of analgesics (medication reviews) and promoting self-
management (patient education). Both pharmacist-led medication review and 
nurse-pharmacist managed pain clinics can reduce pain intensity and improve 
physical functioning The long term impact of the pain clinic could not be fully 
elucidated from this research as the planned follow-up data collection could not 
be completed due to decommissioning of the service.  
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CHAPTER 1                                                         
INTRODUCTION 
This thesis presents research work carried out for the author’s PhD degree 
undertaken at the School of Healthcare, University of Leeds, Leeds, UK. The 
School of Healthcare’s Pain research group and, partly by, the Medicines 
Management research group, supported the author for his PhD degree to 
specifically build on the former group’s earlier work on an innovative community-
based, nurse-pharmacist managed pain service. Therefore, the focus of the 
studentship and subsequent research study was to develop further evidence on 
the effectiveness of the nurse-pharmacist managed pain clinic. 
This introductory chapter provides a brief overview of the prevalence and 
socioeconomic burden of chronic pain, the challenges in relation to its 
management, and the role of pharmacists and nurses in chronic pain 
management. Following this is a description of the research paradigm/world 
view which guided this research. A brief account of the author’s journey through 
his  PhD is then described and finally, a summary of the contents of each 
chapter is provided.  
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1.0  Background 
Being a subjective and personal experience, pain is a difficult phenomenon to 
define and measure. The International Association for Study of Pain (IASP) has 
defined pain as “an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage, or described in terms of such damage” 
(IASP subcommittee on Taxonomy, 1979). Chronic pain has been defined as 
continuous, long-term pain of more than 12 weeks (3-months) or after the time 
that healing would have been thought to have occurred in pain after trauma or 
surgery (The British Pain Society, 2006). The 3-month cut off to differentiate 
chronic pain from acute is not universal and a 6-month cut-off has also been 
used (Merskey and Bogduk, 1994, Breivik et al., 2006). Furthermore, defining 
chronic pain solely by duration has also been challenged, as ‘duration’ solely 
neither reflects the multi-dimensional nature of chronic pain nor indicates 
whether or not long-term pain is clinically significant (Turk and Rudy, 1988, Turk 
and Melzack, 2001). Nonetheless, to date, duration-based definitions, although 
questionable, are frequently used to describe chronic pain in both research and 
clinical practice settings. Chronic pain is broadly categorised into two types: 
nociceptive pain and neuropathic pain. Nociceptive pain is caused by damage 
to body tissue and usually described as a sharp, aching, or throbbing pain. 
Neuropathic pain results when there is actual nerve disease or damage and is 
often described as spontaneous burning pain (IASP subcommittee on 
Taxonomy, 1986, Merskey and Bogduk, 1994).  
The growing prevalence of chronic pain presents a significant threat to 
public health globally. Worldwide, the point prevalence estimates derived from 
population-based studies vary considerably, ranging from 2% to over 55% 
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(Verhaak et al., 1998, Elliott et al., 1999, Blyth et al., 2001, Catala´ et al., 2002, 
Moulin et al., 2002, Eriksen et al., 2003, Breivik et al., 2006, Neville et al., 2008). 
This wide variation in the prevalence of chronic pain is principally attributed to 
the differences in the definitions of chronic pain used, types of populations 
studied, and the survey methodology used (Johannes et al., 2010). In the USA, 
a recent internet-based survey estimated weighted point prevalence of chronic 
pain to be 30.7% (95% CI, 29.8–31.7) with a higher prevalence among females 
(34.3%) than males (27.4%) (Johannes et al., 2010). In Europe, a survey 
reported that chronic pain affected 19% of adults (Breivik et al., 2006).  In the 
UK, it has been estimated that five million people develop chronic pain each 
year (Chief Medical Officer for England, 2008). Estimation of chronic pain 
burden in the community is essential so that necessary healthcare and social 
services can be developed to effectively manage the problem. 
Chronic pain often interferes with daily activities and is associated with 
loss of productivity, work absenteeism, carer burden and high utilisation of 
healthcare resources (Steenstra et al., 2005, Breivik et al., 2006). It was 
estimated that lost productive work due to arthritis cost the US economy US$ 
7.1 billion (£4.3 billion) during 2003-04 (Ricci et al., 2005). In the UK, the indirect 
cost of back pain alone was estimated to be more than £10 billion (Mainiadakis 
and Gray, 2000). Furthermore, chronic pain is the second most common reason 
for claiming incapacity benefit in the UK (Chief Medical Officer for England, 
2008). In terms of burden on healthcare systems, chronic pain accounted for 4.6 
million appointments per year within primary care in the UK at a cost of around 
£69 million on appointments alone. In 2007, the National Health Services (NHS) 
in England spent £584 million on 67 million prescriptions for analgesic and anti-
inflammatory drugs (Chief Medical Officer for England, 2008). 
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Given these negative consequences of chronic pain both on individuals 
and society, timely and effective management of chronic pain is crucial. Chronic 
pain is primarily managed within primary care. However, suboptimal and 
inadequate management of chronic pain within primary care has been reported 
in the literature (Breivik et al., 2006, McDermott et al., 2006). Barriers to 
effective pain relief are multifactorial and include: clinician related-barriers; 
patient related-barriers and healthcare system-related barriers (Glajchen, 2001). 
Clinician-related barriers include: inadequate knowledge and  assessment skills, 
negative attitudes toward prescribing of opioid analgesics, and fear of regulatory 
scrutiny for prescribing controlled substances (Von Roenn et al., 1993, 
Cleeland, 1993, Glajchen, 2001). Patient related-barriers include: 
communication problems, psychological issues such as anxiety, depression and 
anger, and other issues such as non-compliance with the prescribed medication 
and fear of addiction, tolerance and side effects (Ward et al., 1993, Glajchen, 
2001). Healthcare system related-barriers include: inaccessibility and 
unaffordability of multidisciplinary pain clinics, lack of neighbourhood 
pharmacies, non-availability of high doses of opioids at the pharmacy (not 
relevant in the UK), and long waiting times for appointments in secondary care 
(Glajchen, 2001). These multifactorial problems make chronic pain 
management challenging. 
In terms of chronic pain management in the UK, the CMO’s annual report 
of 2008 was the first government document that highlighted the issues of 
inadequate pain management in primary care and the lack of clear clinical 
standards for chronic pain management, and called for immediate action to 
address these issues (Chief Medical Officer for England, 2008).  The report also 
directed the relevant agencies to improve the quality of local pain services. 
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Subsequent to the CMO’s report, the National Pain Audit was conducted  to 
assess the nature and quality of, and access to chronic pain services in the UK. 
The audit also found a “clear variation in provision of service and no agreed 
standards of care”  (Price et al., 2012, P. 5).Additionally, the audit also found 
that a number of services were not even meeting the minimum requirement for 
an effective pain service set by the International Association for the Study of 
Pain (IASP) and the Faculty of Pain Medicine of the Royal College of 
Anaesthetics (Price et al., 2012), indicating a considerable room for 
improvement in the delivery of chronic pain services.  
Within the NHS, there has been a desire to shift the focus of care from 
hospitals to the community to reduce the burden on secondary care and to 
improve timely access to care. To accomplish this and to meet patients’ growing 
expectations, given the economic constraints, the roles of nurses and 
pharmacists within the healthcare system has evolved and become more 
patient centred, leading to the development of a number of nurse-led and 
pharmacist-led services. These reforms began in 2000 when the Department of 
Health (DoH) published health services plan for the NHS incorporating  a 
proposal to extend nurses’ role within the NHS (Department of Health, 2000). 
In the context of chronic pain management, there is a growing interest 
among researchers to evaluate these nurse and/or pharmacist managed 
services as chronic pain is often inadequately managed in primary care. The 
research work conducted and presented in this thesis is a small step towards 
improving chronic pain management in community. Firstly, a systematic review 
evaluating the effectiveness of pharmacist-led medication review in chronic pain 
management is presented (Chapter 3). Secondly, the effectiveness of a 
community based nurse-pharmacist managed pain clinic, one of the initiatives of 
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the local primary care trust (PCT) to improve access to quality pain service, 
reduce burden on secondary care and waiting times, is evaluated. The specific 
aims and objectives are outlined in section 2.9. A brief historical overview of the 
development of the clinic and its working is outlined in the next chapter (section 
2.8.1).  
1.1 About the author and his PhD journey   
Like most of the children born in Pakistan, I was raised to become a medical 
doctor. To fulfil my father’s dream, who is a physician himself, I worked hard but 
was unable to secure admission in a medical college. Subsequently, I joined a 
pharmacy school at a local university in 2002. On the first day of my university, I 
made a promise to my father that I would complete a PhD to fulfil his dream. At 
that time, I had no idea what a PhD was except that it would enable me to write 
“Dr” before my name. That is how I initially acquired the idea and motivation of 
doing a PhD.  
My first experience with ‘research’ was during my Master’s degree 
(Clinical Pharmacy) in Malaysia. It was short but an exciting experience which 
gave me a glimpse of future PhD research. Subsequently, I developed an 
interest in research and my motivation for doing a PhD also grew beyond 
merely adding the “Dr” title before my name. After completing master’s degree, I 
started looking for a PhD scholarship whilst working as a lecturer in Clinical 
Pharmacy at a public university in Malaysia. Subsequently, I was awarded a 
PhD scholarship by the School of Healthcare, University of Leeds.  I chose this 
project, a mixed-methods evaluation of a nurse-pharmacist managed pain clinic, 
for two main reasons: 1) In the past, I was predominantly a quantitative 
researcher with very limited experience of qualitative research, therefore, I saw 
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this project as a training opportunity to develop in-depth understanding of 
qualitative, quantitative and mixed-methods methodologies and gain some 
hands on experience in using different methodologies; 2) The project  had 
elements of both pharmacy practice research and health services research,  my 
areas of interest. 
Over all, I enjoyed and learnt a lot during my PhD. But there were some 
hard and long days as well. From applying for the scholarship to developing the 
protocol, to submitting the applications for ethics and research governance 
approval, to recruiting patients, to undertaking the qualitative and the 
quantitative analysis, and to finally writing up thesis, it was a series of 
challenges one after another. However, I received excellent support from family 
and supervisors, which helped me to overcome these challenges. Publication of 
my work in peer-reviewed journals gave me motivation and pushed me forward. 
Ultimately, during the third year of PhD I was successful in applying for a 
lecturer in pharmacy practice position in a reputable university. However, 
moving countries with my family and starting a new job in the middle of thesis 
write up was very challenging. Again support from family and supervisors 
enabled me to overcome these challenges and complete my write-up.   
1.1.1 Author’s research paradigm: Pragmatism 
Being a practice researcher rather than a philosopher, this was the most difficult 
and challenging part of the thesis perhaps due to author’s limited knowledge of 
the subject area. The aim of this section was not to start a philosophical debate 
to prove the superiority of one paradigm over another, rather the purpose of 
including this section in the introduction chapter is to make the author’s stance 
(philosophical assumptions) clear from the outset, enabling the reader to 
meaningfully understand the research work detailed in the later chapters. 
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“A paradigm is a basic set of beliefs that guide action”  (Guba, 1990, P. 17). 
It is also known as philosophical assumptions, epistemologies and ontologies 
(Crotty, 1998), broadly conceived research methodologies and alternative 
knowledge claims (Creswell, 2003). There are various research paradigms, 
descriptions of which are beyond the scope of this thesis. Among the most 
commonly used paradigms are (Creswell, 2007): Positivism - claims of 
knowledge are based on cause and effect thinking and reductionism, often 
associated with quantitative approaches (Phillips and Burbules, 2000); 
Constructivism - individuals seek understanding of the world in which they live 
and work; Advocacy/participatory – which states that the research should have 
an action agenda to help people involved in the research study (study 
participants) (Kemmis and Wilkinson, 1998); and Pragmatism - focuses on the 
outcomes of the research and chooses methods on the principle of “what-
works”. The key features of pragmatism are as follows (Creswell, 2007): 
 
 Pragmatism is not associated with any specific system of philosophy and 
reality. 
 Researchers using pragmatism as their research paradigm are free to 
choose the methods and procedures that are most suitable in answering 
the research question.  
 Pragmatic researchers can use multiple methods of data collection and 
analysis within a research study, if deemed necessary. 
 Pragmatist researcher believes that the research is not free from social, 
political and historical contexts. 
 
In this thesis, the author has taken the stance of a pragmatist researcher – 
where the research question dictates the choice of methods used. Methods 
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belonging to different research paradigms were chosen because of their 
suitability to answer the research questions. For example, a meta-analysis was 
undertaken, typically associated with positivist paradigm, to evaluate the 
effectiveness of pharmacist-led medication review in chronic pain management 
(See chapter 3). Whereas, a qualitative approach was adopted to explore 
patients’ views about their experiences of the nurse-pharmacist managed pain 
clinic, typically associated with the constructivist paradigm (See chapters 4 and 
7).  
1.2 Structure of the thesis and writing style 
This thesis consists of eight chapters. At the beginning of each chapter, a brief 
summary about the contents of the chapter is provided to facilitate reading.  A 
third person objective style has been adopted throughout the thesis. The author 
has identified himself in this thesis as “the author” and/or MAH, except for this 
chapter where first person style has been used occasionally as well. 
 
Chapter 1: Introduction 
This chapter provides contextual background of the study. A brief account of the 
author’s journey through his PhD is presented. Following that, the world 
view/paradigm governing the whole thesis is explained. Finally, a brief 
description of the contents of each chapter of this thesis is outlined. 
Chapter 2: Literature review 
In this chapter, the objectives of conducting the literature review and the search 
strategy used for searching electronic databases are presented. To give the 
reader a broader picture of the roles of nurses and pharmacists in chronic pain 
management, studies describing and/or evaluating their roles are summarised 
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in this chapter. Then  the historical background and working of the nurse-
pharmacist managed pain clinic under investigation is explained. Finally, the 
aims and objectives of the present study in relation to the limitations of the 
current evidence supporting the clinic’s effectiveness are outlined. 
Chapter 3:  Effectiveness of pharmacist-led medication review in chronic 
pain management: a systematic review and meta-analysis 
This chapter presents the rationale, aim and objectives, methods, and results of 
a systematic review undertaken to evaluate the effectiveness of pharmacist-led 
medication review in chronic pain management.  Implications of findings on 
clinical practice are discussed and recommendations for future research are 
also suggested. 
Chapter 4: Methodology 
In this chapter, a brief overview of various research methodologies available to 
healthcare researchers is presented. The selection of a particular research 
methodology, mixed-methods, underpinning this study is justified in relation to 
the aim and objectives of the study. Finally, the rationale for selecting an 
embedded design for this study is described together with the selection of 
specific quantitative (quasi-experimental) and qualitative (descriptive qualitative) 
designs is justified. 
Chapter 5: Methods 
In this chapter, the choice of particular methods used in this study, from sample 
size calculation to data analysis is debated and justified. Although in the same 
chapter, the methods used within quantitative and qualitative phases are 
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presented separately to improve clarity. The steps taken to ensure ethical 
conduct of the study are also outlined. 
Chapter 6: Results - Quantitative 
As the name suggests, this chapter presents results of the quasi-experimental 
study (quantitative phase). Tables and figures are used, where necessary, to 
illustrate and summarise findings. In order to facilitate reading, the chapter is 
divided into small sections in line with the research questions. 
Chapter 7: Findings - Qualitative 
In this chapter, the findings of the qualitative descriptive study are presented. 
Anonymised quotations from patients’ interviews are also given to support 
findings of the study.  
Chapter 8: Discussion 
In this chapter, findings of both quantitative and qualitative phases are 
discussed. Limitations to this study are highlighted and recommendations for 
future research are described. Plans for dissemination of research findings are 
also outlined.  
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CHAPTER 2 
LITERATURE REVIEW 
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CHAPTER 2                                                                                                            
LITERATURE REVIEW 
2.1 Introduction 
The literature review is an important component in designing and conducting a 
research study as it allows the researcher to place his work in context of what is 
already known, preventing duplication and allowing meaningful comparisons 
with other studies in the similar area of research.  
This chapter presents a critical summary of existing literature on various 
aspects of chronic pain including its epidemiology and management with the 
aim of highlighting  the growing socioeconomic burden of chronic pain and 
challenges in its management. There were four objectives for conducting the 
literature review: 
I. To obtain an overview of chronic pain prevalence and challenges in its 
management 
II. To gather evidence on the role of pharmacists and nurses in chronic pain 
management. 
III. To inform the development of the methodology for the current study. 
IV. To identify key outcome measures commonly used to evaluate the 
effectiveness of chronic pain management interventions. 
The first two objectives are comprehensively dealt with in this chapter. The 
remaining  two objectives are related to the methodology and methods of the 
present study and are discussed in detail in the methodology (Chapter 4) and 
methods (Chapter 5) chapters, where an overview of various research 
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methodologies in healthcare research is provided and selection of a particular 
methodology and methods is debated and justified.   
This chapter begins with a detailed account of the search strategy employed 
to identify relevant articles. In order to facilitate easy comprehension for readers 
the chapter is divided into two sections: Chronic pain burden and its challenges; 
and the role of nurses and pharmacists in chronic pain management. In the first 
section, the prevalence of chronic pain, health resource utilisation due to 
chronic pain and its impact on physical and emotional functioning (quality of life) 
are discussed to establish the scope of the problem. Current challenges in 
chronic pain management within primary care are also discussed. The second 
section critically assesses current research evidence to support the role of 
nurses and pharmacists in chronic pain management. Following this, the 
working of the nurse-pharmacist managed pain clinic under investigation, is 
explained. The limitations of the research evidence supporting the pain clinic 
are then highlighted, leading to the aim(s) and objectives for this study. 
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2.2 Literature search 
In order to ensure a robust and in-depth search of the literature, in line with the 
search objectives, the search strategy was divided into three groups. In the first 
group, literature related to the prevalence and socioeconomic burden of chronic 
pain was searched and reviewed. The rationale for presenting epidemiological 
aspects of chronic pain and existing challenges in its management is to highlight 
the necessity for development of innovative services to reduce disease burden 
and ensure optimum care. In the second group, papers evaluating the roles of 
general practitioners (GPs), multidisciplinary pain clinics, nurses and 
pharmacists in chronic pain management were searched. In the third and final 
group, literature related to the methodological innovations in health services 
research in general and chronic pain in particular were searched with an aim to 
inform methodology, methods, outcome measures and scales for the present 
study. Electronic databases including Medline (via Ovid), EMBASE (via Ovid), 
Cochrane Library, Cumulative Index to Nursing and Allied Health Literature 
(CINAHL) (via EMBSCO), Google Scholar and PsycINFO were searched from 
the date of their inception. Each of these databases was searched from the date 
of their inception to January 2011. However, the literature search and review 
was regularly updated throughout the study period in order to keep abreast with 
the latest research in the field. The key terms used were: chronic pain; non-
malignant pain; quality of life; physical functioning; emotional functioning; 
anxiety; depression; pain management; non-pharmacological management; 
pharmacological management; multidisciplinary pain clinic; interdisciplinary pain 
clinic; nurse-led; nursing interventions; pharmacist-led; pharmaceutical care; 
medicines management; pharmacist; community; pain scales; outcome 
measures. These search terms were combined with Boolean operators such as 
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AND, OR and NOT to refine search results wherever necessary. In addition to 
the search of electronic databases, websites of the British Pain Society, the 
American Pain Society and the International Association for Study of Pain 
(IASP) were also searched. Reference lists of relevant articles were also 
searched to identify any additional articles. The retrieved articles were critically 
appraised.  
2.3 Prevalence of chronic pain 
Keeping in view the growing prevalence, multidimensional nature as well as 
complexity of its management, chronic pain has become a challenging issue not 
only for the patients but also for the healthcare professionals and systems, and 
society.  A considerable increase in the prevalence of chronic pain has been 
reported over the past two decades. A study conducted in the US reported an 
increase in the prevalence of chronic low back pain alone from 3.9% in 1992 to 
10.2% in 2006 (Freburger et al., 2009). Likewise, a two to fourfold increase in 
the prevalence of chronic pain has  also been reported in the UK (Harkness et 
al., 2005).   As mentioned earlier in chapter 1 (section 1.0), owing to differences 
in definitions of chronic pain, variation in study populations and the research 
methodology used for surveys, the estimated prevalence of chronic pain varies 
substantially, ranging from 2% to 55% (Verhaak et al., 1998, Elliott et al., 1999, 
Blyth et al., 2001, Catala´ et al., 2002, Moulin et al., 2002, Eriksen et al., 2003, 
Breivik et al., 2006, Neville et al., 2008). Recent studies from the US (Johannes 
et al., 2010) and the Europe (Breivik et al., 2006) have estimated the prevalence 
of chronic pain to be approximately one in three and one in five respectively. In 
Europe, the prevalence of chronic pain was highest in Norway (30%) and least 
in Spain (12%) (Breivik et al., 2006). These studies also reported a higher 
prevalence of chronic pain among females compared to males. In addition to 
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female gender, other significant predictors of chronic pain include: old age, poor 
housing and type of employment (Price et al., 2012). In Europe, back pain was 
noted to be the most common type of chronic pain followed by knee pain 
(Breivik et al., 2006). 
In the UK, it has been estimated that chronic pain of moderate to severe 
intensity affects 7.8 million people (Chief Medical Officer for England, 2008). In 
2011, the National Health Survey in England reported that chronic pain affects 
more than 14 million adults (Bridges, 2012). The National  Health Survey further 
reported that 31% men and 37% women suffer from chronic pain, with older 
people more likely to report chronic pain than younger people (Bridges, 2012). 
The National Pain audit reported the average annual incidence estimated at 
8.3% with the average annual recovery rate of 5.4% (Price et al., 2012). The 
growing prevalence would require additional human and financial resources to 
cater for patients’ needs, putting an additional burden on the healthcare system.  
2.4 Economic and societal burden of chronic pain 
Loss of productivity, carer burden and high utilisation of healthcare resources 
are often associated with chronic pain (Steenstra et al., 2005). Additionally, 
chronic pain patients have been reported to have poorer health related quality of 
life compared to the patients with other chronic diseases (Laas et al., 2009). In 
terms of loss of productivity, 9.9 million work days are lost annually in Australia 
(van Leeuwen et al., 2006) and one million in Denmark  due to chronic pain 
(Eriksen et al., 2003). Breivik et al. (2006) reported that the mean number of 
work days lost, among 15 European countries and Israel, in the past 6 months 
was highest in Finland (19.8 days) and lowest in France (5 days). Furthermore, 
one in four participants reported that pain had an impact on their employment 
status. Similarly, in the UK, it has been estimated that 25% of chronic pain 
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patients will lose their jobs because of pain (Chief Medical Officer for England, 
2008).  
A number of studies have estimated the economic burden due to work 
absenteeism and loss of productivity associated with chronic pain (Maniadakis 
and Gray, 2000, Walker et al., 2003, Phillips, 2009, Gaskin and Richard, 2012). 
In the UK, the indirect cost of back pain alone was estimated to be £10.7 billion 
(Maniadakis and Gray, 2000). In the US, a recent study reported that the value 
of lost productivity due to pain ranged from $299 to $335 billion (£182.4 billion to 
£216.5 billion) (Gaskin and Richard, 2012). Although significantly less than the 
indirect costs, the direct costs associated with chronic pain are quite substantial. 
In 2007, The National Health Service (NHS) in England spent £584 million on 
67 million prescriptions for analgesics (Chief Medical Officer for England, 2008). 
In Australia, the direct cost of lower back pain alone in 2001 was estimated to 
be AU$ 1.02 billion (£56.4 million) with an overall cost of AU$9.17 billion (£5.06 
billion) (Walker et al., 2003). In the US, the overall annual cost associated with 
chronic has been estimated to range from $560 to $635 billion (£ 341 billion to 
£387 billion), more than the annual costs of heart disease ($309 billion; £188 
billion), cancer ($243 billion; £148 billion), and diabetes ($188 billion; 114 
£billion) (Gaskin and Richard, 2012).  
The utilisation of healthcare resources by chronic pain patients is 
significantly more than other chronic diseases with women utilizing more 
healthcare resources than men (Blyth et al., 2004, Eriksen et al., 2004, Breivik 
et al., 2006, Kaur et al., 2007, Price et al., 2012). In Denmark, patients with 
chronic pain had on average 12.8 contacts per year with a primary healthcare 
provider compared with 7.3 for the control group (Eriksen et al., 2004). 
Australian data showed that compared to non-chronic pain patients, chronic 
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pain patients were five times more likely to visit the Accident and Emergency 
department (Blyth et al., 2004). Data from Europe (n=4780) demonstrated that 
more than half (54%) of the respondents had seen two to six different doctors 
for their pain and 60% visited their doctors two to nine times in the past 6 
months due to pain (Breivik et al., 2006) . 
Given this high economic and societal burden of chronic pain, early and 
effective management of chronic pain is crucial not only for improving patient 
outcomes but also for avoiding unnecessary humanistic and financial burden on 
the healthcare system and society.   
2.5 Management of chronic pain  
Chronic pain is commonly managed within primary care. However, given 
the complex nature of chronic pain, care provided within the primary care is 
often suboptimal and inadequate (Breivik et al., 2006, McDermott et al., 2006). 
This is primarily because treatment approaches in primary care are usually uni-
disciplinary and are often based on the biomedical model, which assumes that 
the presentation of chronic pain is due to a specific physical pathology. The 
treatment is then targeted to rectify that physical pathology either 
pharmacologically or surgically (Gatchel and Okifuji, 2006). However, this 
approach is not applicable to all cases of chronic pain, because it is not always 
possible to identify a specific physical cause (Gatchel and Okifuji, 2006). The 
alternative, biopsychosocial pain model assumes that the clinical presentation of 
chronic pain is a result of complex interactions among physiological, 
psychological and social factors. An effective treatment modality should 
therefore focus on all three areas (Turk and Gatchel, 2002, Gatchel, 2005).  
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In theory, multidisciplinary pain clinics based on the biopsychosocial 
model can effectively manage chronic pain. Various systematic reviews have 
documented the effectiveness of multidisciplinary pain management 
programmes/clinics in various settings and chronic pain conditions (Flor et al., 
1992, van Tulder et al., 1997, Guzmán et al., 2001, Thomsen et al., 2001, 
Scascighini et al., 2008). Multidisciplinary pain clinics have been reported to 
reduce pain intensity ranging from 14% (Moore et al., 1984) to 60% (Tollison et 
al., 1985), with an average reduction of 20% to 30% (Flor et al., 1992).  Flor et 
al. (1992) reported, in a meta-analysis, a 65% increase in physical activity in 
patients receiving multidisciplinary pain treatments compared to a 35% increase 
in patients receiving conventional medical care. Similarly, return to work rate 
was reported to be higher in patients in multidisciplinary programmes compared 
to conventional medical treatments (mean 66% vs. 27% respectively).  
More recently, Scascighini et al. (2008) conducted a comprehensive 
systematic review of RCTs to evaluate the effectiveness of multidisciplinary pain 
programmes in chronic pain management. The review included 35 studies but 
the authors were unable to undertake meta-analysis due to heterogeneity in 
study design, patient population and nature of the intervention. The authors 
drew conclusions on the effectiveness of the multidisciplinary interventions 
based on a four level rating system (strong evidence, moderate evidence, 
limited evidence and no evidence) developed by Cochrane Back Review Group 
(van Tulder et al., 2003). They reported: strong evidence (multiple high quality 
RCTs with consistent results) supporting superiority of multidisciplinary 
treatment compared with waiting list control (WLC) and treatment as usual 
(TAU); moderate evidence (one high quality RCT and one or more low quality 
RCTs with consistent results) in favour of multidisciplinary pain clinics compared 
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with non-multidisciplinary treatments (e.g. physiotherapy with discussion group, 
patient education). In terms of aetiology of chronic pain, patients with 
fibromyalgia and/or chronic back pain were likely to gain more benefit from 
multidisciplinary treatment modalities compared with patients with other chronic 
pain diagnoses (moderate evidence). For mixed chronic pain patient population, 
limited evidence (one high quality RCT, or multiple low quality RCTs with 
consistent findings, or contradictory outcomes of studies with high and low 
quality) supporting effectiveness of multidisciplinary treatment compared with 
WLC or TAU was reported. Furthermore, comprehensive inpatient programmes 
were found to be more effective than the outpatient programmes (moderate 
evidence). However, neither the duration of programme nor the programme 
components influenced the effectiveness of the programme. The authors 
highlighted the need for internationally recognised standards of multidisciplinary 
programmes to ensure better outcomes for chronic pain patients. Notably, trials 
were not excluded based on their quality therefore many of the RCTs included 
in the systematic review may have lacked quality in design or 
execution/reporting. 
Finally, in addition to clinical effectiveness, multidisciplinary pain clinics 
have been found to be cost effective (Gatchel and Okifuji, 2006). However, 
timely acceptable access and affordability of such multidisciplinary pain clinics 
remains an issue.   
2.5.1 Barriers to effective chronic pain management 
As mentioned earlier (Chapter 1, section 1.1), there are a number of barriers 
related to the healthcare-systems, clinicians and patients which interfere with 
achieving optimal pain relief (Glajchen, 2001). Clinicians’ inadequate knowledge 
and limited assessment skills are frequently seen as barriers to effective 
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management of chronic pain. In a survey in the UK, GPs described 
helplessness and dissatisfaction with their ability to manage chronic pain 
patients (Stannard and Johnson, 2003). In another study in the USA, 88% of the 
physicians reported that their training in pain management as poor in medical 
school, and 73% felt that residency training was fair or poor (Von Roenn et al., 
1993, Von Gunten and Von Roenn, 1994). Other clinician-related barriers 
include: negative attitudes toward prescribing of opioid analgesics (due to fear 
of abuse and addiction), and fear of regulatory scrutiny for prescribing controlled 
substances (Von Roenn et al., 1993, Cleeland, 1993, Glajchen, 2001). 
 Patient-related barriers include: communication problems, psychological 
issues such as anxiety, depression and anger; and other issues such as non-
adherence with the prescribed medication and fear of addiction, tolerance and 
side effects (Ward et al., 1993, Glajchen, 2001). Anxiety and depression are 
frequently occurring co-morbidities and are associated with chronic pain 
(Sagheer et al., 2013, Wong et al., 2011). In the UK, 49% of chronic pain 
patients experience depression (Chief Medical Officer for England, 2008). 
Adherence with the prescribed medicines is essential for effective pain relief. 
However, non-adherence with the prescribed medicines and abuse of opioid 
analgesics by the chronic pain patients have frequently been reported in the 
literature (Berndt et al., 1993, Broekmans et al., 2009, Couto et al., 2009). A 
retrospective analysis of 938,586 patients’ urine test samples to estimate 
compliance with prescribed opioid analgesics,  found that 3 out of 4 patients 
were not taking their medicines as prescribed by their clinicians and 38% of 
patients  had no detectable level of prescribed medicine (Couto et al., 2009). 
More importantly, 29% had a non-prescribed medication present and 27% had a 
drug level higher than expected in their urine samples. However, the study did 
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not explore the reasons for non-adherence and abuse of opioid analgesics. 
Fear of addiction and intolerance towards the side effects might be responsible, 
at least in part, for the above mentioned findings. 
Healthcare system-related barriers include: inaccessibility and 
unaffordability of multidisciplinary pain clinics, lack of a neighbourhood 
pharmacy, non-availability of high doses of opioids at the pharmacy, and long 
waiting times for appointments in secondary care (Glajchen, 2001). The waiting 
time for six months or more from the time of referral to treatment is associated 
with a worsening of health-related quality of life and psychological wellbeing. 
(Lynch et al., 2008). In Canada, the median waiting time for a first appointment 
in public multidisciplinary pain treatment facilities was six months, 12 times 
more than similar private facilities (Peng et al., 2007). Unfortunately, no 
established benchmarks or guidelines for acceptable wait times specific to the 
treatment of chronic pain exist (Lynch et al., 2007). However,  generic standards 
are followed in the UK  (Price et al., 2012), usually 18 weeks. (Price et al., 
2012). These multifactorial problems make chronic pain management 
challenging. 
2.5.2 Chronic pain management: The UK perspective 
The access to and quality of pain services in the UK is a matter of deep 
concern. In 2008, there was one pain specialist for 32,000 people in pain (Chief 
Medical Officer for England, 2008). The National Pain Audit found a lack of clear 
standards of care and variation in access to multidisciplinary care. Of the 204 
pain services evaluated, the audit reported that only 40% of clinics in England 
met the minimum criteria for multidisciplinary clinics by having a psychologist, a 
physiotherapist and a physician (Price et al., 2012). Furthermore, 80% of clinics 
in England and 50% in Wales met the 18 week generic standard waiting time. 
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The report also found that many of the chronic pain services were not even 
meeting the minimum criteria for an effective pain service as outlined by the 
IASP and the Faculty of Pain Medicine of the Royal College of Anaesthetists. 
The report made a number of recommendations aiming to improve access to 
and quality of pain services in the UK. The key recommendations included: 
information about local pain services should be made readily available to 
patients; the Royal College of Anaesthetists should adopt IASP guidance on 
minimum waiting times for pain services; service commissioners should 
integrate physiotherapy and psychology services into local care pathways for 
pain; and every specialist pain service should be supported by a medical 
consultant to provide expert advice.   
Given the limited capacity of GPs, the lack of pain specialists and issues 
surrounding accessibility and affordability of multidisciplinary pain clinics, the 
role of pharmacists and nurses has grown significantly in the past decade. In 
the following sections, the evidence to support the roles of nurses and 
pharmacists in chronic pain management, both independently or as part of 
multidisciplinary teams, is  explored. 
2.6 The role of pharmacists in chronic pain management 
Until recently, and still in some developing countries, the role of pharmacists 
within healthcare systems globally was limited to the dispensing of medications. 
Although dispensing of medications still remains an important responsibility of 
pharmacists, with the introduction of the concept of pharmaceutical care, the 
focus of pharmaceutical services has shifted from products to patients.  
Consequently, a number of patient-oriented pharmacist-led services have been 
developed in both hospital and community settings. Pharmaceutical care is 
defined as “the responsible provision of drug therapy for the purpose of 
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achieving definite outcomes that improve a patient's quality of life” ” (Hepler and 
Strand, 1990, P. 539). These outcomes include: curing and/or preventing 
disease; slowing down its progress; and an elimination or reduction of a 
patient's symptomatology (Hepler and Strand, 1990). The basic essence of 
pharmaceutical care is that the pharmacist develops, implements and monitors 
a therapeutic plan in consultation with the patient, with the patient playing an 
active role in decision making.  The aim of pharmaceutical care is to identify, 
prevent and resolve actual or potential drug related problems (Hepler and 
Strand, 1990). More recently, terms such as “medicines management” and 
“medicines optimisation” have frequently been used in literature to describe 
pharmacist’s activities to promote safe and effective use of medicines (Barber, 
2001). 
  In the context of chronic pain, the role of pharmacists in its management 
has expanded significantly in the past two decades. Research evidence to 
support the role of pharmacists in chronic pain management is also growing. 
During the literature search, both observational studies and randomised 
controlled trials evaluating the effectiveness of the role of the pharmacists in 
chronic pain management were found. Based on the literature review, 
pharmacist-led interventions for chronic pain management can be broadly 
categorised into two categories: medication review and prescribing; and 
educational interventions. However, in most instances medication review and 
patient education were delivered concurrently as part of pharmacist-led 
interventions. These interventions have been delivered either independently or 
as part of multidisciplinary teams in different settings. In the following 
paragraphs, research studies evaluating the role of pharmacists in chronic pain 
management are critically reviewed. A description of the nature of the 
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intervention(s) and settings has also been provided to highlight the variations in 
the nature, mode and delivery of pharmacist-led interventions in chronic pain 
management. A systematic review evaluating the effectiveness of pharmacist-
led medication review is presented in the next chapter (Chapter 3).  
For clarity, studies evaluating the role of pharmacists in chronic pain 
management have been divided into two sections: Descriptive observational 
studies and randomised controlled trials. 
2.6.1 Descriptive observational studies 
The literature review found a few observational studies, described below, which 
only described the nature of pharmacist-led intervention in chronic pain 
management without providing any significant data to support their 
effectiveness.  
Weitzel et al.  (2004) described the development and working of a 
pharmacist-managed headache clinic in an interdisciplinary community health 
centre affiliated with the University of Florida, USA. The clinic was established in 
2000 on the request of the clinical nurse practitioner and followed a stratified 
care approach for the management of migraine. In the stratified care approach, 
patients were stratified and treated based on the severity of their migraine 
(Lipton et al., 2000). In terms of the working of the clinic, patients were referred 
to the pharmacist by the patients’ primary care physician (PCP), and during the 
initial one hour long consultation, the pharmacist conducted a medication review 
and obtained a headache history. The pharmacist, in consultation with the 
patient, developed a therapeutic plan based on the available guidelines. During 
follow up appointments, the pharmacist reviewed the pharmacotherapeutic plan 
and adjusted it according to the patients’ needs. From 2000 to 2003 the clinic 
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enrolled 37 patients. Pharmacist’s recommendations included: requested non-
pharmacologic treatment for 1 patient, addition of immediate-relief drug therapy 
for 20; addition of prophylactic drugs for 14; modification of treatment regimen 
for 7; and referral to consultant for 3 patients. Twenty-six patients (70%) 
reported a decrease in headache frequency and severity, while the rest reported 
no change. The main focus of the paper was to describe the nature of service 
rather than to evaluate its effectiveness. 
Similarly, three more studies (Rapoport and Akbik, 2004, Dole et al., 
2007, Fan and Elgourt, 2008) described the working of a pharmacist managed 
pain clinic with little or no data to support their effectiveness.  Rapoport and 
Akbik (2004) described a pharmacist-managed pain clinic within a 
multidisciplinary pain service, consisting of a neurologist, a psychiatrist, an 
anaesthesiologist, an anaesthesiology fellow and two pharmacists, at a 
Veterans Affairs medical centre in Boston, USA. Fan and Elgourt (2008) 
described a pain management pharmacy service in a community hospital in the 
USA and Dole et al. (2007) described a pain service with a pharmacist with 
prescribing authority in Mexico. In all  three studies, the role of the pharmacist 
was to develop a therapeutic plan, monitor outcomes, adjust medicines as per 
the requirement, prevent the abuse of opioid analgesics, improving adherence 
to prescribed medication, refill prescriptions, prevent drug related problems and 
side effects, and make referrals to other healthcare professionals if necessary. 
The overall aim of these services was to ensure effective, efficient and 
adequate analgesia to all patients referred to these services.  Dole et al. (2007) 
also reported a significant reduction in pain intensity scores (Mean difference 
1.1; SD ± 2.5), measured on a 1 to 10 visual analogue scale (VAS) (P < 0.001), 
and the pain service generated an overall profit equivalent to a 9% return on 
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investment (annual revenue $107,550 (£65,755); annual salary 
$98,851(£60,437).  
In the UK, McDermott et al. (2006) described a method of identifying 
chronic pain patients in primary care and the feasibility and acceptability of a 
pharmacist-led medication review in one general practice in Aberdeenshire, 
Scotland, UK.  Chronic pain patients were identified using a Microsoft Access 
based Audit Tool (NIMROD). In total, the case notes of 132 patients were 
reviewed and the pharmacist made 192 recommendations about the safe and 
appropriate use of medications. Of these 192 recommendations, 108 (56%) 
were directly related to the use of analgesics. However, outcomes such as pain 
intensity and physical functioning were not measured. This was the first study in 
the UK to report a method for the identification of chronic pain patients in the 
general practice and was therefore instrumental in the development of an RCT, 
which evaluated the effectiveness of pharmacist-led medication reviews in the 
primary care setting (described below; section 2.6.2). 
In addition to descriptive studies, one quasi-experimental study using a 
single group pre-test post-test design and multiple outcome measures was also 
found (Chelminski et al., 2005). Typical single group pre-post study designs lack 
control group and randomization, which threatens the validity and reliability of 
the findings (Fisher et al., 2002). Nevertheless, such studies are important in 
providing important information about the nature of the intervention and patient 
population, the suitability of the intervention in the desired population, and, most 
importantly, informing the design of future RCTs (Shadish et al., 2002). 
Chelminski et al. (2005), in the USA, evaluated a primary care based multi-
disciplinary disease management programme for chronic pain patients with a 
high burden of psychiatric comorbidity. The multi-disciplinary team consisted of 
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patient’s primary care physician (PCP), a clinical pharmacist, a psychiatrist with 
a sub-specialisation in pain management and a programme assistant with 
training in health behaviour. The aims of the programme were to: prevent 
substance (opioids) abuse; titrate patients’ pain medications to ensure optimal 
analgesia; and identify and manage patients with depression. Once enrolled, 
participants were asked to complete the Brief Pain inventory (BPI) (Cleeland 
and Ryan, 1994), the Centre for Epidemiological Studies-Depression Scale 
(CESD) (Radloff, 1977) and the Pain disability Index (PDI) (Tait et al., 1987) at 
baseline and 3-month follow up. Substance abuse was monitored through 
clinical history and urine toxicological screening (UTS). Eighty five patients 
enrolled in the study with an average baseline pain score of 6.5. Fifteen patients 
withdrew from the study after identification of substance abuse. At 3-month 
follow-up, the authors reported a statistically significant (p=0.003) 1 point 
reduction in pain score, from 6.5 to 5.5 on an 11 point NRS. Importantly, the 
reduction in the pain score was statistically significant but not clinically 
significant. However, there were significant improvements in mean PDI score 
(p<0.001) and CESD score (p<0.001). Remarkably, the proportion of depressed 
patients fell from 79% to 54% (p=0.003). However, substance abuse was 
reported in 32% of the patients.  
2.6.2 Randomised controlled trials (RCTs) 
In healthcare research, RCTs are considered the gold standard to evaluate the 
effectiveness of an intervention. In addition to a number of descriptive and 
observational studies described above, a few randomised controlled clinical 
trials evaluating the effectiveness of pharmacist-led interventions in chronic pain 
management were also found (Gammaitoni et al., 2000, Hay et al., 2006, 
Hoffmann et al., 2008, Petkova, 2009, Marra et al., 2012, Bruhn et al., 2013). 
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These RCTs vary in terms of the nature of the intervention, settings, patient 
population, duration of follow-up, and outcome measures and scales used. A 
detailed description of all of these trials, except for a trial by Petkova (2009) is 
provided in the next chapter as they are part of the systematic review 
undertaken as part of this thesis. The trial by Petkova (2009) did not fulfil the 
inclusion criteria for the systematic review (described in the next chapter). 
Although, the trial by Bruhn et al. (2013) was included in the systematic review, 
the detailed results were published after its completion, therefore it was not 
included in the data analysis and is briefly presented here.  
In Bulgaria, Petkova (2009) conducted a randomised controlled trial to 
evaluate the effectiveness of a community pharmacy-based pharmacist-led 
education programme for arthritis patients. The educational leaflets were 
prepared in the form of a self-study program based on the National Health 
Insurance Fund for treatment of arthritis diseases (clinical paths for physical 
treatment and rehabilitation of arthritis diseases and musculoskeletal system) 
and by the Arthritis Foundation. However, the nature of education programme 
was not described extensively. In total 90 patients were enrolled, 45 each in the 
intervention and control groups. Neither the method of power calculation nor the 
method for allocation concealment was reported. Furthermore, instead of 
making comparisons between the intervention and control groups for all the 
outcomes, comparisons within groups (pretest-posttest) were only reported. 
Nevertheless, significant reduction in the frequency of ‘severe pain’ was 
reported in the intervention group compared to the control, the only comparison 
reported in paper. Therefore, in the presence of a high risk of selection and 
reporting bias, the trial provided limited useful information about the 
effectiveness of the intervention.  
32  
 
In the UK, Bruhn et al. (2013) conducted an exploratory trial to evaluate 
the effectiveness of pharmacist-led medication review, with or without 
pharmacist prescribing in primary care among patients with chronic pain . 
Patients were randomised to one of the three arms: pharmacist medication 
review and prescribing (prescribing arm); pharmacist medication review and 
recommendations to the GP (review arm); and treatment as usual (TAU) arm. At 
6 months follow-up, compared to the TAU, there was a significant reduction in 
pain intensity in both the intervention groups (p=0.02). However, there was no 
difference in the disability, measured by the chronic pain grade questionnaire 
CPG (p=0.05). Similarly, there was no significant improvement in the SF-12 
physical composite score (PCS) between the trial arms (p=0.75) and a slight 
deterioration in SF-12 mental composite score (MCS) in the intervention arms, 
and a statistically significant deterioration in the TAU arm (p= 0.002). Since it 
was an exploratory trial the authors did not perform any power calculations, 
leading to a higher risk of type II error.   
2.6.3 Systematic reviews 
During the literature search, two systematic reviews (Bennett et al., 
2011, Elias et al., 2011) were also found. Elias et al (2011) conducted a 
systematic review to evaluate the impact of pharmacist-led interventions in the 
management of osteoporosis. Since the focus of this thesis is on chronic pain, 
therefore further details of the systematic review are not included here.  
Bennett et al. (2011) conducted a systematic review to evaluate the 
effectiveness of pharmacist-led educational interventions in chronic pain 
management. They included RCTs in which educational interventions were 
delivered by pharmacists independently or as part of a multicomponent 
intervention to chronic pain patients (pain lasting ≥ 3 months). Four RCTs, 
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including one involving cancer patients, randomizing 400 patients in total were 
identified. The authors undertook a meta-analysis and reported: on average, a 
0.5 point reduction in pain intensity on a 0 to 10 numerical rating scale in the 
intervention group compared to the control;  more than 50% reduction in 
adverse effects; and an approximately 1 point  improvement in patient 
satisfaction with treatment on a 0 to 10 rating scale.  However, the interventions 
had no effect on reducing pain interference with daily activities and improving 
self-efficacy. Although the effect on pain intensity was statistically significant, 
the authors were unable to demonstrate clinical significance of the interventions. 
Furthermore, the effect of the intervention on “worst pain” and “current pain” 
were not statistically significant - 0.11 and - 0.003 points, respectively. There 
were two limitations in terms of the conduct of meta-analysis: Firstly, a RCT 
involving cancer pain patients was included together with RCTs involving 
chronic pain patients, leading to clinical heterogeneity. Secondly, the time points 
at which follow-up measures were obtained varied between 1 to 16 weeks; 
combing short-term trials with long-term trials is not recommended as it 
produces a larger treatment effect than combining longer term trials alone 
(Moore et al., 2010a). 
From the above discussion, despite the highlighted limitations, it can be 
concluded that there is a potential role of pharmacists in chronic pain 
management. However, more evidence is required before a wider clinical role of 
pharmacists in chronic pain management can be advocated.  
2.7 Role of nurses in chronic pain management 
Since the 1980s nurses have been actively involved in managing chronic pain 
patients. However, over the past four decades, with changes in healthcare 
systems globally, the role of nurses in chronic pain management has evolved 
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substantially and has become more independent (e.g. nurse prescribing), 
although nurses still remain an integral part of most of the multidisciplinary pain 
programmes (Middleton, 2004). Various nurse-led interventions have been 
developed and evaluated in chronic pain management including the teaching of 
coping strategies such as breathing exercises and relaxation, cognitive 
behavioural therapy (CBT), sensorial stimulations, psycho-education, magnetic 
therapy, guided imagery and music therapy, motivational interviewing,  hypnosis 
training and prescribing (Lefort et al., 1998, Schofield et al., 1998, Mannix et al., 
1999, Becker et al., 2000, Kim, 2001, Simmons et al., 2002, Wells-Federman et 
al., 2002, McCaffrey and Freeman, 2003, Siedliecki and Good, 2006).  Nurse-
prescribing in chronic pain is perhaps the most recent nursing intervention in 
chronic pain management. Specialist pain nurses with prescribing authoritiy can 
improve access to appropriate pain medicines, a barrier to effective pain 
management (Stenner and Courtenay, 2008). In the UK, the two main forms of 
nurse prescribing are: nurse independent prescribing (NIP), and nurse 
supplementary prescribing (NSP) (Department of Health, 2006). NIP enables 
nurses to prescribe any licensed medicine within their area of competence, 
including thirteen controlled drugs (Department of Health, 2006). For NSP, any 
medicine can be prescribed in line with the clinical management plan (CMP) 
agreed between the physician, who makes the initial diagnosis, the nurse 
prescriber and the patient. 
Given that the nature of nurse-led interventions is quite diverse in chronic 
pain management, a number of studies, both observational and RCTs have 
been conducted to evaluate their effectiveness. The detailed presentation of all 
these studies is beyond the scope of this thesis, therefore only key RCTs and 
systematic reviews are briefly described below.  
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2.7.1 Randomised controlled trials 
As mentioned above, a number of randomised controlled trials have been 
conducted to evaluate the effectiveness of various nurse-led interventions in 
chronic pain management. To avoid duplication, RCTs included in the 
systematic reviews have been briefly discussed in the systematic review section 
(section 2.6.2). The other key clinical trials are described below.  
Jones et al. (2002)  conducted an RCT and cost analysis to evaluate the 
effectiveness of a nurse-led education programme in reducing the chronic use 
of non-steroidal anti-inflammatory drugs (NSAIDs) by chronic pain patients in 
general practice in Nottinghamshire, UK. Of the 237 patients randomised 222 
completed the 6-month follow-up. Patients in the control group received simple 
advice regarding the use of NSAIDs while  the patients in the intervention group 
received advice, from a nurse practitioner trained in musculoskeletal 
assessment, on weight reduction, aerobic exercises, use of local heat and cold, 
back and neck care, massage and relaxation techniques. In addition, a 
therapeutic plan was drawn up in consultation with individual patients, tailored to 
their needs, in the intervention group to stop or reduce the use of NSAID. The 
intervention session lasted for 30-60 minutes. Change in NSAID use in 6-
months post intervention was the primary outcome measure. The secondary 
outcome measures included changes in health status (measured by SF-36), 
quality of life (measured with EQ-5D) and the cost of drug and health services. 
Compared with control, an additional 28% of patients in the intervention group 
either stopped taking NSAIDs or reduced their dosage more than 50% at 6 
months post intervention without having a negative impact on health status and 
quality of life. Furthermore, the authors reported a significant reduction in 
NSAID prescription costs in the intervention group compared with the control 
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(median reduction in NSAID costs per patient  of £-2.61 in the intervention 
group was vs control over the 6-months). However, although non-significant, an 
increase in the overall drug prescription costs was noticed in both groups.  
Another RCT conducted in the UK by Ryan et al. (2006) evaluated the 
effectiveness of a rheumatology expert nurse-led drug monitoring programme 
and reported statistically significant improvement in the Arthritis Impact Scale in 
the intervention group compared to the usual care group (p=0.03). In addition, a 
mean improvement of 1.8 in the Rheumatology Attitude Index (RAI) score was 
also reported in the intervention group compared to a mean deterioration of 0.3 
in the usual care group. However, the change in the Disease Activity Scores 
(DAS) was not statistically significant, in the intervention group compared with 
the control, at 3 and 7 months follow-up but was significant at 12 months. 
Furthermore, there were no differences in terms of the use of NSAIDs (61% in 
the intervention group vs 53% in the control group) and steroids (39% in the 
intervention group vs 38% in the control group) in both the groups. The trial 
randomised 71 new RA patients who were about to start new disease modifying 
anti-rheumatic therapy at a district general hospital. The intervention was based 
on the Pendelton’s framework (seven consultation tasks), explained elsewhere 
(Pendleton et al., 1984),  to assess patients’ needs in addition to the monitoring 
of drug safety delivered by a trained rheumatology expert nurse. Patients in the 
control group received care from an outpatient staff nurse for drug safety 
monitoring. Data were collected at the baseline, 3, 7 and 12 months. 
Interestingly, despite the fact that one of the aims of the intervention was to 
monitor drug safety, no data were reported on safety /adverse events. Mazzuca 
et al. (2004) in the USA, similar to the findings of Ryan et al. (2006), also 
documented a statistically significant reduction in the use of NSAIDs among 
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osteoarthritis patients in the intervention group (received nurse-led education on 
non-pharmacological modalities including quadriceps strengthening exercises, 
counselling on the principles of joint protection, and the use of thermal 
modalities) compared to the control (26% in the intervention vs 5% in the control 
; p=0.02).  
The above mentioned trials reported positive outcomes in the nurse-led 
intervention group. However, a few studies (4 studies) found during the 
literature search failed to demonstrate the effectiveness of nurse-led 
interventions.  
Victor et al. (2005), in the UK, conducted a cluster randomised trial to 
compare the effectiveness of a nurse-led primary care based education 
programme, consisting of a home visit and four 1-hour teaching sessions, for 
patients with osteoarthritis of the knee with a waiting list control group. In total, 
193 patients (73 controls; 120 interventions) were recruited and followed up at 
1,3, 6 and 12 months. Only 125 patients (53 controls; 72 interventions) 
completed the 12 months follow up, dropout rate 35.2%. There were no 
statistically significant differences between the intervention and control groups 
in any of the outcome measures including the arthritis helpfulness index (AHI), 
quality of life (measured by the SF-36), pain, disability and stiffness (measured 
by WOMAC), and osteoarthritis knowledge at either 1-month or 12-month 
follow-up. The authors linked the lack of benefit to the short duration of the 
intervention and the heterogeneous nature of the population studied.  
Tijhuis et al. (2002) compared the effectiveness of care provided by a 
clinical nurse specialist with an inpatient team care and day patient team care in 
patients with RA. In total, 210 (nurse specialist 71; inpatients 71; day patients 
68) patients were recruited from the outpatient clinics of the rheumatology 
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departments of 6 hospitals in Leiden, The Netherlands. The clinical nurse 
specialist provided information about RA, prescribed, in consultation with the 
rheumatologist, and provided joint splints, adaptive equipment and other house 
adaptations if necessary. On an average, the duration of care provided by the 
nurse specialist was 12 weeks with a mean of 3 appointments per patient. Both 
day care and inpatient care teams consisted of nurses, a rheumatologist, an 
occupational therapist, a physical therapist, and a social worker. Both inpatients 
and day patients were prescribed a treatment programme of equal intensity 
tailored to the individual patient needs. Inpatients stayed overnight in the clinic 
for 12 consecutive days. On the other hand, day care patients stayed for 3 days 
a week (10am to 4pm) for 3 weeks with a fixed bed rest for 1.5 hours. After the 
intervention, the patients in all three groups received routine treatment from 
their rheumatologist. Outcomes were assessed at the baseline, 6, 12, 26 and 52 
weeks. There were significant improvements in functional status (measured with 
the Health Assessment Questionnaire (HAQ)), quality of life (measured with the 
RAND 36-item Health Survey 1.0 and the Rheumatoid Arthritis Quality of Life 
(RAQoL) questionnaire), health utility (measured with the Health Utility Index 
scale) and disease activity (measured with the Disease Activity Score (DAS)) 
from the baseline (all p < 0.05). However, there were no significant differences 
between the three groups for any outcome measure except for patient 
satisfaction; where patients in the clinical nurse specialist care were significantly 
less satisfied than the patients in the inpatient care and day care (P<0.001).The 
reasons for dissatisfaction, however, were not explored. This was probably due 
to the fact that the patients in the other two groups were provided with more 
intense care compared to the patients in the clinical nurse specialist care. But 
the clinical benefit of all the interventions was similar.  Since there were no 
significant differences in any of the clinical outcomes between the three groups, 
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the authors would have been able to make a strong case for nurse-led care for 
patients with RA by performing the cost-minimization analysis. 
In a German primary care setting, Leonhardt et  al. (2008) conducted a 
cluster randomised controlled trial to evaluate the effectiveness of a 
Transtheoretical Model (TTM) based motivational counselling approach  by 
trained practice nurses to improve physical activity among patients with low 
back pain (LBP). TTM is a theory based counselling technique designed to 
promote physical activity (Prochaska and DiClemente, 1983), and is often used 
in combination with motivational interviewing (Miller and Rollnick, 1991). This 3-
arm cluster RCT compared motivational counselling by trained nurses (Group 
A) to general counselling by the GPs (Group B) and usual care (Group C). The 
GPs in group A and B were trained in using German LBP guidelines. However, 
in Group B, the nurses received additional training in TTM-based motivational 
counselling. Patients had up to three counselling sessions with the nurses, 15 to 
20 minutes each. In the usual care group, the GPs received LBP guidelines in 
mail with no training with regards to its implementation. Outcome measures 
included a total physical activity score measured with the Freiburger  
Questionnaire on Physical Activity (FQPA) (primary outcome) and a mean self-
efficacy score (secondary outcome) measured on a 1 to 5 numerical rating 
scale (NRS),  assessed at baseline, 6 and 12 months. The trial recruited 1378 
LBP patients both with acute and chronic symptoms. One hundred and sixty 
seven (12.1%) patients dropped out by 12 months. There were significant 
improvements in patients’ physical activity in all study arms both at 6 and 12 
months compared to the baseline. However, there was no significant 
improvement in physical functioning when compared with the control (usual 
care) group, indicating the lack of intervention effect. The lack of benefit could 
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be partly explained by the inadequate performance of the practice nurses, 
implementation barriers within German healthcare system and the 
heterogeneous sample. 
Sørensen and Frich (2008) performed a cost consequence analysis, 
based on an RCT, of a nurse-follow up intervention for chronic pain patients 
discharged from a multidisciplinary pain centre in Copenhagen, Denmark. In 
total, 102 chronic pain patients attending a multidisciplinary pain centre at a 
university hospital were randomised into a control and intervention group, and 
followed up for two years.  Over two years, the nurses visited patients 7 times in 
total (every fourth month). The purposes of these visits were to: monitor 
pharmacotherapy and side effects, and refer to the GP if required; reinforce 
patients’ knowledge about chronic pain and coping strategies; and detect 
symptoms depression associated with pain. There were no statistically 
significant differences in the health status, measured by SF-36, between the two 
groups. The cost of the nurse intervention was €35,000 (£29,066) over the two 
years, with an average cost of €648 (£538) per patient. Although not statistically 
significant, patients in the control group used more health resources worth 
€7046 (£5851) compared with €4004 (£3325) (difference €3460 (£2873), 46%). 
However, the overall cost of the intervention was much more than the savings 
on the usage of other health resources. Therefore the intervention  was not 
deemed to be cost-effective. 
2.7.2 Systematic reviews 
The literature search found three systematic reviews (Sindhu, 1996, 
Castillo-Bueno et al., 2010, Ndosi et al., 2011). One of the systematic (Sindhu, 
1996) reviews evaluated the effectiveness of non-pharmacological nursing 
interventions among patients with acute pain, therefore it is not presented here.  
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Castillo-Bueno et al. (2010)  conducted a systematic review to evaluate 
the effectiveness of nursing interventions, specifically non-pharmacological,  in 
the management of chronic pain. There are two important aspects in terms of 
the design of the systematic review: Firstly, the authors used a six-month cut 
off, instead of a more frequently used 3-month cut off, to define chronic pain in 
the systematic review. Secondly, the inclusion criteria also included quasi-
experimental studies in addition to the RCTs. Of the 1666 articles retrieved, 
eight randomised controlled trials were included in the review. The authors were 
unable to undertake meta-analysis due to heterogeneity among the included 
studies in terms of study population, nature of intervention and duration of 
follow-up. Of the eight trials included, two trials evaluated the effectiveness of 
music as a nursing intervention for the management of chronic pain (McCaffrey 
and Freeman, 2003, Siedliecki and Good, 2006); one trial each evaluated 
cognitive behavioural therapy (Becker et al., 2000), psycho-education 
programme (Lefort et al., 1998), physical exercise programme (Simmons et al., 
2002), magnetic field therapy (Kim, 2001), guided imagery (Mannix et al., 1999), 
and sensorial simulation (Schofield et al., 1998). The review found that the 
cognitive behavioural and the sensorial stimulation programmes were effective 
in reducing perceived pain, and psycho-education and music therapy 
programmes reduced osteoarticular pain.  Guided imagery and magnetic field 
therapy benefited patients with chronic headache while physical exercise 
programme improved mobility among elderly but did not relieve pain. However, 
the clinical significance of these findings were not demonstrated in the review. 
Furthermore, it should be noted here that, since the meta-analysis was not 
undertaken, the findings of this systematic review were based on the findings of 
small 1 to 2 individual trials for each nursing intervention. Therefore, no 
conclusive evidence can be drawn to support the effectiveness of these 
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interventions in chronic pain management from this systematic review. 
Furthermore, the cost-effectiveness of these findings were not demonstrated in 
the review. Despite these limitations, the review authors concluded that these 
interventions were effective, except the physical exercise programme, and 
should be considered in addition to the standard pharmacological treatment for 
the management of chronic pain. On the contrary, this author believes that the 
use of these interventions in routine clinical practice should not be 
recommended until more high quality evidence is available to support their 
effectiveness. 
Ndosi et al. (2011) conducted a systematic review of randomised 
controlled trials to compare the effectiveness of nurse-led interventions with 
usual care among rheumatoid arthritis patients. The review included 4 RCTs 
involving 431 patients in total. The included trials had an overall low risk of bias 
and followed up patients for 1 to 2 months. Three trials were reported from the 
UK and one from the Netherlands. There were no statistically significant 
differences between the groups (usual care vs nurse-led care) for the two 
disease activity scores (DAS) primary outcomes; DAS 28 (ratio of means (RoM) 
= 0.96, 95%CI [0.90–1.02], P= 0.16); and  plasma viscosity (RoM = 1 95%CI 
[0.8–1.26], p= 0.99). However, significant improvement was noticed in the 
Ritchie Articular Index (RoM = 0.89, 95%CI [0.84–0.95], P<0.001) in the nurse-
led care group compared with the usual care group. Furthermore, statistically 
significant improvements were found in the nurse-led care group compared to 
the usual care group for quality of life (RAQoL RoM = 0.83, 95%CI [0.75–0.92], 
P<0.001), patient knowledge (PKQ RoM = 4.39, 95%CI [3.35–5.72], P<0.001) 
and fatigue (median difference = - 330, P= 0.02). However, statistically non-
significant differences were reported for other secondary outcomes including 
43  
 
functional status, stiffness and coping with arthritis. Interestingly, the results of 
two of the secondary outcomes (satisfaction and pain) varied in their statistical 
significance when assessed using different tools. In summary, the systematic 
review and meta-analysis could not generate conclusive evidence to support the 
nurse-led interventions in the management of RA, necessitating more good 
quality RCTs to strengthen the evidence. 
To summarise, the RCTs evaluating the effectiveness of the nurse-led 
interventions have documented mixed results. The RCTs varied in terms of the 
nature of intervention, patient population, duration of follow up, settings and 
outcomes measures. Due to this heterogeneity, systematic review authors were 
unable to undertake meta-analysis. Subsequently, no conclusive evidence can 
be drawn from the existing literature. However, it would not be incorrect to 
conclude here that there is a potential role for nurses in the management of 
chronic pain, but more high quality research work is required to identify the type 
of patients who could  benefit more from such services.  
2.8 Combined nurse-pharmacist managed pain clinics 
Despite a number of studies supporting the role of nurses and pharmacists in 
chronic pain management, examples of combined nurse-pharmacists managed 
clinics are almost non-existent in the literature. This is perhaps due to the fact 
that the role of pharmacists in chronic pain management is relatively new unlike 
nurses who have traditionally been part of multidisciplinary pain management 
teams. The author could only retrieve two studies evaluating the impact of 
combined nurse-pharmacist managed pain clinics on patient reported 
outcomes. One study was conducted by Weidemer et al. (2007) in the USA and 
the other by Briggs et al. (2008) in the UK. The nature of the services, and type 
of patients referred to the clinics were completely different in the two studies, 
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however there were some similarities in the roles of nurses and pharmacists 
within both of the services. This study was conceived in order to address the 
limitations of the Briggs et al. (2008) study and to further evaluate the 
effectiveness of a nurse-pharmacist managed chronic pain service. Since this 
study was based on the Briggs et al. (2008) study, the working of the clinic, 
limitations to the current evidence are presented in more detail to give 
contextual background and rationale for this study (described below; section 
2.8.1). 
In the USA, Weidemer et al. (2007) conducted a naturalistic prospective 
study to evaluate the impact of a combined nurse practitioner (NP) and clinical 
pharmacist run pain management clinic in a large primary care medical centre, 
the Opioid Renewal Clinic (ORC) For the ORC, the NP and clinical pharmacist 
developed and implemented a structured approach to prescribing and 
monitoring of opioids to ensure their safe and effective use. The overall aim was 
to reduce abuse of opioids among patients.  The NP and clinical pharmacist 
were supported by a multidisciplinary team of consultants (psychiatrist, 
rheumatologist, orthopaedist and neurologist)Limitations of single group pre-
post study designs have already been discussed earlier in this chapter (section 
2.6.1). Patients were referred to the programme by their primary care 
practitioners (PCP).. A multidisciplinary pain management team arranged bi-
weekly meetings with a nurse practitioner and clinical pharmacist and advised 
them on treatment plans. The authors reported that ‘aberrant’ behaviours were 
resolved in 77 (45%) of the 171 patients with documented ‘aberrant’ behaviour. 
Furthermore, significant pharmacy cost savings were also reported. Twenty-two 
patients were further referred for addiction treatment. No data on pain relief and 
physical functioning were reported.  
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2.8.1 The nurse-pharmacist managed pain clinic (NPMPC) 
The foundation of the clinic was laid with the establishment of the Community 
Pain Forum in 2001 (Closs et al., 2011). The forum then undertook focus group 
interviews involving 72 healthcare professionals to assess local needs for the 
provision of chronic pain service (Briggs et al., 2004). In 2004, upon completion 
of the pain service needs assessment project, a multidisciplinary Chronic Pain 
Steering Group was set up consisting of representatives of the primary care 
trust (PCT) and the Leeds Teaching Hospitals NHS Trust (LTHT) (Closs et al., 
2011). The group developed guidelines for the management of chronic pain and 
proposed the establishment of a community-based pain clinic, jointly managed 
by a nurse and a pharmacist. Subsequently the clinic was established and 
started receiving chronic pain patients in 2005.   
In order to provide the best possible professional service, a district nurse 
(KM) underwent a specialized pain management training programme at an 
associated hospital pain clinic. The services of a community pharmacist were 
secured through a working arrangement between Boots Pharmacy and the 
PCT. The community pharmacist worked for one day per week at the pain clinic. 
To ensure a smooth work flow, comprehensive referral pathways and clinical 
guidelines were also developed.  The patients with chronic pain were referred 
by general practitioners (GPs) either to the pharmacist-nurse managed pain 
clinic or to secondary care based on local guidelines. For example, patients with 
malignant pain, or psychiatric disorder were directly referred to secondary care. 
However, if deemed necessary, the nurse and/or the pharmacist could further 
refer any patient to secondary care. Together with the referral note, the GPs 
also sent the details of patients’ and current and past medical and medication 
history to the clinic. 
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Prior to the first consultation, while waiting to be seen by the nurse and 
the pharmacist, the clinical nurse specialist (CNS) administered the Brief Pain 
Inventory (BPI) (Cleeland and Ryan, 1994) to assess pain intensity, severity and 
interference with daily activities; and the Hospital Anxiety and Depression Scale 
(HADS) (Zigmond and Snaith, 1983) to assess anxiety and depression 
(emotional functioning) to all patients. During consultation, the pharmacist 
obtained all relevant medication and medical history. The pharmacist then 
discussed any adverse effects and the degree of pain relief with the current 
prescribed medication with the patient. Issues such as adherence to the 
prescribed medicines and use of any over the counter (OTC) medicine or 
complementary and alternative therapy were also explored during the 
consultations. The pharmacist then reviewed patients’ medicines, provided 
medication counselling and checked for drug interactions with the aim of 
ensuring optimal use of analgesics through a concordant approach. The nurse 
educated the patient about pain, clarified any misconceptions, and supported 
the development of skills needed  to self-manage. Finally, the pharmacist and 
nurse discussed the future treatment plan with the patient and, where needed, 
made recommendations to the GP. Safety and suitability of analgesic use was 
assessed based on medical and medication history before making any 
recommendation. The common medication related recommendations included: 
dose adjustment, stopping a particular analgesic and addition or substitution of 
analgesics (opioid to non-opioid or NSAID and vice versa). The GP then 
reviewed the treatment and changed it as appropriate. During the follow-up 
visits, the patients were seen only by the clinical nurse specialist unless 
considered necessary by the clinical nurse specialist. BPI and HADS were also 
administered on follow-up visits to monitor progress with the treatment. During 
the follow up visits the clinical nurse specialist reinforced self-management 
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skills, provided further patient education, resolved any issues with medication 
use and monitored patients for any adverse events. On average, the first 
session lasted for one hour and the follow-up sessions lasted for 30–40 minutes 
and the patient was usually discharged after three to four sessions. The clinic 
received more than 150 to 200 new patients every year. 
In 2012, the local PCT decommissioned the service, despite the fact that 
the pilot study showed favourable outcomes and a mixed-methods study, this 
one, was going on at that time. The services of the nurse pain specialist were 
transferred to the musculoskeletal services. However, pharmacist services were 
discontinued, a decision not based on existing evidence which supports the role 
of pharmacist in chronic pain management. How the termination of the service 
affected this study is highlighted later in the thesis (Chapter 5). 
2.8.2 Research evidence 
A pilot study was conducted by Briggs et al. (2008) to evaluate the impact of the 
nurse-pharmacist managed pain clinic on pain intensity, using a retrospective 
single group pre-test-post-test design. A research nurse (JB) who was not 
involved in delivering the service collected data by reviewing patients’ clinical 
notes available at the pain clinic. Sixty five patients were included in the study 
with a mean age of 57 (SD 15) years. The discharge pain score was only 
available for 37 patients. The pain intensity was assessed using an 11-point (0 
to 10) Numerical Rating Scale (NRS). The authors reported a significant 
reduction in pain score from a mean of 8 upon referral to 6.3 at discharge 
(P<0.0001). Furthermore, referrals to secondary care were also reduced. Of the 
120 patients attending the clinic, only 13 were further referred to secondary 
care. However, the pilot study provided limited information about the nature of 
the intervention, sociodemographic and clinical characteristics of patients 
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referred to the clinic, and the clinical significance of the effect size. Additionally, 
the retrospective study design, small sample size, and the use of pain scores 
alone as an outcome measure, further limits the usefulness of the findings. The 
present study was designed to address these issues and develop robust 
evidence to establish the effectiveness (or otherwise) of the nurse-pharmacist 
managed pain clinic described above.  
2.9 Aims and objectives 
After carefully reviewing the existing literature, two main research gaps were 
identified. Firstly, there was a lack of clear evidence to support the effectiveness 
of pharmacist-led medication review in chronic pain management as RCTs have 
reported inconsistent results. Secondly, further research evidence was required 
to support the effectiveness of the nurse-pharmacist managed pain clinic and to 
overcome the limitations of Briggs et al. (2008). As mentioned earlier, this clinic 
provided an excellent example of public-private sector partnership in healthcare 
settings. This was another important reason to further evaluate the 
effectiveness of the clinic, so that, if effective, more such services could be 
established widely. This thesis was set to fulfil these research gaps. Therefore, 
the first aim was to conduct a systematic review to evaluate the effectiveness of 
pharmacist-led medication review in chronic pain management. The objectives 
were: 
1. Does pharmacist-led medication review decrease pain intensity?  
2.  Does it reduce medication-related adverse effects?  
3.  Does it improve patients’ physical functioning and quality of life?  
4.  Are patients satisfied with the service provided by pharmacists? 
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The second aim was to evaluate the impact of a nurse-pharmacist managed 
pain clinic (NPMPC) on patient reported outcomes.  
The objectives were to: 
1. study the socioeconomic and clinical characteristics of patients attending 
the NPMPC. 
2. assess the impact of NPMPC on pain intensity. 
3. evaluate the impact of NPMPC on physical functioning, emotional 
functioning and health related quality of life (HRQoL). 
4. explore issues around patients’ satisfaction with the pain management 
service provided by NPMPC. 
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CHAPTER 3 
EFFECTIVENESS OF PHARMACIST- LED MEDICATION 
REVIEW IN CHRONIC PAIN MANAGEMENT: SYSTEMATIC 
REVIEW AND META-ANALYSIS 
3.1  Introduction 
As described in the earlier chapter, mixed results have been reported by 
the randomised controlled trials (RCTs) evaluating the effectiveness of 
pharmacist led medication review in chronic pain management. With the aim of 
generating substantial evidence, a systematic review of RCTs evaluating the 
effectiveness of pharmacist-led medication review in chronic pain management 
is reported in this chapter.   
The chapter begins with a brief general overview of systematic reviews 
and the importance of the development of a systematic review protocol and its 
registration. That is followed by the discussion on the rationale of undertaking 
the present systematic review, and then its aim and objectives are presented. 
Then methods and results are described in detail. Finally, the results are 
discussed and implications for future research and practice are suggested.  
3.2 Systematic review: An overview 
Chalmers and Altman (1995) described systematic review as a review 
that has been assembled using a systematic approach, thoroughly described in 
the methods section, to minimize bias and random errors. It aims to identify and 
summarise relevant research evidence against pre-determined inclusion criteria 
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with the intention of answering a particular review/research question (Higgins 
and Green, 2011). Since systematic reviews use pre-set inclusion criteria and 
systematic methods to minimize biases, the results obtained are more reliable 
thus facilitating the decision making process. The systematic review differs from 
traditional literature reviews and commentaries as being reproducible, 
transparent and less biased. Systematic reviews not only collate research 
evidence but also identify research gaps. 
Until recently, systematic reviews were only used in medical research to 
synthesize evidence on the effectiveness of healthcare interventions by 
combining data extracted from controlled trials. However, with the growing use 
of qualitative and mixed-methods research designs in healthcare to inform 
policy and practice, systematic review methods for qualitative and mixed-
methods research have also been developed in the last decade (Gough et al., 
2012). The detailed description of each method is beyond the scope of this 
thesis. The choice of which data (quantitative, quantitative or both) to be used is 
primarily determined by the scope of the review and the review questions.  A 
number of methods are available for the synthesis of qualitative research 
including  Meta-ethnography (Noblit and Hare, 1988), Meta-study (Paterson et 
al., 2001), Meta-narrative (Greenhalgh et al., 2005), Critical Interpretive 
Synthesis (Dixon-Woods et al., 2006), Frame work synthesis (Brunton et al., 
2006) and Textual Narrative synthesis (Lucas et al., 2007). Broadly, there are 
two approaches to integrate qualitative and quantitative data in mixed-methods 
systematic reviews: Multilevel synthesis (Thomas et al., 2004) and parallel 
synthesis (Noyes and Popay, 2007). Quantitative systematic reviews synthesise 
data obtained from primary studies either narratively or statistically. The 
quantitative data for systematic review can be extracted from both randomised 
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controlled trials (RCTs) and non-randomised studies (epidemiological studies). 
However, being considered as the ‘gold standard’ for measuring effectiveness 
of a intervention, RCTs are the most frequently used research methodology in 
systematic reviews especially for ‘what works’ systematic reviews.  
The statistical combination of data from two or more primary studies is 
referred to as meta-analysis (Higgins and Green, 2011). Meta-analysis 
generally produces a single estimate of treatment effect (Huque, 1988) thereby 
increasing the power and precision of the results of primary studies (Higgins 
and Green, 2011). Other advantages of meta-analysis include resolving 
disagreements between results of different primary studies, if any, and 
answering unaddressed questions of primary studies. Therefore it is not always 
feasible or reasonable to conduct a meta-analysis due to variations in research 
design, differences in study population and quality of reported data within 
primary studies. Meta-analysis of studies at high risk of bias and in the presence 
of publication bias may also not be appropriate and may be criticised for 
combining ‘apples with oranges’ (Higgins and Green, 2011). Meta-analysis can 
be misleading if the above mentioned issues are not carefully considered. If 
statistical combination is not possible in a review, data are combined narratively. 
The process involved in conducting a systematic review is similar irrespective of 
the type of data to be combined. The basic steps involved in conducting a 
systematic review are shown in Figure 3.1. 
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Defining the scope of the review and review questions 
Developing a comprehensive search strategy 
Defining explicit inclusion and exclusion criteria for including studies 
Rigorously selecting studies based on the inclusion and exclusion 
criteria 
Extracting relevant data from included studies 
Analysing and synthesising extracted data 
Interpreting and disseminating the results 
Figure 3.1. Basic steps in conducting a systematic review 
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3.2.1 Systematic reviews in evidence-based medicine 
“Evidence-based medicine (EBM) is the conscientious, explicit and 
judicious use of current best evidence in making decisions about the care of 
individual patients. The practice of evidence-based medicine means integrating 
individual clinical expertise with the best available external clinical evidence 
from systematic research” (Sackett et al., 1996, P. 71). Over the past two 
decades, there has been an enormous increase in the volume of health related 
published research and consequently it has become increasingly difficult for 
researchers and practitioners to keep abreast of the latest findings. It is 
impossible for healthcare professionals and policy makers to have the time, 
expertise and resources to locate, read, critically appraise and interpret all 
relevant research findings to make an informed decision about patient care 
based on current evidence (Higgins and Green, 2011). Systematic reviews can 
potentially resolve this problem by identifying, critically appraising, and 
synthesising the research evidence. Depending on the research question, well 
designed and conducted systematic reviews may provide the best research 
evidence (Merlin et al., 2009); therefore they have an important position in 
evidence-based medicine in guiding healthcare policies and informing clinical 
decision-making. 
3.1.3 The review protocol: Rationale and importance  
A systematic review protocol details the research questions, search 
strategy, inclusion/exclusion criteria and planned data analysis (Higgins and 
Green, 2011). The protocol should always be written in advance to ensure 
transparency and reproducibility. The PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) guidelines (Moher et al., 2009) also 
recommend the development of and adherence to systematic review protocols 
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to avoid the introduction of bias. Changes in protocol may be necessary but 
should always be reported together with the reason in the review (Moher et al., 
2009). Changes such as adding or removing outcomes, or performing 
unplanned subgroup analyses have the potential  to introduce bias and the 
prospective registration/publication of protocols can help safeguard against 
these biases as it allows the reader to compare what was planned (protocol) 
with what has been reported in the finished systematic review (Stewart et al., 
2012). Furthermore, registration helps researchers in complying with PRISMA 
guidelines and increasing awareness of their review (Stewart et al., 2012). 
In order to ensure transparency and avoid duplication, the systematic 
review protocol was registered with PROSPERO, an international register for 
prospective registration of systematic reviews developed and maintained by the 
National Institute of Health Research’s (NIHR) Centre for Reviews and 
Dissemination (CRD) at the University of York, UK. (Registration number: 
CRD42012001957) and published in the Canadian Pharmacists Journal (Hadi 
et al., 2012). PROSPERO is the only international online resource to register 
systematic reviews in healthcare (Centre for Reviews and Dissemination, 2012). 
3.2 Rationale for the review 
The management of chronic pain is complex as chronic pain does not 
only interfere with physical functioning but also causes deterioration in 
emotional functioning and quality of life. Accessibility and affordability of 
multidisciplinary pain clinics further complicates its management. A large 
European survey reported that one-third of the chronic pain patients were not 
receiving any treatment and 40% were inadequately managed.  
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Medications are widely employed for the treatment of chronic pain and 
pharmacists, being experts in pharmacotherapy, have a potential role in chronic 
pain management by ensuring the safe and effective use of medicines. Sub-
optimal use of analgesics (Hanlon et al., 1996), inadequate monitoring of repeat 
prescriptions (The Accounts Commission for Scotland, 1999), and  self-
medication with over the counter (OTC) analgesics in combination with 
prescribed analgesics resulting in overdosing (polypharmacy)  (Porteous et al., 
2005) have been reported in the literature, and pose a threat to the successful 
management of chronic pain. 
Medication review is a structured critical examination of a patient’s 
medicines with the aim of optimising medicines use, preventing  medication-
related problems and reducing waste, in an agreement with the patient 
(Taskforce on Medicines Partnership and The National Collaborative Medicines 
Management Services Programme, 2002).  Medication review has the potential 
to overcome all the above mentioned obstacles in the management of chronic 
pain. Theoretically, pharmacist-led medication review may improve pain-related 
outcomes by optimising the choice and dose of analgesics, improving 
adherence to prescribed medication, reducing adverse effects and resolving 
drug-related problems (DRPs).   However, limited and inconsistent clinical and 
research evidence is available to support these claims in the context of chronic 
pain (Suh et al., 2004, Weitzel et al., 2004, McDermott et al., 2006, Phelan et 
al., 2008). A well conducted systematic review has the potential to generate 
conclusive quality evidence to support, or refute, the effectiveness of 
pharmacist-led medication review in chronic pain management. However, to 
date, no systematic review has evaluated the effectiveness of pharmacist-led 
medication review for chronic pain management. This systematic review was 
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undertaken to fulfil this important research gap and to resolve controversies 
surrounding the effectiveness of pharmacist-led medication review in chronic 
pain management. 
3.2.1 Aim and objectives 
As highlighted earlier, the aim of this systematic review was to evaluate 
the effectiveness of pharmacist-led medication review in chronic pain 
management in adult patients. The specific research questions were:  
1) Does pharmacist-led medication review decrease pain intensity?  
2) Does it reduce medication-related adverse effects?  
3) Does it improve patients’ physical functioning and quality of life?  
4) Are patients satisfied with the service provided by pharmacists? 
3.3 Methods 
3.3.1 Study selection 
The following databases were searched using pre-defined search strategy. The 
searches were conducted during April-June 2012.  
 MEDLINE (via Ovid) …….(1946 to June 2012), 
 EMBASE (via Ovid)…….. (1947 to April 2012) 
 Cochrane Central Register of Controlled Trials…….  (Issue 6 of 12, June 
2012) 
 Cumulative Index to Nursing and Allied Health Literature (CINAHL)  
(via EMBSCO)….. (1960 to June 2012), 
 PsycINFO……….. (1806 to June 2012) 
 International Pharmaceutical Abstracts (via Ovid)…….. (1970 to June 
2012) 
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Randomised controlled trials (RCTs) and non-randomised studies (quasi-
experimental, controlled before-and-after study) having at least one control 
group were considered for inclusion. Non-randomised studies were only to be 
considered for inclusion if less than three randomised controlled trials were 
eligible for inclusion (Karjalainen et al., 2003). Waiting list controls, usual care, 
attention only and any other active control were accepted as appropriate 
controls. Studies were considered for inclusion if one of the arms received either 
pharmacist-led medication review delivered independently, or as part of more 
complex multidisciplinary interventions, provided that the pharmacist was part of 
the multidisciplinary team. In addition to database searches, websites of 
American, Canadian and Royal (British) Pharmaceutical societies were also 
searched together with the reference lists of the retrieved articles to identify any 
additional eligible studies. Studies published only in English language (full text 
or abstract) were considered. The corresponding authors of the included studies 
were contacted to obtain additional information where required and to identify 
any other unpublished studies. An example of the search strategy is presented 
in Appendix I. 
The search strategy was developed in consultation with an experienced 
health science librarian. The process of study selection involved three steps 1) 
The author ran the pre-defined specific search strategy on each of the chosen 
databases. All the searched results were exported to an Endnote file. 2) Study 
titles and abstracts of the studies were screened independently by the author 
and one of his supervisors (DPA). Disagreements were resolved through 
discussion and if agreement was not reached, another supervisor (MB) was 
consulted. Full texts of all studies considered potentially relevant studies were 
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retrieved. 3) Finally, the author and one of his supervisors (DPA) independently 
selected studies meeting the pre-defined and pilot-tested inclusion criteria.  
3.3.2 Types of participants 
Studies involving chronic pain patients 18 years and older were included 
regardless of their gender, type and aetiology of chronic pain. In this systematic 
review, The International Association for the Study of Pain (IASP) definition of 
chronic pain: “Pain without apparent biological value that has persisted beyond 
the normal tissue healing time (usually taken to be 3 months)” was used 
(International Association for the Study of Pain, 1986). Studies involving 
patients with malignant or cancer pain were excluded as these would have 
introduced clinical heterogeneity.    
3.3.3 Outcome measures 
The primary outcome measure was pain intensity measured using a 
validated scale (e.g. numerical rating scale). The secondary outcome measures 
included: 1) reduction in adverse effects; 2) physical functioning measured 
using a validated scale (e.g. Brief Pain Inventory); 3) patient satisfaction using a 
validated scale; and 4) quality of life measured using a validated scale (e.g. SF-
36). 
3.3.4 Assessment of risk of bias   
The risk of bias was assessed for all the included studies by the author 
and checked by one of his supervisors (SJC) using a standardised form 
(Appendix II). Bias is a “systematic error or deviation from the truth, in results or 
inferences”  (Higgins and Green, 2011, P.188). Bias attributed to a particular 
design deficiency (e.g. lack of allocation concealment) may inflate the effect size 
in one study and deflate it in another (Higgins and Green, 2011). A number of 
61  
 
scales and checklists exist in the literature to assess ‘quality’ or risk of bias in 
randomised controlled trials but the use of these quality scales and checklists is 
discouraged (Higgins and Green, 2011) as the scales give unreliable 
assessments of validity (Jüni et al., 1999) and lack transparency (Higgins and 
Green, 2011). Therefore, the risk of bias was assessed using the Cochrane 
Collaborations’ tool for assessing risk of bias (Higgins and Green, 2011), a 
domain-based evaluation rather than a checklist or scale, covering the following 
criteria: 1) random sequence generation; 2) allocation concealment; 3) blinding 
of participants and personnel; 4) blinding of outcome assessment; 5) incomplete 
outcome data and; 6) selective reporting and other bias (e.g. baseline 
differences between control and active arms, use of invalid questionnaires). For 
cluster randomised controlled trials, risk of bias was assessed across additional 
domains including loss of clusters and appropriate statistical analysis. Each 
domain was assessed and categorised into low risk of bias, high risk of bias or 
unclear risk of bias based on the recommendations of Higgins and Green 
(2011).  Disagreements were resolved through discussion and if consensus was 
not reached a third reviewer (MB) was consulted. 
3.3.5 Data extraction 
Data was extracted by the author (MAH) and checked by one of his 
supervisors (MB) using a standardised data collection form. The data collection 
form was pilot tested. Disagreements were resolved through discussion, and if 
no consensus was reached, opinion of a third reviewer (SJC) was requested.  
3.3.6 Data synthesis 
The data was analysed using the Cochrane Collaboration’s software 
Review Manager (RevMan 5.1). For all continuous variables (e.g. pain 
intensity), mean difference (MD) was calculated when outcomes were 
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measured using the same scale and standardised mean difference (SMD) when 
different scales were used with corresponding 95% confidence intervals. For 
dichotomous variables, relative risk (RR) with 95% confidence intervals was 
calculated. Pooling of data using meta-analysis was performed depending on 
the clinical homogeneity in terms of the population, intervention, outcome 
measures and timing of outcome measures.  
Clinical heterogeneity was determined by discussion among the author 
and his supervisors, and clinically heterogeneous trials were not combined 
statistically. Statistical heterogeneity was determined by using chi-square (χ2) 
and I
2
 statistic. Statistical heterogeneity determined the choice of using random-
effects model or fixed-effects model for meta-analysis. A χ2 P value of greater 
than 0.1 and an I
2
 value of less than 50% was used to indicate statistical 
homogeneity (Higgins and Green, 2011). Random-effects model was used to 
combine clinically homogeneous but statistically heterogeneous clinical trials, 
whereas clinical and statistical homogenous trials were combined using the 
fixed-effects model.  
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Figure 3.2. Work flow of this systematic review 
 
64  
 
3.4 Results 
3.4.1 Study characteristics 
Six hundred and sixty-four articles were retrieved through database 
searches (578 after deduplication). Of these 578 articles, 27 were considered 
relevant to the review after initial title and abstract screening. An additional five 
articles were found through other sources including two each through author 
contact and reference list searching, and one through website searching. Of 
these 32 articles, nine reports from five studies met the inclusion criteria for 
review (Marra et al., 2008, Bruhn et al., 2011b, Phelan et al., 2008, Hoffmann et 
al., 2008, Hay et al., 2006, Bond et al., 2011, Bruhn et al., 2011a, Marra et al., 
2012, Gammaitoni et al., 2000). Figure 3 shows a PRISMA flow diagram to 
explain the search process and the reasons for exclusion from the review.  Two 
trials were conducted in the UK (Hay et al., 2006, Bruhn et al., 2011a) and one 
each in Canada (Marra et al., 2012), Germany (Hoffmann et al., 2008) and the 
USA (Gammaitoni et al., 2000)  . 
The included studies consisted of three individually randomised (Hay et 
al., 2006, Gammaitoni et al., 2000, Bruhn et al., 2011a)  and two cluster 
randomised controlled studies  (Marra et al., 2012, Hoffmann et al., 2008) 
randomising 1035 patients in total. All trials followed up the patients for at least 
3 months. Three trials followed-up patients for 6 months and one trial for 12 
months. All studies had their first follow-up at 3 months except for Hoffman et al 
study (2008) where the first (and the last) follow-up was made at 4 months. In 
total, 131 patients (12.7%) were lost to the first follow-up. Two trials included 
patients with chronic pain of various aetiologies (Bruhn et al., 2011a, 
Gammaitoni et al., 2000), another two involved patients with knee pain 
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associated with osteoarthritis (Hay et al., 2006, Marra et al., 2012) and one trial 
involved chronic headache and migraine patients (Hoffmann et al., 2008).  In 
four trials where gender was reported, the majority of the participants were 
females (61.8%).  The mean age of participants varied between 62.7 years (SD 
± 9.2) in Marra et al. (2012) study, 67.9 years (SD ± 8.2) in the Hay et al. (2006) 
study and 42.70 years (SD ± 13) in the Hoffman et al. (2008) study.  The study 
by Bruhn et al. (2011) did not report age and participants in the Gammaitoni et 
al. (2000) study ranged from 35-64years. 
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Figure 3.3. PRISMA flow diagram 
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3.4.2 Nature and delivery of intervention 
In three trials (Bruhn et al., 2011a, Hay et al., 2006, Hoffmann et al., 
2008), the intervention group received pharmacist-led medication review alone 
where as in the other two trials (Marra et al., 2012, Gammaitoni et al., 2000) the 
intervention group received medication review as part of a multi-component 
intervention. In the Gammaitoni et al. trial (2000), the intervention comprised of 
two components.  The first component was a specialised prescription service 
provided by a palliative care pharmacy company (PainRxperts) which delivered 
patients’ medication to their home or to the clinic, when requested. The aim of 
the service was to improve accessibility to pain medicine and to reduce the 
burden of managing medication treatment for clinical practice. The second 
component was proactive monitoring of patients’ medication therapy for any 
potential or actual drug related problem (DRP) by a palliative care trained 
pharmacist, with an access to patients medical records, to ensure that the drug 
therapy was achieving desired patient outcomes (i.e. improvement in quality of 
life). In total, 81 phone calls were made by the pharmacist including 45 to 
patients (mean 1.2 calls per patient) and 36 to the clinic staff. Majority of the 
calls were made for patient monitoring/administration of Brief Pain Inventory 
(BPI) (n=36), questions related to medication use (n=22) and delivery of 
medications (n=11). On average, each contact with the patient lasted 12 
minutes and 9 minutes for clinic staff. Fifteen out of sixteen recommendations 
made to the clinic staff were accepted which included: addition of an adjuvant 
(n=4), change drug (n=2), change dose (n=3), change frequency (n=2), dosing 
conversion (n=5) The control group received usual care as prior to study with 
the exception of filling in questionnaires at baseline and 3 months follow-up. 
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In the Marra et al. study (2012), the intervention comprised of two 
components as well (medication review and physiotherapist guided exercise). 
The patient had a face to face consultation with a pharmacist who educated 
patients on various aspects of osteoarthritis (OA), conducted medication review 
to ensure safe use of analgesics, referred patients to a physiotherapist-guided 
exercise programme (second component) and requested patients’ primary care 
physicians to approve their inclusion. It was not made clear whether the 
pharmacists had an access to patients’ electronic medical records or not. Over 
the 6 months follow-up period, 297 patient-pharmacist contacts were recorded 
resulting in 255 comments and recommendations, including 49 medication-
related recommendations to patients’ primary care physician. The pharmacist 
also followed-up with the patients each month for six months to monitor their 
progress. The physiotherapist recommended an individualised home exercise 
programme after a one-hour consultation with each patient.  The participants 
attended an exercise class twice per week for six weeks. Participants in the 
control group received an educational leaflet on knee OA developed by the 
Canadian Arthritis Society 
In the Hay et al. study (Hay et al., 2006, Phelan et al., 2008), there were 
two independent intervention groups: pharmacy review group and community 
physiotherapy group. Data of the pharmacy review group  were only extracted 
for this systematic review. Together with an education leaflet, participants in the 
pharmacy review group received an enhanced pharmacy review by an 
experienced community pharmacist in general practice surgeries with access to 
patients’ medical records. The trial protocol permitted three to six sessions of 
approximately 20 minutes each over 10 week period. The pharmacist used a 
pre-defined set of questions for initial assessment and optimized/changed drug 
69  
 
therapy, if necessary, based on an algorithm after accounting for personnel 
preferences and clinical needs. In total, 335 pharmacist-patient consultations 
took place (mean 3.2 per patient; range 2-5). The mean amount of time spent 
per patient was around 63 minutes in 3 sessions. Participants in the control 
group received the same education leaflet and a telephone call from a 
rheumatology nurse to reinforce the advice on the leaflet within seven days of 
randomization. 
 In the Hoffmann et al. study (2008), participants in the intervention group 
received an individualised counselling session by trained community 
pharmacists with the aim of optimising pharmacotherapy, promoting self-
management, goal setting and pacing activities. It was not clearly reported 
whether the community pharmacists were given access to patients’ electronic 
medical records or not. During intervention phase, each patient received 
approximately two hours of counselling and each pharmacy counselled 4.6 ± 
3.06 patients on average (range 1-15). Participants in the control group 
continued to receive usual pharmaceutical consultations with pharmacists who 
were not formally trained in headache/pain management. 
In the Bruhn et al. study (Bruhn et al., 2011a, Bruhn et al., 2011b, Bond 
et al., 2011), there were two independent intervention groups as well: 
pharmacist medication review with recommendations to the GP and pharmacist 
medication review with pharmacist prescribing. Pharmacists in the intervention 
arms had access to patients’ medical records. Further data on the nature and 
duration of the intervention were not available at that time. Authors were 
contacted to obtain additional data but the request was declined due to 
restrictions from the funding agency. 
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Table 3.1. Characteristics of included studies 
Study/Year 
country 
Trial 
design 
Setting Sample recruited 
(completed) 
Follow 
up 
(months) 
Intervention    Dose of intervention Pharmacist  
trained in  
pain 
management  
Gammaitoni 
et al/ 
2000  
(USA) 
I-RCT University  
pain clinic 
N=74 
I=38 (20) 
C=36(21) 
3 MR through 
telephone 
interviews, and a 
specialized 
prescription 
delivery service. 
81 phone calls (45 to 
patients and 36 to clinic 
staff managing patients) 
were made in 12 weeks. 
Mean 1.2 calls per patient. 
Yes 
Hay et 
al/2006 
(UK) 
I-RCT General 
practice 
N=325
* 
I=108(100,103,99) 
C=108(92,98,90) 
3, 6 and 
12 
MR and advised 
patients face-to-
face individually 
based on leaflet 
3 to 6 sessions of 20min 
each over 10 weeks 
Not known 
Hoffmann et 
al/2008 
(Germany) 
CRCT Community 
pharmacy 
N=410
 
I=201 (163) 
C=209 (194) 
4  Face-to-face MR 
plus advice on 
pacing activities 
and goal setting. 
Each pharmacy 
counselled on average 
4.6±3.01 patients (range 1-
15) for 2hrs/per patient. 
Yes 
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Bruhn et 
al/2011 
(UK) 
I-RCT General 
practice 
N=196
*
 
I=70(60,58) 
I**=63(50, 49) 
C=63(54,55) 
3 and 6 MR plus 
recommendations 
to the GP  
Data not available 
 
 
 
Yes 
Marra et 
al/2012 
Canada 
C-RCT Community 
pharmacy 
N=139 
I=73(72) 
C=66(65) 
3 and 6 MR + education+ 
Physiotherapist 
guided exercise 
297 pharmacist-patient 
follow ups  were 
performed over 6 months 
resulting in 355 
recommendations to 
patients’ primary care 
physicians (4.8 
recommendations/patient)  
Yes 
*Two intervention groups in trial. ** The second intervention group also received medication review as part of intervention. Data for only one 
intervention group is presented here. I-RCT=Individual randomised controlled trial, C-RCT= Cluster randomised controlled trial, MR= 
Medication review, GP=General Practitioner, I=Intervention group, C=Control group.
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3.4.3 Risk of bias  
Three trials (Marra et al., 2012, Hay et al., 2006, Gammaitoni et al., 2000) 
described adequate methods for random sequence generation (Figure 3.4). Hay 
et al. (2006) used a random number generator which allocated the participants 
in intervention and control groups in pre-determined sequence blocks of six by 
general practice.  The study statistician generated values from a uniform (0, 1) 
distribution in the Marra et al. (2012) study and a computer programme was 
used to randomly assign the names to either the intervention group or the 
control group in the Gammaitoni et al. (2000) trial. However, Gammaitoni et al. 
(2000) did not describe how the selection of 107 patients from pain clinics was 
undertaken prior to this random allocation to groups. Methods of random 
sequence generation were not adequately explained by Bruhn et al. (2011a) 
and Hoffman et al. (2008). Only Hay et al. (2006) described an adequate 
method of allocation concealment (sequentially numbered opaque envelops). 
Since Marra et al. (2012) and Hoffmann et al. (2008) were cluster randomised 
trials, allocation concealment was not possible and is not considered an issue 
(Higgins and Green, 2011).  
In all the trials, it was impossible to blind pharmacists delivering the 
intervention and the participants receiving it due to the nature of intervention. 
However, it would have been possible to blind outcome assessors of the 
allocation of participants to minimize detection bias. Outcome assessors were 
blinded in two trials only (Marra et al., 2012, Hay et al., 2006). Hoffmann et al. 
(2008) collected data through a computer aided, standardised telephone 
interview but it was not made clear whether people who handled and analysed 
the data were blinded or not. 
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All trials (Hay et al., 2006, Marra et al., 2012, Hoffmann et al., 2008, 
Bruhn et al., 2011a) except one (Gammaitoni et al., 2000) used the intention to 
treat principle for analysing their data thus minimizing attrition bias. There was 
low risk of selective reporting of an outcome across four trials (Hay et al., 2006; 
Marra et al., 2012; Hoffmann et al., 2008; Gammaitoni et al., 2000) and unclear 
risk in one of the trials (Bruhn et al., 2011a). Although, the study protocol was 
available for only one study (Marra et al., 2012), the decision was made to 
assign low risk to other trials based on the fact that the authors reported 
outcomes with non-significant P-values as well. 
 
Figure 3.4. Risk of bias in included trials across each domain 
 
There were no baseline differences between intervention and control 
groups in any of the trials except one (Marra et al., 2012). In the Marra et al. 
(2012) trial, there were significant differences at baseline in pain scores 
measured by the Health Utilities Index-3, a generic instrument to measure 
quality of life, between intervention and usual care groups but there were no 
significant differences in pain scores when measured by the Western Ontario 
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Baseline differences
Invalid questionnaires
Loss of clusters
Appropirate statistical analysis (Cluster RCTs)
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
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and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale. 
Furthermore, participants in the intervention group were slightly more educated 
(86% reported more than high school education compared to 79%), belonged to 
higher socioeconomic class (71% reported an income over $50,000 compared 
to 59%) and were of Asian origin (21% compared to 9%) compared with the 
usual care group. 
Only one patient was lost to follow up in each group in the Marra et al. 
(2012) study and the authors took “clustering” into consideration in sample size 
calculation and data analysis. However, in the cluster randomised controlled 
trial by Hoffmann et al. (2008), the authors did not use appropriate statistical 
techniques and did not allow for the clustering effect in sample size calculation 
and data analysis. 
 
 
 
 
75  
 
 
Figure 3.5. Risk of bias across individual trials.          = unknown risk,  
      = high risk           = low risk 
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3.4.4 Outcomes assessment 
3.4.4.1 Pain intensity 
Pan intensity was reported in the all the trials but used different scales. 
Gammaitoni et al. (2000) measured pain intensity on a 0 to 10 numerical rating 
scale where 0 = no pain and 10 = pain as bad as you can imagine as part of the 
Pharmacotherapeutic Pain Inventory (PhPI), a survey instrument derived from 
the Brief Pain Inventory (Cleeland and Ryan, 1994) and the Health Background 
Questionnaire-Initial Patient Visit (Gallagher, 2000). Hay et al. (2006) reported 
pain intensity on a 0 to 10 numerical rating scale where 0 = no pain and 10 = 
pain as bad as you can imagine and on a 0 to 20 subscale of WOMAC 
(Bellamy, 1996). Bruhn et al. (2011b) assessed pain intensity using the pain 
intensity subscale of the chronic pain grade questionnaire (CPG), a 7-item 
questionnaire to measure pain intensity, severity and functional disability (Von 
Korff et al., 1992). Marra et al. (2012) measured pain intensity on a 0 to 10 pain 
subscale of WOMAC while Hoffman et al. (2008) measured it on a 1 to 10 
numerical rating scale where 1 = no pain and 10 = pain as bad as you can 
imagine. Although pain intensity was measured using different scales in 
Gammaitoni et al. (2000), Hay et al. (2006) and Mara et al. (2012), all the scales 
ranged from 0 to 10 where 0 = no pain and 10 = pain as bad as you can 
imagine. 
Of the five trails, four reported statistically significant reduction in pain 
scores at follow-up (Hay et al., 2006, Hoffmann et al., 2008, Bruhn et al., 2011b, 
Marra et al., 2012). Gammaitoni et al. (2000) reported a reduction in pain scores 
which was not statistically significant (p=0.67) at 3-month follow up. Although, 
Hay et al.  (2006) reported a statistically significant reduction in pain scores at 3-
month follow-up (p=0.04), the pain scores were statistically non-significant at 6 
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(p = 0.3) and 12 months (p=0.5). However, Marra et al. (2012) reported a 
statistical significant reduction at both 3 and 6 months follow-ups (both p<0.05). 
In the study by Hoffmann et al. (2008), there was a significant reduction in 
‘untreated’ pain intensity in both intervention (p<0.001) and control group 
(p<0.001); however, reduction in ‘treated’ pain intensity remained non-
significant in both intervention (p=0.52) and control groups (p=0.92) at 4-month 
follow-up. 
Pain scores were pooled using meta-analysis. Since the study by 
Hoffmann et al. (2008) involved patients with chronic headache and migraine it 
was deemed clinically heterogeneous and not combined statistically. The data 
reported by Bruhn et al. (2011b) were insufficient for meta-analysis. Therefore, 
data from three RCTs only were pooled statistically. As described earlier, pain 
intensity was measured on different scales therefore the standardised mean 
difference (SMD) and corresponding standard error was calculated for each of 
the three studies. For the purpose of meta-analysis, change in score from 
baseline rather than final score was used as the former is  more efficient and 
powerful as it eliminates between-person variability (Higgins and Green, 2011). 
But if the ‘adjusted’ change in score derived from regression model accounting 
for baseline measurements was reported, it was preferred over the crude 
change in score to calculate SMD, as statistically, adjusted scores are 
considered most precise and least biased (Higgins and Green, 2011). Meta-
analysis was undertaken at 3 and 6 month follow-ups. 
Compared to the control group, there was a significant reduction in pain 
intensity in the intervention group with SMD of – 0.37 (95% confidence interval - 
0.58, - 0.16) (Figure 3.6). This corresponds to a 0.83 point reduction on a 0 to 
10 numerical rating scale where 0=no pain and 10 pain as bad as you can 
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imagine (95% confidence interval -1.28, - 0.36). There was no heterogeneity in 
the result (I
2
=0%). Only two studies (Hay et al., 2006, Marra et al., 2012) 
reported pain intensity at 6-months. At 6 months, there was also a significant 
reduction in pain intensity in the intervention group compared to the control with 
SMD – 0.31 (95% CI -0.53, - 0.09) corresponding to a 0.7 point reduction on a 0 
to 10 numerical rating scale (95% CI -1.19, - 0.20). There was slight 
heterogeneity in the result (I
2
=39%) [Chi
2
=1.64, df=1, p=0.20] which is 
statistically considered non- significant (Higgins and Green, 2011).  
3.4.4.2 Physical functioning 
Physical functioning was assessed as an outcome measure in all the 
studies. Marra et al. (2012) and Hay et al. (2006) assessed physical functioning 
using a 0 to 10 and 0 to 68 physical functioning subscale of WOMAC 
respectively (Bellamy, 1996). Higher scores on the WOMAC subscale 
represented worse (limited) physical functioning. Hoffmann et al. (2008) and 
Bruhn et al. (2011b) used the physical health subscale of SF-36 (Ware and 
Sherbourne, 1992) and SF-12 (Ware Jr et al., 1996)  respectively to assess 
physical functioning. Gammaitoni et al. (2000) assessed pain interference with 
various daily activities (general activity, mood, waking, normal work, 
relationships, sleep and enjoyment of life) as part of PhPI, a survey instrument 
derived from the BPI (Cleeland and Ryan, 1994) and the Health Background 
Questionnaire-Initial Patient Visit (Gallagher, 2000). But instead of reporting a 
recommended summary score calculated from these seven interference items 
(Cleeland and Ryan, 1994), the authors reported each item individually.  
Marra et al. (2012) reported a statistically significant improvement in 
physical functioning at 3-months [-0.65; 95% CI (-1.20 to -0.10)] and 6-months [-
0.84; 95% CI (-1.45 to -0.24)] in the intervention group compared to the control. 
79  
 
Hay et al. (2006) reported a non-significant improvement in functioning at 3- 
months [-2.12; 95%CI(-0.5 to 4.8)], 6 months [-0.96 ; 95% CI(-4.0 to 2.1)] and 
12 months [-0.39; 95% CI (-3.8 to 3.0)]  in the intervention group. Compared 
with the control group, Gammaitoni et al.  (2000) reported non-significant 
improvement in pain interference with mood (p=0.07), general activity (p=0.37), 
walking (p=0.92), work (p=1.00), relationships (p=0.72), sleep (p=0.62) and 
enjoyment of life (p=0.76) at 3-months follow up. Similarly, Hoffmann et al 
(2008) reported a non-significant improvement in physical health (p=0.85) at the 
end of the 4-month study period. Bruhn et al (2011b) also reported a non-
significant improvement in physical health (p=0.75) at 6-months follow-up.  
Data were pooled using meta-analysis for three studies excluding 
Hoffman et al. (2008) for clinical heterogeneity and Bruhn et al. (2011b) for 
insufficient data. Meta-analysis was undertaken at 3 and 6 months follow-up.  At 
3-month follow-up there was a statistically significant improvement in the 
intervention group with SMD of -0.38 (95% CI -0.58, -0.18) compared to the 
control group (Figure 3.7). This effect is equivalent to 4.84 points (95% CI -7.38, 
-2.29) on a 0 to 68 point function subscale of WOMAC. There was no 
heterogeneity in the result (I
2
=0%). Only two trials (Marra et al., 2012, Hay et al., 
2006) reported physical functioning status at 6-months. Meta-analysis showed a 
significant improvement in physical functioning at 6-month follow-up as well in 
the intervention group compared to the control group with SMD -0.30 (95% CI -
0.51,- 0.09) corresponding to -3.82 points (95% CI -6.49, -1.14) on WOMAC 0 
to 68 function subscale. There was non-significant heterogeneity in the result 
(I
2
=33%). 
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3.4.4.3 Patient satisfaction 
Three studies (Gammaitoni et al., 2000, Hay et al., 2006, Bruhn et al., 
2011b) reported patient satisfaction as an outcome. Gammaitoni et al.  (2000) 
assessed patient satisfaction with different components of the service using the 
Treatment Helpfulness Questionnaire (THQ), a validated measure to assess 
patient satisfaction with chronic pain management service (Chapman et al., 
1996). The questionnaire was modified to include measures regarding 
satisfaction with the pharmaceutical care programme. The questionnaire 
assessed satisfaction with the following components of the programme: access 
to medication, pharmacy service, delivery of medication, pharmacist phone 
calls, time spent obtaining medications, pharmacist medication counselling and 
information provided by the pharmacist. Each item was ranked on a 11 point 
scale ranging from -5 (extremely harmful) to +5 (extremely helpful). Hay et al. 
(2006) assessed satisfaction as a dichotomous outcome (satisfied, not 
satisfied). In the case of Bruhn et al. (2011b), patient satisfaction was reported 
in another linked abstract by Bond et al. (2011). Patient satisfaction was 
assessed at the end of 3 months using Likert scale ratings of statements about 
their pain and pharmacist consultation, and open ended questions on good and 
bad things about pharmacist consultations (Bond et al., 2011).  
In the Gammaitoni et al. study (2000),  patients in the intervention group 
were significantly more satisfied with various components of the pharmaceutical 
care programme including pharmacy service (p=0.001), delivery of medication 
(p=0.001), pharmacist phone calls (p=0.003), time spent in obtaining 
medications (p<0.001), pharmacist medication counselling (p=0.003), and 
information provided by the pharmacist (p=0.013). However, there was no 
significant difference in satisfaction with the whole programme domain (p=0.72) 
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of the patient satisfaction survey.  In the control group, patients were not 
significantly satisfied with any component of the service except for psychological 
assessment and treatment (p<0.05). It should be noted here that Gammaitoni et 
al. (2000) only compared the difference in patient satisfaction from baseline to 
3-month study period in both intervention and control groups independently, but 
did not compare control with the intervention group. In the Hay et al. study 
(2006), compared to the control group, patients in the intervention group were 
significantly more satisfied  with the received treatment at 3-month [-20%; 95% 
CI (-33 to -6)] and at 12-months-[-19%; 95%CI (-32 to -4)] follow-up but not at 6-
month [-14%; 95%CI (-28 to 1)]. Bond et al. reported that 85% (38/46) of the 
patients in the prescribing arm were totally satisfied with the received treatment. 
Patient satisfaction rates were not reported for the other intervention 
(medication review alone) and control groups. 
Data for patient satisfaction were pooled for two studies only (Figure 
3.8). Meta-analysis showed significant patient satisfaction in the intervention 
group compared to the control group with SMD -0.39 [95% CI (-0.68, -0.10)]. 
Using the universal rule of thumb, this effect size corresponds to ‘small to 
moderate effect’ (Cohen, 1988, Higgins and Green, 2011).  
3.4.4.4 Quality of life 
Three studies assessed quality of life (QoL) (Marra et al., 2012, Hoffmann 
et al., 2008, Bruhn et al., 2011b). Hoffmann et al. (2008) assessed quality of life 
using the Medical Outcomes General Health Survey (SF-36). While Bruhn et al. 
(2011b) assessed QoL using SF-12, a validated shorter version of SF-36. Marra 
et al. (2012) assessed QoL using WOMAC (global) and Health Utilities Index-3 
(HUI-3), a generic and preference-scored instrument for measuring health 
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status and health related quality of life. Higher scores on HUI-3 indicate better 
health. 
In the Hoffmann et al. (2008) trial, compared to the control group, there 
was no significant difference in the intervention group in the physical health 
subscale  (p=0.85) of SF-36 but a statistically significant difference  was found 
in the mental health subscale (p=0.02) of SF-36 at the end of the 4-month study 
period.  Similarly, Bruhn et al. (2011a) reported a significant improvement in the 
mental health component of SF-12 (p=0.04) but not on the physical health 
component (p=0.75) at 6-months follow-up.  Marra et al. (2012) reported a 
significant improvement in WOMAC (Global) at 3-months  [-1.99; 95% CI (-3.45, 
-0.54)] and 6-months [-2.40; 95% CI (-4.10,-0.71)] in the intervention group 
compared to the control. However, HUI-3 failed to measure significant 
differences in QoL between the intervention and control group at 3-months 
[0.04; 95% CI (-0.03, 0.12)] and 6-months [0.01; 95%CI (- 0.06, 0.10)]. 
Meta-analysis was not undertaken as clinical heterogeneity and 
insufficient data ruled out Hoffmann et al. (2000) and Bruhn et al. (2011a) 
studies respectively. 
3.4.4.5 Adverse effects 
Surprisingly, none of the studies except Phelan et al. (2008), linked to 
the Hay et al. (2006) trial, reported adverse effects.  The authors reported 
adverse effects in 30 patients including constipation (10), drowsiness (8), gastro 
intestinal upset (8) and others (4) from prescribed analgesics at the initial 
consultation.  During follow-up the side effects were reduced or stopped in 25 
patients by altering, adding or substituting their medication. The remaining five 
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patients continued with their medication unchanged as the medications were 
effective and the side effects were tolerable.  
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   Figure 3.6. Meta-analysis of pain intensity at 3-month and 6-month  
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          Figure 3.7. Meta-analysis of physical functioning at 3-month and 6-month  
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         Figure 3.8. Meta-analysis of patient satisfaction at 3-month
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3.5 Discussion 
3.5.1 Main results 
The search strategy identified five studies which met the inclusion criteria 
including three individually-randomised (Gammaitoni et al., 2000, Hay et al., 
2006, Bruhn et al., 2011a) and two cluster-randomised controlled trials 
(Hoffmann et al., 2008, Marra et al., 2012). The ‘grey-literature’ was not 
searched and studies published only in the English language were included in 
the systematic review. The potential implications of restricting the searches to 
databases and websites, and English language are discussed in the limitations 
section (section 3.6). Pharmacists delivered interventions in different settings 
such as community pharmacies (Hoffmann et al., 2008, Marra et al., 2012), 
general practices (Hay et al., 2006, Bruhn et al., 2011a) and university pain 
clinic (Gammaitoni et al., 2000) indicating that the intervention can potentially be 
delivered in multiple settings. Furthermore, the included trials involved patients 
with various chronic pain aetiologies, demonstrating that the pharmacist-led 
medication review may be effective for different types of chronic pain conditions.  
Two trials originated from the UK (Hay et al., 2006, Bruhn et al., 2011a) 
and one each from the USA (Gammaitoni et al., 2000), Canada (Marra et al., 
2012) and Germany (Hoffmann et al., 2008) indicating that there is growing 
interest in evaluating the role of pharmacists in chronic pain management in the 
developed world. This may be due to the high disease burden of chronic pain 
and a growing necessity to involve other healthcare professionals such as 
pharmacists and nurses actively in direct patient care to reduce the workload on 
general practitioners (GPs)/primary care physicians (PCPs) in these countries. 
A survey conducted among GPs in the UK reported that the GPs were 
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dissatisfied with their management of chronic pain patients and they were 
worried about the long waiting time for secondary care appointments (Stannard 
and Johnson, 2003). Therefore, the growing number of independent nurse and 
pharmacist prescribers can potentially fill this gap and improve patient care, 
especially for chronically ill patients. 
The risk of bias was assessed for all of the included studies. There was 
low or unclear risk of bias across all the domains except for blinding of 
participants and personnel where there was high risk of bias across all trials. 
Due to the nature of the intervention, it was practically impossible to blind the 
pharmacists conducting medication reviews and the patients receiving them as, 
in most instances, the medication review was conducted face-to-face. Although 
the nature and mode of delivery of intervention prevented blinding of 
participants and personnel, outcome assessors were blinded in two of the three 
trials involved in the meta-analysis, and in the third trial the outcome 
assessments were carried out using a standardised computer aided interview 
minimising detection bias. The research evidence suggests that, on average, 
lack of blinding in RCTs is associated with a 9% increment in the intervention 
effect when measured as odds ratio (Pildal et al., 2007).  Trials with more 
subjective outcomes, such as pain trials, are likely to be affected more than 
those which measure objective outcomes (Wood et al., 2008). Concealment of 
allocation is necessary to limit selection bias but allocation concealment may 
not be possible for cluster-randomised controlled trials. Among the included 
trials, only one study by Hay et al. (2006) described adequate method for 
concealment of allocation (opaque envelopes). However, treatment allocation 
was disclosed to study nurse by 15 of 325 participants (4.6%). A meta-
epidemiologic study of 16 meta-analyses involving osteoarthritis patients 
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reported statistically significant differences in effect sizes in 46 trials with 
adequate allocation concealment compared with 112 trials with inadequate or 
unclear concealment of allocation (difference -0.15; [95% CI, -0.31 to 0.02]) 
(Nüesch et al., 2009). However, there was no statistically significant difference 
in effect sizes in trials involving non-pharmacological interventions -0.05 [95% 
CI (-0.22 to 0.12)] (Nüesch et al., 2009). 
Clinical homogeneity was considered before pooling data statistically. 
Data from a study by Hoffmann et al. (2008) were not considered for meta-
analysis as the study involved patients with chronic headache and migraine, 
which is a neurological condition and has an episodic nature (National Institite of 
Neurological Disorders and Stroke, 2012) unlike other chronic pain conditions. 
Furthermore, it requires a different therapeutic approach. The full report of 
Bruhn et al. (2011a) study was not available at that time and the data reported 
in conference abstracts (Bond et al., 2011, Bruhn et al., 2011a, Bruhn et al., 
2011b) was not enough to be pooled statistically. The corresponding author was 
contacted to obtain additional data but unfortunately the author declined the 
request due to restrictions by the funding agency.  Other trials were relatively 
similar in terms of nature of intervention, patient follow-up and patients’ pain 
scores. Meta-analysis was conducted at two time points; 3-months and 6-
months because the studies included in the systematic review reported follow-
up results ranging from 3-months to 12-months. Combining short with long term 
trials is not recommended as it produces larger treatment effect than combining 
longer term trials alone (Moore et al., 2010a).  Furthermore, the response to 
placebo tends to be larger in longer trials (Quessy and Rowbotham, 2008) and 
research evidence also suggests that the efficacy of interventions, especially of 
less effective interventions decrease over 2-12 weeks (Moore et al., 2010b). 
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Therefore, meta-analysis was conducted at two time points to limit any bias 
arising from combining short-term trials with long-term trials.  
The included trials measured the same outcomes using different scales 
therefore data were pooled using SMD for each outcome. The potential problem 
with SMD is that it expresses the intervention effect in standard units rather than 
the original units of measurement making clinical interpretations difficult for 
patients and practitioners (Higgins and Green, 2011). To interpret SMD, in line 
with the Cochrane’s guidance (Higgins and Green, 2011), it was re-expressed in 
the units of a specific measurement scale for two of the three outcome 
measures that were statistically combined, pain intensity and physical 
functioning. This was achieved by multiplying SMDs for pain intensity and 
physical functioning with the standard deviation of the numerical rating scale (0 
to 10) and physical functioning subscale of WOMAC (0-20) respectively. Both of 
the standard deviations were obtained as pooled standard deviations of 
baseline scores from the Hay et al. study (2006). Only the summary measure of 
effect was back-transformed to enhance clinical interpretation. For the third 
outcome measure, patient satisfaction, SMD was re-expressed using rules of 
thumbs for effect sizes (Cohen, 1988, Higgins and Green, 2011) as one of the 
trials (Hay et al., 2006) measuring patient satisfaction reported it as 
dichotomous outcome measure and the other trail (Gammaitoni et al., 2000) 
used an adapted and modified version of a validated questionnaire  thus 
compromising its validity and reliability .  
Meta-analysis showed that there was a statistically significant reduction 
in pain intensity and statistically significant improvement in physical functioning 
in the intervention group compared to the control group. However, the clinical 
significance of these findings is arguable and needs careful consideration. The 
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use of average results of continuous data (e.g. pain intensity) can be misleading 
(McQuay et al., 1996) as it is argued that the population distributions of pain 
scores and/or pain relief are usually ‘U-shaped’ (as opposed to being normally 
distributed) therefore patients tend to have either very good or very poor pain 
relief. Consequently, it has been suggested that pain scores/pain relief should 
be reported as percentage of patients responding to the treatment instead of 
average pain scores to reflect the actual number of patients who have improved 
or deteriorated. All the trials included in the systematic review reported average 
pain scores only rather than reporting percentages of patients responding to the 
treatment. As a result, making clinical recommendations about the effect size of 
the effectiveness of the pharmacist-led medication review in chronic pain 
management is difficult due to the nature of reported data. The evidence from 
the meta-analysis indicates potential benefit for patients; however, there is 
uncertainty around the clinical significance of this benefit which limits wider 
clinical implementation. Furthermore, medication review was conducted as part 
of multi-component interventions in three of the five included studies and 
consequently, the “active ingredient” of the intervention is not known. However, 
the impact of the intervention on other drug-related outcomes such as the 
reduction in side effects documented by Phelan et al. (2007) linked to Hay et al. 
(2006), the reduction in the use of non-steroidal anti-inflammatory drugs 
documented by Hay et al. (2006) and the high acceptance of pharmacists’ 
recommendations as documented by Gammaitoni et al. (2000), Hoffmann et al. 
(2008) and  Marra et al. (2012) suggest that pharmacist-led medication review is 
an important component in overall pain management and can improve patient 
reported outcomes. 
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3.5.2 Implications for pharmacy practice and policy 
Medications are widely used in chronic pain management with two-thirds 
of chronic pain patients receiving prescription medicines and half of them taking 
non-prescription medicines (Breivik et al., 2006). Therefore, the safe and 
effective use of analgesics is critical to ensure optimum analgesia, prevention of 
adverse effects and drug related problems, and abuse of analgesics. In the 
USA, in 2007, almost 12,000 cases of unintentional drug poisoning involved 
prescription analgesics (Centers for Disease Control and Prevention, 2010) and 
in 2008, 14,800 people died due to overdoses of opioid analgesics (Centers for 
Disease Control and Prevention Analysis: Morbidity and Mortality Weekly 
Report (MMWR), 2011). The report also suggested that, in 2009, misuse and/or 
abuse of prescription analgesics resulted in more than half a million emergency 
Department visits (Centers for Disease Control and Prevention Analysis: 
Morbidity and Mortality Weekly Report (MMWR), 2011). Given these alarming 
negative consequences of inappropriate use of analgesics and the potential for 
abuse of opioid analgesics, regular review of medicines is important to optimise 
pain relief whilst ensuring safe use of analgesics. 
With the advancement of the concept of pharmaceutical care (Mikeal et 
al., 1975), the focus of pharmacist-led services has shifted from being product-
centred to patient-centred.  A number of pharmacist-led services have been 
developed both in hospital and community settings to improve patient care. 
Research evidence to support the effectiveness for such services is critical for 
their sustainability. The present systematic review has identified and 
synthesised data which demonstrates the effectiveness of pharmacist-led 
medication review in chronic pain management. The findings have raised two 
questions which need to be considered by service commissioners and policy 
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makers before a wider role for pharmacists in chronic pain management is put 
into practice. Firstly, certain issues related to delivery of the intervention such as 
‘how much’, how often’, ‘how long’, must be carefully considered as limited 
exposure to the service may not be adequate to achieve desired outcomes and 
prolonged use of the service may not be cost-effective and may put an 
additional burden on healthcare systems. Furthermore, it is still unknown 
whether the pharmacist-led medication review benefits all types of chronic pain 
patients or only certain types of patients. However, it can be argued that 
medication review by an expert pharmacist should be able to reduce drug-
related problems and adverse effects in all patients irrespective of the pain 
aetiology. Secondly, short-courses/programs/residency training must be 
developed to provide specialised education and training in pain management to 
all the pharmacists in order to achieve maximum clinical benefit. In the past, the 
need for specialised training programmes has also been advocated in the 
literature (LaPerriere, 1994). However, to date, such training programmes are 
not widely available for pharmacists especially outside the USA. Some 
examples include specialised pain management residency programmes for 
pharmacists in the USA (Departmant of Pharmacy, 2012)  with palliative care as 
a key focus area and pharmacotherapy traineeship in pain management among 
geriatric patients offered by American Society of Consultant Pharmacists 
(ASCP) Foundation (2012). Some universities in the UK also offer ‘generic’ 
postgraduate programmes (MSc/Post-Graduate Diploma) and short courses (2-
3 days) in pain management but no specialised training programmes for 
pharmacists are currently available in the UK. Training programmes to produce 
skilled pharmacy human resource in pain management is essential to ensure 
sustainability and clinical effectiveness of pharmacist-led pain management 
service.  
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With regard to the developing countries, the findings of the systematic 
review may not be transferable as the pharmacy profession is undergoing 
transition from ‘industry-oriented’ to ‘patient-oriented’. Over the past decade, 
changes in undergraduate curriculum have been made together with the 
development of clinical oriented postgraduate programs (Hadi et al., 2010) to 
equip pharmacists with necessary clinical knowledge to meet growing needs of 
the patients (Hadi, 2010, Hadi and Awaisu, 2010). However, there is still a long 
way to go before these changes can make significant impact in transforming 
pharmacy practice and relevant polices in these countries. 
3.5.3 Implications for future research 
High prevalence of chronic pain and its associated burden on healthcare 
systems and societies across the globe calls for high quality research to 
improve both diagnosis and management of chronic pain. However, the 
literature suggests that research into chronic pain is not well funded  (The 
Mayday Fund Special Committee on Pain and the Practice of Medicine, 2009). 
In 2008, in the USA, less than one percent of National Institutes of Health (NIH) 
budget was given for pain research (National Institues of Health, 2008). 
Underfunding of pain research is concerning and it may damage initiatives to 
improve pain management due to a lack of research evidence. A survey in the 
USA reported that almost six in ten adults (57%) were willing to pay one dollar 
more per week in taxes to increase federal funding for the research into pain.  
The purpose of a systematic review is not only to synthesise research 
evidence but also to identify the limitations of current knowledge and propose 
directions for future research (Higgins and Green, 2011). The role of 
pharmacists in chronic pain management is still relatively new and requires 
further exploration. The current evidence suggests that pharmacist-led 
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medication review is effective in reducing pain intensity, medication-related 
adverse effects and improve physical functioning. Future research must 
evaluate the optimum and cost-effective mode/method and duration of delivery 
of the intervention to achieve maximum clinical benefit. Standardisation of the 
intervention may not be possible due to the individualised needs of the patients 
especially those taking opioid analgesics may need a more frequent medication 
review to limit abuse and ensure safety.   
There is a need to improve the quality of reporting of clinical trials 
involving chronic pain patients. In addition to CONSORT guidance  on the 
conduct and reporting of clinical trials (Moher et al., 2010), the  researchers 
should also adhere to the Initiative on Methods, Measurement, and Pain 
Assessment in Clinical Trials (IMMPACT) guidance (Turk et al., 2003, Dworkin 
et al., 2005, Moore et al., 2010a) in designing, conducting and reporting their 
findings. The IMMPACT group has developed consensus reviews and 
recommendations for improving the design, conduct, reporting and 
interpretation of clinical trials of treatments for pain. A list of core outcome 
domains and their respective measurement scales have also been developed to 
allow meaningful comparisons among different patient populations, treatments 
and settings (Turk et al., 2003).  As discussed earlier, the researchers instead of 
reporting average pain scores only should always report percentages of patients 
achieving minimally important, moderately important and substantial clinical 
difference in accordance with the recommendations of IMMPACT group 
(Dworkin et al., 2008).  
Trials involving only non-malignant pain patients were included as the 
inclusion of trials involving cancer pain would have introduced clinical 
heterogeneity and complicated clinical interpretation of the findings.  It would be 
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interesting to evaluate the effectiveness of pharmacist-led medication review 
among patients with cancer pain as effective management of cancer pain is 
very important in overall cancer management, especially in end of life care. 
Finally, the cost-effectiveness of pharmacist-led medication review in chronic 
pain management is yet to be evaluated. In the present global financial 
environment, healthcare systems across the world are taking measures to 
reduce healthcare costs and data demonstrating cost-effectiveness of an 
intervention is important in the commissioning of services.  
3.6 Limitations 
In terms of the design of the systematic review there were two major 
limitations. Firstly, studies reported only in English language were included in 
the systematic review, which might have led to language bias (Moher et al., 
1996). One study (Marti et al., 2005) was excluded during screening of full-texts 
of included studies as it was published in the Spanish language. However, 
conflicting results have been reported in the literature examining the extent of 
the effect of language bias on the findings of the systematic review (Higgins and 
Green, 2011). In a study, Jüni et al. (2002) reported that trials published in non-
English languages were more likely to produce significant results and, on 
average, the intervention effects were 16% (95%CI 3% to 26%) greater in these 
trials compared to trials published in English. On the contrary, Moher et al. 
(2003) did not report any significant effect of excluding non-English trials on the 
results of meta-analysis. Furthermore, Galandi et al. (2006) reported a decline 
in publishing clinical trials in German-language indicating a shift from using non-
English language to English-language in disseminating clinical trials.  It was 
decided during protocol development not to include non-English studies as the 
review team lacked expertise in translating non-English studies in English and 
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had no funds to hire services of professional translators. Secondly, publication 
bias may have been introduced as no attempt was made to locate unpublished 
trials (grey literature).  The findings of the research evaluating the impact of 
inclusion or exclusion of ‘grey’ literature in meta-analysis of RCTs are 
inconsistent.  Hopewell et al. (2007) in a review reported, on average, a 9% 
larger intervention effect in published trials than grey trials. The problems 
associated with the inclusion of unpublished trials include (Higgins and Green, 
2011): difficulty in locating such studies, data acquisition from the study 
investigators, and absence of peer-review. Furthermore, the methodological 
quality of unpublished trials has been reported to be lower than published trials 
in terms of allocation concealment and blinding outcome assessment (Egger et 
al., 2003). On the contrary, Hopewell et al. (2004) did not find such 
methodological limitations. The major issue with data acquisition is that only 
investigators with positive results may be willing to share their results which may 
introduce bias in to the systematic review. Finally, the located studies may only 
be a small part and ‘unrepresentative’ (Page 309) of all the unpublished studies 
(Higgins and Green, 2011). Systematic review authors in future may consider 
including studies published in non-English languages and unpublished studies 
to overcome the above mentioned limitations. 
3.7 Conclusion 
Pharmacists can play an important role in improving chronic pain 
management. Pharmacists can deliver interventions independently and as part 
of multidisciplinary teams in both community and hospital settings. The present 
systematic review suggests that pharmacist-led medication review is effective in 
reducing pain intensity and improving physical functioning. Furthermore, 
patients were generally satisfied with the service provided by the pharmacists. 
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There is also weak evidence of preventing/stopping adverse effects associated 
with the use of medicines among chronic pain patients. The clinical significance 
of these findings remains to be established. Future clinical trials evaluating the 
effectiveness of pharmacist-led interventions in chronic pain must adhere to the 
IMMPACT guidance (Turk et al., 2003, Dworkin et al., 2005) in designing, 
conducting and reporting their findings in addition to the CONSORT guidance 
(Moher et al., 2010). This will ensure selection of the recommended uniform 
outcome domains and measures, and quality reporting of the trial results 
facilitating not only clinical interpretation but also data synthesis in future.  As 
the focus of care shifts from secondary to primary care,  pharmacists especially 
community pharmacists have the potential to reduce the chronic pain burden on 
healthcare system and society by ensuring the safe and effective use of 
medicines. 
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CHAPTER 4                                                          
METHODOLOGY 
4.1 Introduction 
This chapter outlines the research methodology used to guide this research 
project and answer the research questions related to the second aim of the 
research presented in this thesis. The chapter begins with a brief introduction to 
various research methodologies commonly used in healthcare research. Then 
the strengths and weaknesses of these methodologies are discussed and in 
particular, mixed-methods. Following that, the selection of a particular mixed-
methods design for the present study is also debated and justified. 
Whilst conducting the literature review for the present study, the author 
found that mixed-methods designs are infrequently used by pharmacy practice 
researchers and recognised a need to advocate the use of mixed-methods 
research in pharmacy practice. Furthermore, the quality of reporting of mixed-
methods research was also deemed to be suboptimal. Consequently, two 
papers highlighting various aspects and challenges of mixed-methods research 
and a framework to improve its reporting were published in a peer reviewed 
journal (Hadi et al., 2013, Hadi et al., 2014).  
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4.2 Research methodology 
Research methodology is an approach to systematically solve/answer 
the research problem/question and it may be considered as the science of 
exploring how research is conducted scientifically (LINGAYAS Institute of 
Management and Technology, 2012). Broadly, there are three research 
methodologies available to researchers in health sciences namely qualitative, 
quantitative and mixed-methods. A number of research designs are available 
within these three methodologies. There are specific philosophical assumptions, 
advantages, applications and limitations associated with each research 
methodology. Therefore, the choice of a particular methodology should be 
based on the nature of the research question. In the following sections, each of 
these three methodologies and some important research designs within these 
methodologies are explained briefly.  
4.2.1 Qualitative research methodology 
There is little agreement between methodologists on a single definition of 
qualitative research, probably because qualitative research encompasses a 
diverse range of methods (Holloway, 2005). In general, qualitative research is a 
collection of interpretative methods which aim to describe, understand and 
explain people’s experience of a certain phenomenon with non-numerical data 
(Holloway, 2005, Denzin and Lincoln, 2005).  Qualitative research, in its 
structured form, was first used by sociologists and anthropologists in the early 
20
th
 century (Al-Busaidi, 2008). In healthcare research, after receiving 
significant criticism and resistance in the 1980’s and 1990’s, qualitative research 
is now widely used to inform healthcare practice and policy.  
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Qualitative inquiry, in contrast to quantitative inquiry, explores the 
meaning people attribute to their experiences and explains the process of  
social construction that shape these meanings (Popay, 1992).  There are four 
specific characteristics of qualitative research (Avis, 2005): Firstly, it obtains and 
analyses textual (interview transcripts, diaries, observation notes, photographs, 
videos) rather than numeric data. Secondly, since qualitative research aims to 
view the social world through participants’ eyes, it involves extensive interaction 
with the study population, referred to as ‘field work’ (Creswell, 2007). 
Engagement with study participants ensures that instead of merely studying the 
participants, the researcher learns from them (Spardley, 1979) and develops a 
common understanding. Thirdly, it has a ‘flexible plan of inquiry’ – the design 
evolves as the study progresses. Finally, it is ‘context bound’- it studies 
participants in their natural environment rather than experimental settings, 
referred to as ‘naturalism’. The researchers cannot disengage themselves from 
the research process and therefore constantly need to critically reflect on their 
own role in the process of generating data.  
There are at least forty different research designs under the umbrella of 
qualitative research (Tesch, 1990). It is beyond the scope of this thesis to 
provide a description of each of these methods. However, a brief introduction of 
a few methods which are important and relevant to healthcare research is 
described below.  
Phenomenology aims to describe the shared lived experiences of groups 
of individuals of a particular phenomenon rather than a single individual. 
Phenomenology advances a collective in-depth description of the essence of 
the experience of all the study participants (van Manen, 1990). The data 
analysis involves finding “significant statements” or quotes, a process called 
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horizonalisation. Researchers then develop themes from these statements and 
together with the statements, these themes provide a textual description of the 
experience. Alongside the textual description, a structural description is 
provided  that refers to context and settings that have influenced the 
experience. 
Grounded theory study, as the name indicates, aims to generate or 
discover a theory which is ‘grounded’ in the views of participants who have 
experienced the phenomenon (Strauss and Corbin, 1990). The development of 
theory provides an in-depth explanation of participants’ practices (Creswell, 
2007). The concept of grounded theory was proposed by Glaser and Strauss in 
1967 (Glaser and Strauss, 1967) but the authors later disagreed about the 
procedures of conduct of grounded theory research leading to the development 
of two variants of the grounded theory approach (Strauss, 1987, Glaser, 1992). 
Charmaz (2006) introduced another variant by proposing the concept of 
constructivist grounded theory. Creswell (2007) described data collection and 
analysis in grounded theory as a ‘zigzag’ process as it occurs simultaneously – 
the researcher undertakes fieldwork to collect data and then analyses it in the 
office, and then returns to the field to collect more data.  
 Ethnography aims to describe shared beliefs, views, values and 
behaviours of a culture sharing group (Harris, 1968). Data are often collected 
through participant observation and interviews and therefore, the researcher 
spends a significant amount of time with the group to understand their beliefs 
and cultural values. The concept of ethnography was first introduced in the early 
20
th
 century in the field of cultural anthropology (Creswell, 2007). There are 
many variants (types) of ethnography but the most commonly used are: realist 
ethnography (Van Maanen, 1988) and critical ethnography (Thomas, 1993). 
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Case study methodology has been defined in a number of ways and 
what constitutes a case study is also widely debated among researchers 
(Hammersley, 1992, Wolcott, 2002, Yin 2009). Yin defined case study as “an 
empirical inquiry about a contemporary phenomenon (e.g., a “case”), set within 
its real-world context—especially when the boundaries between phenomenon 
and context are not clearly evident” (Yin, 2009, P. 18). It involves studying a 
phenomenon in its context (e.g. traditional ethnographies). Broadly, there are 
two types of case studies, single case study and multiple case study. It typically 
involves multiple sources of evidence and data is collected through 
documentation, archival records, interviews, direct observations, participant 
observation and physical artefacts (Yin, 1994). Case studies, whether single or 
multiple, typically answer either a descriptive question (e.g. what is happening?) 
or an exploratory question (e.g. how or why something happened?). However, 
questions about the effectiveness of an intervention and prevalence are not best 
answered using case study design (Yin, 2009). Since the aim of the study was 
to investigate the effectiveness of the pain clinic and explore patients’ 
satisfaction with the service, case study was not considered suitable 
Qualitative description is not often described as a distinctive method in 
the literature (Sandelowski, 2000, Sandelowski, 2010) but it is widely used in 
practice disciplines (Sullivan-Bolyai et al., 2005, Julion et al., 2007, Van Hulle 
and Gaddy, 2009). This is probably because qualitative description draws 
heavily on the principles of phenomenology, ethnography and grounded theory, 
but compared to these traditional approaches it is less interpretative. However, 
as the name may suggest, it is not free of interpretation. Sandelowski (2000, 
P.335) described the interpretive nature of qualitative description as “All inquiry 
entails description, and all description entails interpretation.”  A variant of 
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qualitative description is ‘interpretive description’ (Thorne et al., 1997). 
Qualitative description, being the chosen qualitative design, is explained in 
detail later in the chapter. 
4.2.2 Quantitative research methodology 
Quantitative research uses statistical procedures to test a theory and 
relationship among the variables, measured in numbers, with an aim to 
establish or refute the generalizations of the theory (Creswell, 2003).  
Quantitative research designs have dominated healthcare research because 
their findings are often generalizable and they have the ability to address a wide 
range of clinical topics (e.g. risk factors, diagnosis, prognosis and treatment 
choice) through a systematic process. Quantitative approaches are often 
associated with a positivist worldview – that there is a ‘single reality’ which can 
be studied objectively. In contrast to qualitative research, the researcher 
remains independent of the research process and does not bring his values and 
beliefs into the research (Leedy and Ormrod, 2001, Creswell and Plano Clark, 
2011). The generation of knowledge is based on cause-and-effect, 
reductionism, comprehensive observations, measures of variables, and testing 
and refining of hypotheses and theories (Slife and Williams, 1995). Broadly, 
quantitative research designs are divided into observational and experimental 
designs.  
In observational studies, the researcher does not intervene in the care of 
the patient and only observes what happens (Seers and Critelton, 2001). There 
are three major types of observational studies: cross-sectional surveys, case-
control studies and cohort studies (Creswell, 2003). Cross-sectional surveys are 
mostly descriptive in nature and are undertaken at a single point in time or over 
a short period of time. Data are usually collected through structured 
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questionnaires. They are used to assess the burden of disease(s) and/or the 
health needs of a population and are particularly useful in informing the planning 
and allocation of health resources (Rothman, 2002). Case-control studies are 
typically retrospective as they look back in time to find an association, if any, 
between a previous exposure with an outcome of interest. Case-control studies 
are relatively quick, inexpensive, and easy to carry out. They are particularly 
appropriate for investigating disease outbreaks and studying rare diseases or 
outcomes (Rothman, 2002). Cohort studies are typically prospective as they 
follow-up individuals over time until the outcome of interest appears or the study 
time ceases. Since cohort studies involve patient follow-up over a long period of 
time, they are expensive and time-consuming. They are particularly useful in 
studying causes, natural history and prognosis of diseases (Rothman, 2002).  
In experimental studies, the researcher intervenes in the care of patients 
and evaluates the effectiveness of the intervention (Seers and Critelton, 2001). 
Experimental studies include quasi-experimental studies, controlled clinical trials 
(CCTs), and randomised controlled clinical trials (RCTs). The overall aim of 
experimental designs is to evaluate the effectiveness of an intervention.  
Controlled Clinical trials and randomised controlled trials are similar in terms of 
their design except that in RCTs the assignment of participants to control and 
intervention groups is random. RCTs are considered the gold standard for 
evaluating the effectiveness of healthcare interventions as they are considered 
the least biased (Rothman, 2002). Quasi-experimental designs, also known as 
“before-after intervention” and “pre-post intervention”, are also frequently used 
in healthcare research when conducting RCTs or CCTs is not possible (Harris 
et al., 2004). Quasi experimental studies may or may not have a control group. 
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Being the chosen design, quasi-experimental designs are discussed in more 
detail later in the chapter. 
4.2.3 Mixed-methods research methodology 
Since mixed-methods methodology has been used to guide this research,  
it is described in more detail. Mixed-methods research, as the term indicates, 
entails both qualitative and quantitative components. Although a number of 
definitions exist in the literature, what constitutes a mixed-methods study and, 
how and when qualitative and quantitative components should be combined 
remain open for debate. Tashakkori and Creswell (2007) defined mixed 
methods research as “research in which the investigator collects and analyses 
data, integrates the findings, and draws inferences using both qualitative and 
quantitative approaches or methods in a single study or program of inquiry 
(Page 4).” Johnson et al. (2007, P. 123) reviewed 19 definitions of mixed-
methods and concluded with the following definition: “Mixed-methods research 
is the type of research in which a researcher or team of researchers combines 
elements of qualitative and quantitative research approaches (e.g., use of 
qualitative and quantitative viewpoints, data collection, analysis, inference 
techniques) for the purposes of breadth and depth of understanding and 
corroboration.” It is noteworthy that mixed-methods research should not only be 
used as a tool to collect qualitative and quantitative data, but the two datasets 
should be meaningfully integrated (Creswell and Plano Clark, 2011). 
Mixed-methods research combines the strengths of the two 
methodologies to overcome their respective limitations. It allows researchers to 
choose and merge different methodologies to develop ‘the best possible 
method’ to comprehensively answer a specific research question (Creswell and 
Plano Clark, 2011). Mixed-methods research can potentially answer different 
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research questions within a single study that addresses the same research 
problem, but requires different methodologies. Nonetheless, if the research 
problem requires a mono-method study design to answer the question then it 
should be chosen bearing its limitations in mind.   
4.2.3.1 Typologies of mixed-methods research 
Broadly, mixed-methods designs are either fixed or emergent (Creswell 
and Plano Clark, 2011). In fixed designs, the use of qualitative and quantitative 
methods is pre-planned and executed accordingly. Emergent designs arise 
when data from a single method is insufficient to comprehensively answer the 
research question and a second approach (qualitative or quantitative) is added 
to an on-going study (Morse and Niehaus, 2009). Various classifications or 
typologies of mixed-methods designs exist in the literature (Greene et al., 1989, 
Greene, 2007, Tiddlie and Tashakkaori, 2009, Morse and Niehaus, 2009, 
Creswell and Plano Clark, 2011). However, it should be noted that no 
classification system is superior to another. Choosing an appropriate research 
design is one of the most complex and challenging issues in mixed-methods 
research (Teddlie and Tashakkori, 2006).  
Four basic mixed-methods research designs proposed by Creswell and 
Plano Clark (2011) are briefly described below. 
The Convergent parallel design also known as ‘current triangulation’ 
(Creswell et al., 2003), ‘simultaneous triangulation’ (Morse, 1991a), and ‘parallel 
study’ (Tashakkori and Teddlie, 1998),  involves conducting qualitative and 
quantitative components concurrently. Both components are given equal priority 
and are kept independent during data collection and analysis, and mixing 
occurs during interpretation. The convergent design is best suited for ‘obtaining 
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different but complementary’ data on the same topic (Creswell and Plano Clark, 
2011); overcoming weaknesses of one method; triangulating findings for 
confirmation and validation; and developing a complete understanding of the 
research problem.   
The explanatory sequential design involves two distinct interactive 
phases. In the first phase, quantitative data are collected, analysed and given 
priority in answering the research question. Following this, qualitative data are 
collected with the purpose of explaining the findings of the quantitative phase.  
The exploratory sequential design also has two distinct sequential 
phases. However, unlike the explanatory design, it prioritises qualitative data 
collection and analysis which occur in the first phase. The quantitative phase 
builds on the results of qualitative data analysis to test or generalize its findings.  
The embedded design was first described by Caracelli and Grenne in 
1989 (Greene et al., 1989). In embedded design there is one principal method 
(qualitative or quantitative) and it is given priority depending on the purpose of 
the research and the other method provides supportive data. Qualitative and 
quantitative data can be collected concurrently or sequentially. The embedded 
design is particularly useful when a single dataset is not sufficient and different 
questions requiring different methodologies need to be answered within a single 
study.  
Advanced mixed-methods designs include transformative design and 
multiphase design. In the following sections, first the rationale for choosing a 
mixed methods approach is presented and then the choice of embedded design 
is debated and justified in depth. 
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4.3 Rationale for choosing mixed-methods design 
The rationale for choosing a mixed-methods approach should always be 
presented since not all research problems require mixed-methods research 
methodology (Creswell and Plano Clark, 2007). The essence of mixed-methods 
research is to allow the research question to dictate the choice of the method 
rather than the inclination towards a specific “quantitative only” or “qualitative 
only” methodology. Greene et al. (1989) identified five reasons for conducting 
mixed-methods research including triangulation, complementarity, development, 
initiation and expansion. In 2006, Bryman expanded the list and identified 16 
reasons for conducting mixed-methods research including triangulation, offset, 
completeness, process, different research questions, unexpected results, 
instrument development, sampling, credibility, context, illustration, utility or 
improving usefulness of findings, confirm and discover, diversity of views, and 
enhancement or building upon quantitative and qualitative findings (Bryman, 
2006).   
For the present study, the decision to use mixed-methods methodology 
was made based on the nature of the research question(s). The rationale for 
choosing mixed-methods methodology is justified by reflecting on the reasons 
identified by Bryman (2006) for conducting mixed-methods research. Choosing 
among the 16 reasons identified by Bryman (2006), the rationale to use a 
mixed-methods approach for this particular study included: different research 
questions; offset; utility and illustration. Each of these are explained in detail in 
the following paragraphs. 
The primary reason for using mixed-methods methodology was its ability 
to answer different research questions requiring different methodologies. This 
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author believes that no methodology is superior to another and no single 
methodology can answer all the research questions within the context of 
healthcare research.  Broadly there were two components to the inquiry: one 
focused on the evaluation of ‘effectiveness’ of the nurse-pharmacist managed 
pain service requiring a quantitative approach; and the other looked at exploring 
patients’ experiences, satisfaction and views about the service requiring a 
qualitative approach.  Patient satisfaction is a multidimensional phenomenon 
with clinical outcomes, relationship with healthcare professionals, and 
bureaucratic and environmental issues being the three key areas (Wensing et 
al., 1994, Gray, 1997). Patient satisfaction is considered an indicator of quality 
of healthcare (Fitzpatrick, 1990, Fitzpatrick, 1991, May, 2000).  Patient 
satisfaction is associated with increased compliance with medical advice 
(Fitzpatrick and Hopkins, 1981), continuity of care (Orton et al., 1991) and 
health status improvement (Fitzpatrick et al., 1983). Both structured 
questionnaires and qualitative interviews have been used in literature to assess 
patient satisfaction (Williams et al., 1998, May, 2000, Kleefstra et al., 2010, Xiao 
and Barber, 2008). Questionnaires accessing patient satisfaction have been 
criticized for not being reliable and valid (Sitzia, 1999). Furthermore, 
questionnaires designed by clinicians might not truly reflect patients’ opinions 
and preferences on quality and satisfaction (Locker and Dunt, 1978, May, 
2000). This shortcoming can be overcome by using a qualitative approach. The 
use of mixed-methods allowed the author to use both quantitative and 
qualitative methods simultaneously within a single study  in order to answer the 
different research questions.  
Offset refers to the “suggestion that the research methods associated 
with both quantitative and qualitative research have their own strengths and 
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weaknesses so that combining them allows the research to offer their 
weaknesses to draw on the strengths of both” (Bryman, 2006, P. 106). In the 
past, methodologists have argued and debated about the respective usefulness 
and limitations of qualitative and quantitative methodologies in answering 
“clinical” and “biopsychosocial” questions and gave an impression that ‘one 
method fits all research problems’ (Berkwits and Aronowitz, 1995, Pope and 
Mays, 1995, Armstrong, 1996, Poses and Isen, 1998). Mixed-methods research 
recognises and appreciates the strengths and weaknesses of both qualitative 
and quantitative research designs. Qualitative research best fits a research 
question which aims to explore  participants’ subjective experiences including 
behaviours, attitudes, perceptions, expectations, motivations and interactions, 
often grouped under the “biopsychosocial” dimension (Pope and Mays, 1995, 
Gilchrist and Engel, 1995).
 
In the present study, as explained earlier, the author 
was not only interested in evaluating the effectiveness of the clinic but also keen 
to explore patients’ experience of the service. The use of structured 
questionnaires (quantitative approach) in evaluating patient satisfaction would 
have merely generated statistically significant or non-significant p-value without 
giving the patients an opportunity to reflect on their overall experiences.  
Utility or improving the usefulness of findings refers to “a suggestion, 
which is more likely to be prominent among articles with an applied focus, that 
combining the two approaches will be more useful to practitioners and others” 
(page 106)  (Bryman, 2006). This is a commonly cited reason for using a mixed-
methods approach in practice disciplines. In the present study, the use of 
mixed-methods research generated both numerical and textual data and 
provided a more comprehensive picture of what was happening in the clinic. 
The use of a qualitative approach provided a ‘voice to the patients’ and 
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generated more in-depth data on patient satisfaction, and general experience of 
living with chronic pain. It was anticipated that patients’ words would enlighten 
the healthcare professionals engaged in managing chronic pain in relation to the 
‘needs’ of their patients. Understanding patients’ needs and expectations will 
hopefully enable practitioners to improve the care provided.   
Illustration refers to “the use of qualitative data to illustrate quantitative 
findings, often referred to as “putting meat on the bones” of “dry” quantitative 
findings” (page 106)  (Bryman, 2006). This is perhaps one of the most useful 
applications of a mixed-methods approach, particularly in health services 
evaluation studies, because a “quantitative only” study can only generate P 
values and effect sizes which may not be enough for a holistic service 
evaluation. Integrating P-values with “words” in the present study, made it 
possible to answer questions like: What were the useful components of the 
service? How do they see the role of the pharmacist in a chronic pain service? 
How can the service be improved? Answering these questions through 
qualitative research can give meaning to numerical results generated through 
quantitative research. 
4.4 Rationale for choosing embedded design 
A brief introduction of the embedded design has been provided earlier in 
this chapter. In the following paragraphs,  the earlier introduction is expanded 
with an aim to justify the choice of the embedded design for this particular study.  
As mentioned earlier, a number of mixed-methods designs are available 
to healthcare researchers and choosing a particular design is perhaps the most 
complex and challenging step in designing a mixed-methods study (Teddlie and 
Tashakkori, 2006). Since each research design within mixed-methods 
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methodology has particular strengths and weaknesses and a different purpose 
and procedure of integrating qualitative and quantitative datasets, the choice 
should always be primarily based on the research question (Creswell and Plano 
Clark, 2011).  
The primary objective of this study was to evaluate the effectiveness of 
the nurse-pharmacist managed pain clinic. A secondary objective was to 
explore patients’ experience of the service provided by the clinic. Keeping in 
mind these research objectives, an embedded design was used because it was 
best suited to answer the different research questions which required a different 
method within the single study (Creswell and Plano Clark, 2011). The 
embedded design enabled the author to choose a quantitative method to 
answer the “effectiveness question” and a qualitative method to “explore 
patients’ experience and satisfaction with the service”. It should be noted here 
that the qualitative method in the embedded design answers a different 
research question, in contrast to the convergent parallel design, where the 
researcher uses both quantitative and qualitative methods to answer a single 
overarching question. As mentioned earlier, in an embedded design study, one 
method is dominant and the other plays a supportive role and answers a 
different research question. In the present study, the main question 
(effectiveness) required a quantitative approach and therefore it was the 
principal method. The qualitative method was used to explore patients’ views 
and experience with the service and had a supportive role.  
One of the challenges of using mixed-methods designs is that the 
researcher or the research team requires the necessary knowledge and skills to 
collect, analyse and interpret both qualitative and quantitative data (Creswell 
and Plano Clark, 2011). To enhance qualitative research skills, as part of PhD 
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training, the author attended specialised workshops at the University of Oxford, 
UK on qualitative interviewing and data analysis. Various training courses in 
statistical analyses were also attended to improve quantitative data analysis 
skills. 
The embedded design in the present study consisted of a quasi-
experimental (quantitative) and qualitative description (qualitative). The rationale 
for choosing these particular designs is justified below. 
4.4.1 Rationale for choosing quasi-experimental design  
As mentioned earlier, the aim of the quantitative research question was to 
evaluate the effectiveness of a nurse-pharmacist managed pain clinic. Ideally, a 
well-designed and conducted  RCT would be the best study design to evaluate 
the effectiveness of an intervention. But practically it is not always possible to 
conduct a RCT for logistic or ethical reasons and in such cases quasi-
experimental studies best serve the purpose (Harris et al., 2004, Harris et al., 
2005). Compared to RCTs, the major weakness of quasi-experimental studies is 
the lack of randomization and, in some quasi-experimental designs, lack of a 
control group. A number of quasi-experimental designs exist and a hierarchy of 
these designs with respect to their ability to establish causal relationships has 
been proposed (Cook and Campbell, 1979, Shadish et al., 2002). Broadly, in 
the social science literature, quasi-experimental designs are classified into four 
types (Cook and Campbell, 1979, Shadish et al., 2002): quasi-experimental 
designs without control groups; quasi-experimental that use control groups but 
no pre-tests; quasi-experimental designs that use control groups and pre-tests; 
and interrupted-time-series designs. In general, among quasi-experimental 
designs, interrupted time series studies are at the top of the hierarchy followed 
by studies with pre-tests and control groups (Harris et al., 2004). Studies without 
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control groups are at the bottom end of the hierarchy but this hierarchy is not 
absolute as it is not always possible to find a suitable control group (Harris et 
al., 2004). Since there was no suitable control group available for this study, a 
prospective single group pretest-posttest design was used. Two post-tests 
(upon discharge and 3-month follow-up) were performed instead of one 
originally proposed by Harris et al. (2004). The modification was made to 
document small to medium term effects of the pain management interventions 
at NPMPC. 
In the present study, a RCT design was not chosen for two major 
reasons: lack of information on the clinical characteristics of patients referred to 
the clinic and lack of a suitable control group. The reasons are interlinked as it is 
important to know the clinical characteristics of the patients receiving the 
intervention in order to identify a suitable control group. The unavailability of 
suitable “controls” was a major problem in designing the RCT. A typical RCT 
evaluating a non-pharmacological intervention in chronic pain management may 
have either one of two controls: waiting lists controls or usual care controls. 
Active-treatment controls are less frequently used in service evaluation studies. 
Recently, the suitability of waiting lists controls in chronic pain has been 
questioned as a waiting time of six months or more has been associated with 
deterioration of HRQoL and an increase in depression scores (Lynch et al., 
2008). Furthermore, waiting lists controls would have been unsuitable for the 
present study because of the nature of the service. Once referred by the GP, it 
takes only 6-8 weeks for patients to have their initial appointment at the clinic 
and usually patients remain in the service for 12-weeks to one year. Therefore, 
the wait-time for treatment was not enough to constitute a control group.  
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At the time of the commencement of this project (and to date) there was 
no mechanism to identify and recruit patients receiving “usual care” through 
general practitioners. McDermott et al. (2006) in Aberdeenshire, Scotland, UK 
used a Microsoft Access based Audit tool (NIMROD) to search the General 
Practice Administrative System for Scotland (GPASS) to identify chronic pain 
patients receiving usual care from their GPs in a single practice. However, the 
author was not aware of any such tool applicable to general practices in the 
local  Primary Care Trust and therefore the idea of using a usual-care control 
group was dropped.  
The pilot study (Briggs et al., 2008) provided only limited information 
about the nature and clinical characteristics of the patients that were referred to 
the pain clinic. Therefore one of the objectives of the present study was to 
examine the clinical characteristics of the patients. The design and evaluation of 
complex interventions (interventions that contain several interacting 
components) such as this is a stepwise process as per the framework proposed 
by the UK Medical Research Council (MRC) (2008). These steps include 
(Campbell et al., 2000, Medical Research Council, 2008): a preclinical or 
theoretical phase to explore relevant theory underpinning the possible 
usefulness of the intervention; modelling (Phase I), identifying the components 
of intervention which may influence outcomes; an exploratory trial (Phase II) to 
test the acceptability and feasibility of the intervention; a definitive randomised 
controlled trial (Phase III) to establish the effectiveness of the intervention; and 
long term implementation (Phase IV) to determine whether the intervention and 
results are replicable. The preclinical or theoretical phase is related to the 
development of the intervention rather than the evaluation of its effectiveness. 
The rest of the four phases are associated with the evaluation of the 
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intervention. More information was required about the population, nature of 
intervention, and how the intervention impacts the target population before 
designing a RCT.  For these reasons designing a RCT was neither practical nor 
logical and therefore a quasi-experimental design was chosen. Findings of  this 
study could be used to inform the design of a RCT in the future.  
4.4.2 Rationale for choosing qualitative description  
So far, in this chapter, the rationale for choosing a mixed-methods 
approach, an embedded design and a quasi-experimental design have been 
explained. In this section, the rationale for choosing a particular qualitative 
design, qualitative description, is presented. 
The selection of a particular qualitative design was challenging. Nurse 
researchers have been criticised for misunderstanding, misinterpreting and 
wrongly labelling their studies as “phenomenology” in the past (Crotty, 1996, 
Paley, 1997). Finding the right label for a qualitative research design within the 
context of healthcare/practice research is challenging probably because: 
qualitative research is a relatively new method of inquiry in healthcare research; 
different schools of thought exist within qualitative research; lack of clear 
understanding of theoretical and philosophical principles underpinning different 
qualitative designs among practice researchers; and the objective(s) of doing 
qualitative  research in health services/practice research is often different to the 
disciplines of sociology and anthropology- where qualitative research originated. 
Sally Thorne and colleagues (1997) recognised the need for a discipline 
specific qualitative design and proposed the idea of “Interpretive Description”- a 
non-categorical qualitative alternative for developing nursing knowledge. They 
proposed the concept of interpretive description as a “generic” nursing 
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adaptation of grounded theory, phenomenology and ethnography (Thorne et al., 
1997) and that is why it is labelled as a non-categorical (non-distinctive; non-
independent) method. In 2000, Sandelowski, inspired partly by interpretive 
description, proposed “qualitative description” as a distinctive method 
(Sandelowski, 2000). Compared to traditional qualitative research designs such 
as ethnography, grounded theory, or phenomenology, qualitative description is 
considered the least theoretical, but not a-theoretical, and probably on the 
lowest rank of the qualitative research hierarchy (Sandelowski, 2000, 
Sandelowski, 2010). In general, principles of naturalistic inquiry guide qualitative 
descriptive studies. Naturalistic inquiry implies: studying something in its natural 
state or as close as possible; no a-priori commitment to any theoretical view of a 
target phenomenon, and no pre-selection of variables to study (Lincoln and 
Guba, 1985). Sandelowski’s qualitative description (Sandelowski, 2000) differed 
from interpretative description (Thorne et al., 1997) in three basic aspects:  She 
considered qualitative description as a distinctive categorical method as 
opposed to a “non-categorical” alternative. Secondly, she believed that 
qualitative description is neither a new method, although unacknowledged, nor 
a nursing adaptation of grounded theory, phenomenology or ethnography as 
proposed by Throne et al. (1997).  However, a researcher whist conducting a 
qualitative description may employ one or two techniques associated with 
phenomenology, ethnography or grounded theory as necessary (Sandelowski, 
2000). Finally, Sandelowski considered qualitative description as less 
interpretive than “interpretive description”. However, this author believes that the 
degree of interpretation should be left to the discretion of the researcher as the 
demarcation between less and more interpretation is very subjective. 
Furthermore, the nature of the research project rather than the label of 
qualitative approach should dictate the degree of interpretation.  
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The research question, to explore patients’ experience and views with 
the service provided at the pain clinic, guided the author to choose the 
appropriate design. The process began with matching the research question to 
the goal(s) of the five most commonly used qualitative research designs 
identified by Creswell (2007) namely case study, ethnography, grounded theory, 
phenomenology and narrative research. After extensive reading of the literature, 
consultations with colleagues, supervisors and other qualitative researchers, it 
was concluded that none of these approaches were a good fit to answer the 
research question. This author realised that it is difficult to apply traditional 
qualitative designs to practice-based research questions. Learning from the 
criticism of nurse phenomenologists, the author was reluctant, although 
tempted, to label his approach as phenomenology as it would have cast doubts 
in the minds of the readers and questioned the credibility of the study. 
Interpretative description and qualitative description were the best labels for the 
qualitative approach being used in the present study. Although the approaches 
are similar in a number of ways, as described in the above paragraphs, the 
study design was labelled as qualitative description: because, the author does 
not see the method as “non-categorical” and believes that interpretation by the 
researcher is the essence of all research methods. Furthermore, findings 
produced by qualitative descriptive studies are data-near – which is what this 
author wanted.  Sandelowski pointed out that qualitative description should not 
be seen as a “quick-fix, data to go, smash-and-grab” type of research. The 
rationale behind all the decisions made during sampling, data collection and 
data analysis should be presented (Sandelowski, 2010). To ensure rigour, in the 
following chapter (Chapter 4), all the choices made during data collection and 
analysis have been debated and justified.  
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CHAPTER 5                                                                                      
METHODS 
5.1 Introduction 
In the previous chapter, research methodologies available to healthcare 
researchers were described and the choice of mixed-methods methodology in 
guiding this research study was justified.  Following that, the rationale for 
choosing an embedded design in relation to answering the research question(s) 
was discussed. Finally, the selection of quasi-experimental and qualitative 
descriptive designs were debated and justified.  
In this chapter, the methods used within the quasi-experimental and the 
qualitative description are explained. The chapter begins with an explanation of 
the process of obtaining ethical and governance approval for the present study, 
and steps taken to ensure the ethical conduct of the research. The chapter 
consists of two interlinked sections:  In the first section, procedures for sample 
size calculation, sampling and subject recruitment, data collection, and data 
analysis for the quasi-experimental design are explained. In the second section, 
the same issues for the descriptive qualitative study are discussed. In both 
sections, alternative approaches considered at each stage are also discussed 
and the choices made are justified.  
123  
 
5.2 Research ethics and governance approval 
In modern day medical research, it has become the norm for any research 
activity involving human participants, human tissues or their clinical data, given 
its sensitive nature, to obtain ethical approval by an independent ethics 
committee. This is to limit abuse of research participants and to safeguard their 
rights. All leading medical and healthcare journals will only publish studies for 
which ethical approval has been granted, where applicable.  
In this study, the ethics application was submitted to the Leeds West 
Research Ethics Committee using the Integrated Research Application System 
(IRAS). The University of Leeds acted as the sponsor for the study. After 
completing the online application, the supporting documents including research 
protocol, invitation letters (Appendices III and IV),  GP information sheet 
(Appendix V), patient information sheets (Appendices VI and VII), patient 
consent forms (Appendices VIII and IX), data collection forms (baseline and 
discharge) (Appendices X, XI and XII), and curriculum vitae of the research 
team were sent to the committee in the post.  The meeting was attended by the 
author and one of his supervisors (MB). The committee members, during the 
meeting, sought clarification on the process of patient recruitment, use of 
multiple questionnaires, and the author’s experience of conducting interviews.  
The committee gave provisional favorable opinion subject to minor corrections 
in the consent forms, patient information sheet and protocol. All suggested 
corrections were made and revised documents were submitted for approval. 
Subsequently, favorable ethical opinion was granted (Appendix XIII) by the 
committee. 
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Following the successful ethics application, research governance 
approval was sought from the NHS for the research to be conducted at Leeds 
Community Healthcare NHS Trust. Subsequently, permission was granted 
(Appendix XIII) and a letter of access for research (Appendix XV) was issued by 
the relevant authorities. Participant recruitment began only after obtaining 
research governance approval. 
During the course of the study, a few changes were deemed necessary 
in the protocol and consequently a notice of substantial amendment, generated 
through IRAS, was submitted to the Leeds West Research Ethics committee for 
review.  The committee gave favorable ethical opinion to the amendments 
(Appendix XVI). The amendments included: a reduction in the sample size from 
105 to 79; only two questionnaires (BPI and HADS) were used for 3-months 
follow-up instead of four (BPI, HADS, SF-36, CPG); 3-months follow-up 
questionnaires posted to only the first 30 patients discharged from the service. 
The reasons for all these changes are provided later in this chapter. 
In the following paragraphs, the key steps taken to ensure ethical 
conduct of research in line with the University of Leeds, Research Ethics Policy 
and Data Protection Act 1998 are explained.  
5.2.1 Informed consent 
The process of obtaining informed consent has two components: 1) 
providing participants with the necessary information; 2) signing of consent 
forms. Since there were two phases of the study, two patient information sheets, 
one general (Appendix VI) and one specifically for the qualitative phase 
(Appendix VII), were developed to provide patients with the necessary 
information to make an informed decision whether or not to participate in the 
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research. The general information sheet and a letter of invitation were sent 
together with the clinic appointment letter to patients at least two weeks ahead 
of their clinic appointment. This was to ensure that patients had sufficient time to 
read, understand and discuss the study with their family and friends. Contact 
details were also provided at the end of the patient information sheet, so that 
patients could contact the author to obtain further information, if required.    
5.2.2 Right of withdrawal 
The patients were informed of their right to withdraw at any stage without 
giving any reason in the patient information sheet. This information was 
reiterated verbally before signing the consent forms before both phases. The 
participants were assured that withdrawing from, or not taking part in, the 
research would have no negative consequences on the care provided by the 
health professionals. During the qualitative interviews, patients were allowed to 
stop the interview at any time without providing any reason. Only one patient 
withdrew from the study, a few days after enrolling in the study. 
5.2.3 Confidentiality and data protection 
All necessary measures were taken to ensure the confidentiality of 
research participants and data protection. To mask the identity of patients, a 
pseudonym and a serial number were assigned to all the patients enrolled in the 
study. The master list was kept electronically on a password-protected online 
University server. Only members of the research team had access to the master 
list. Personal identifiable data were not collected in any of the questionnaires. 
All paper-based data were kept under lock and key in a secure room at the pain 
clinic. After the completion of baseline data collection, all the paper-based data 
were then transferred to the author’s office at the University and placed in a 
filing cabinet protected by lock and key. Audio data, gathered through qualitative 
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interviews, were downloaded on a password protected online University server 
after every interview.  Once downloaded, the audio data were deleted from the 
recorder prior to the next interview. 
5.3 Quasi-experimental study 
As mentioned earlier, a number of quasi experimental designs exist in the 
literature and a single group pretest-posttest design was used. In the following 
sections, procedures related to patient recruitment, data collection and analysis 
are described in detail. 
5.3.1 Patient recruitment 
All the patients referred to the pain clinic between 31
st
 January 2012 and 
31
st
 September 2012 were sent a letter of invitation (Appendix III) and a patient 
information sheet (Appendix VI) together with the clinic appointment letter by the 
secretarial staff at the pain clinic. The patients were screened for eligibility, 
based on the information provided in the referral notes by the GP, against the 
inclusion and exclusion criteria (described below). Patients meeting the 
inclusion criteria were asked verbally by the author or the clinical nurse 
specialist (KM) about their willingness to participate in the research study. 
Patients were given additional information pertaining to their participation in the 
research, if requested. Once all the information was provided, written consent 
was obtained by the author or the clinical nurse specialist (KM). The author 
attended the clinic on Wednesdays for the purpose of patient recruitment, since 
almost all of the new patients were invited for their first appointment on that day 
as routine practice. The patients’ GP(s) were also informed about their 
participation in the research through a letter (Appendix V), if agreed by the 
patient. 
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5.3.1.1 Inclusion criteria 
Patients meeting the following inclusion criteria were recruited: 
 Age ≥ 18 years. 
 History of chronic pain for > 3 months.  
 Adequate ability to read and understand English. 
5.3.1.2 Exclusion criteria 
The following patients were excluded:  
 Patients with malignant pain. 
 Patients with organic brain disease or psychiatric disorders. 
 Pregnant women.  
 Patients who required acute medical/surgical intervention for their pain 
relief. 
5.3.2 Sampling 
In medical research a representative sample is usually chosen from the 
desired population as studying the whole population is often not practical. 
Findings from an unbiased and sufficiently large sample can then be 
generalized to the whole population (Zodpey, 2004).  
Broadly, there are two types of sampling techniques: probability sampling 
and non-probability sampling. Probability sampling is an umbrella term for a 
number of sampling techniques in which all the members of the population have 
an equal chance of being recruited in the sample (Zodpey, 2004). The key 
advantages of probability sampling include: the sample is representative of the 
population; statistical inferences are generalizable to the population; and it 
minimizes the selection bias. Because of these advantages, probability 
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sampling techniques are considered ideal for quantitative research (Zodpey, 
2004). Probability sampling techniques include: simple random sampling; 
stratified random sampling; cluster sampling and systematic sampling (Zodpey, 
2004).  
In non-probability sampling, individuals in a population do not have an 
equal chance of being recruited. Since not all the individuals in the population 
have an equal chance of being recruited, the sample may not be representative 
of the population and statistical inferences made are not often generalizable to 
the population. Consequently, non-probability sampling is considered to be 
inferior to probability sampling in quantitative research (Castillo, 2003). Non-
probability sampling techniques are often employed when probability sampling 
is not possible for practical reasons. Non-probability sampling is quicker, 
cheaper and easier compared to probability sampling (Castillo, 2003). Non-
probability sampling encompasses a number of sampling techniques and the 
commonly used techniques include: quota sampling; consecutive sampling; 
convenience sampling; purposive sampling; and theoretical sampling (Castillo, 
2003).   
In this study, a consecutive sampling technique was used to recruit 
patients. Consecutive sampling, a non-probability sampling technique, aims to 
include all the accessible subjects. Ideally a probability sampling technique, 
either simple random or systematic sampling would have been used to limit 
selection bias. However, consecutive sampling is considered the best non-
probability sampling technique (Castillo, 2003) as it gives an opportunity to all 
the participants to  be recruited thus minimizing the selection bias. Consecutive 
sampling, as opposed to simple random or systematic sampling, was chosen 
due to a limited pool of potential participants as well as slow discharge rate. 
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Being a pretest-posttest study, baseline assessment was necessary; therefore, 
only new patients could have been recruited. On average, 150 to 200 new 
patients used to attend the clinic and were usually discharged after 6 to 8 
months. Furthermore, a three month follow up was also planned to document 
short to medium term outcomes of the intervention. Given the nature of the 
study design and discharge rate of the clinic, employing a probability sampling 
technique would have required more time to recruit research participants. Since 
the research was undertaken as part of a PhD dissertation, the author had a 
maximum of one year to complete the data collection in order to ensure timely 
completion of the degree. Furthermore, the issue of selection bias was not 
substantially important as there was no control group and all patients referred to 
the clinic were invited to participate in the study, rather than based on the 
author’s personal preference.  
5.3.3 Sample size 
One of the most important issues in a quantitative study design is a careful 
estimation of sample size (Emanuel et al., 2000). Irrespective of how robust the 
study design is, if the sample size is smaller than required, it is highly likely that 
the study may fail to detect a difference in the presence of a real difference 
(Type II error) (Zodpey, 2004). Furthermore, underpowered trials are considered 
“scientifically useless” (Altman, 1980) and therefore unethical (Halpern et al., 
2002). However, meta-analysis of clinically homogenous studies can overcome 
the said problem. In practice, it may not be always possible to recruit the 
required number of participants in the research study. On the other hand, 
recruiting more participants than required is also unethical and would result in 
wastage of time and resources (Zodpey, 2004).   
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In this study, pain intensity was the primary outcome and the sample size 
calculations were based on the pain scores measured by the numerical rating 
scale (NRS). Initially a sample size of 105 was calculated using an online 
webulator (Montelpare, 2011) after accounting for a 15% dropout rate. The 
calculation was based on an assumed rather than actual standard deviation 
(SD). After recruiting the first 30 patients, the SD was calculated and the sample 
size was recalculated based on the new SD value using the formula (explained 
below). After accounting for the 15% drop out, the new sample size was 
calculated to be 79.  
The sample size was calculated using the following formula (Eng, 2003): 
  
                
  
  
 
Where N= total sample size; σ = Standard deviation (σ value = 1.60 obtained 
from the first 30 patients); Zcrit = Standard normal deviate corresponding to the 
selected significance criteria and confidence interval (Zcrit value = 1.96 
corresponding to 95% confidence interval and significance criteria of 0.05) ; Zpwr 
=  Standard normal deviate corresponding to selected statistical power (Zpwr 
value = 0.842 corresponding to 80% power); D = minimum expected difference. 
In this study, pain intensity is the primary outcome measure measured on an 
11-point, 0-10 numerical rating scale (NRS). For NRS a 10% to 20 % (1.1 to 2.2 
point) decrease is considered to be the minimum clinically important difference 
(Dworkin et al., 2008). In order to ensure that the study is powered to detect the 
minimum clinically important difference, a D value of 1.1 was chosen for the 
calculation of sample size. 
The recalculation of sample size prevented over recruitment and 
unnecessary burden on patients. As mentioned earlier, the sample size was 
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recalculated because the earlier calculation was based on an assumed SD 
rather than the actual SD. As per the requirement of ethics approval, any 
change in the protocol should be brought to the attention of the committee. 
Therefore, a notice of substantial amendment was submitted to the REC to 
highlight the change in the sample size, together with the other above 
mentioned changes, for review. The reason for the change in the sample size 
was also explained in the application. Subsequently, favorable ethical approval 
was obtained (Appendix XVI).  
5.3.4 Data collection 
Once the written informed consent was obtained from the patients, they were 
requested to fill in the questionnaires (the Brief Pain Inventory, the SF-36, the 
Hospital Anxiety and Depression Scale, and the Chronic Pain Grade 
questionnaire) prior to their first consultation with the nurse and/or the 
pharmacist as part of the baseline assessment (pretest; T0). It should be noted 
here that, as a routine clinical practice, all the patients referred to the pain clinic 
were asked to complete the BPI and the HADS. For the purpose of this study, 
participants completed two additional questionnaires (SF-36 and CPG). The 
rationale for choosing these specific outcome measures and their respective 
instruments is explained in the next section of this chapter. Sociodemographic 
and clinical data were also collected on a structured questionnaire (explained 
below) by the author from patients’ clinical notes and patient interview.   
Two post-tests were undertaken: upon discharge from the pain clinic, 
and at 3-month post-discharge. The decision to discharge patients from the 
service was made by the clinical nurse specialist (KM) in consultation with the 
patient after assessing their clinical needs. Upon discharge, after the last 
consultation, patients were asked to complete the same set of questionnaires 
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(BPI, HADS, SF-36, CPG) by the clinical nurse specialist (KM). The patients 
completed the questionnaires at the pain clinic. For the 3-month follow-up, 
questionnaires (BPI and HADS) were posted to the patients’ home addresses 
together with a letter of invitation (Appendix IV) to complete the 3-month follow-
up and a self-addressed pre-paid envelope. Patients were requested to 
complete the questionnaires and return them within one week of receiving them. 
For each patient enrolled in the study, the date of discharge and a due date for 
3-month follow-up were recorded and kept under lock and key by the author at 
the pain the clinic. The process of data collection is shown in Figure 5.1. 
As mentioned previously (section 5.2), two changes were made in the 
initial protocol in relation to the 3-month follow-up: Firstly, instead of requesting 
the patients to fill in all four questionnaires (BPI, CPG, SF-36, HADS), the 
patients were asked to complete only two questionnaires (BPI and HADS). 
There were two interlinked reasons to make this change: to reduce patient 
burden; and to improve response rate. During the baseline assessment, a 
number of patients expressed concerns about the length of the questionnaire 
especially the SF-36. Furthermore, a low response rate with postal 
questionnaires is well documented in the literature and it was a concern that the 
patients might not fill in and return the questionnaires because of their length. 
Secondly, only the first 30 patients discharged from the service were invited to 
take part in the 3-month follow-up assessment as opposed to all the 79 patients, 
initially proposed. There were two main reasons for reducing the sample size for 
the 3-month follow-up:. Firstly, slow recruitment of patients in the study as the 
research team was only able to recruit less than half of the patients meeting the 
inclusion criteria,. Secondly,  a slow discharge rate from the service was also 
observed. While designing the study, it was assumed that patients would be 
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discharged after 4 to 6 months but in practice it was realized that most of the 
patients were taking more than six months to be discharged from the service. 
Given the limited time to complete data collection, being a PhD research 
project,  all of the above mentioned factors necessitated a reduction in the 
sample size for 3-month follow-up. . The ethics committee was notified about 
these changes through a notice of substantial amendment, generated through 
IRAS. The committee gave favorable ethics opinion after the review of the 
application (Appendix XVI).   
The follow-up data collection was stopped when the service was 
decommissioned by the local PCT in December 2012, effective March 2013. 
However, no new patients were seen at the clinic since December 2013. The 
existing patients were either referred to a local Musculoskeletal service or 
discharged back to their GPs. The implications of decommissioning of the 
service  in relation to the findings of this study are discussed in section 8.5. 
5.3.4 Outcome measures 
The following outcome measures and respective scales were selected 
based on demonstrated validity and reliability in chronic pain clinical trials. The 
selection of outcome domains is supported by the recommendations of the 
Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials 
(IMMPACT) group, an initiative to improve the design, conduct and reporting of 
clinical trials on pain. All the scales described below can be self or interviewer 
administered.  
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5.3.4.1 Sociodemographic and clinical data 
Sociodemographic data (age, gender, ethnicity, and employment status 
etc.) and history of chronic pain (pain sites, duration of pain, and referral to pain 
specialist in the past) were collected through a structured questionnaire 
(Appendix X) by the author. Additionally, at baseline, data on co-morbidities, 
route of referral and medication history were collected on another  structured 
data collection form (Appendix XI). The discharge data collection form 
(Appendix XII) was used to gather data on the change in medication based on 
recommendations made by the clinical nurse specialist and/or the pharmacist, 
the number of visits to the pain clinic and the nature of consultation. The author 
designed these data collection forms. Three senior academics (MB, SJC, DA) 
reviewed the data collection forms for accuracy, adequacy, face and content 
validity. The clinical nurse specialist (KM) was also consulted for the 
appropriateness and practicability of the forms. Subsequently, changes were 
made to the forms in light of the feedback. Finally, the data collection forms 
were pilot-tested on 3 patients.  
5.3.4.2 Pain intensity 
Pain intensity is a quantitative estimate of severity or magnitude of pain. 
Both generic and disease specific questionnaires exist in the literature to 
measure pain intensity (Dworkin et al., 2005). Since various types of chronic 
pain patients are referred to the pain clinic, the use of a disease specific 
questionnaire was deemed inappropriate. The numerical rating scale (NRS), 
visual analogue scale (VAS) and visual rating scale (VRS) are the most 
frequently used generic instruments to measure pain intensity (Dworkin et al., 
2005). NRS is an 11-point scale ranging from 0 = no pain to 10 = ‘pain as bad 
as you can imagine’ (Cleeland and Ryan, 1994). Typically, a VRS categorises 
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pain intensity into one of the four categories: none, mild, moderate, and severe. 
VAS consists of a 10 cm line with no pain at one end and worst imaginable pain 
at the other (McCormack et al., 1988).  All three instruments have demonstrated 
validity and reliability. However, no single scale has persistently established 
greater responsiveness in detecting improvements in pain treatment (Jensen 
and Karoly, 2001). In terms of patient preference, VAS is least preferred 
compared to NRS and VRS (Jensen and Karoly, 2001). VAS is associated with 
greater missing and incomplete data compared to NRS as NRS is relatively 
easy to administer. Furthermore, patients with old age or who take opioid 
analgesics have difficulty in filling in VAS (Jensen and Karoly, 2001). Similarly, 
patients with cognitive impairment find NRS difficult to respond to (Jensen and 
Karoly, 2001). 
After careful consideration of the advantages and disadvantages of each 
of these scales and reviewing the recommendations of The IMMPACT group 
(Dworkin et al., 2005), an 11 point (0-10) numerical rating scale (NRS) ranging 
from 0 = no pain to 10 = ‘pain as bad as you can imagine’ was selected. NRS 
was administered as part of the Brief Pain Inventory (BPI) (Cleeland and Ryan, 
1994).
 
NRS is simple and, easy to administer and score (Jensen and Karoly, 
2001, Dworkin et al., 2005).  
5.3.4.3 Physical functioning 
Chronic pain restricts daily life activities and physical functioning. 
Theoretically, pain relief should be complemented with an improvement in 
physical functioning but studies have shown that pain intensity and physical 
functioning are not significantly associated (Turk, 2002). For this reason, using 
measures of physical functioning in trials assessing the effectiveness of 
interventions in chronic pain management is recommended (Dworkin et al., 
137  
 
2005). Both generic, such as the BPI (Cleeland and Ryan, 1994) and the 
Multidimensional Pain Inventory (MPI) (Kerns et al., 1985), and disease specific 
measures, such as WOMAC (Bellamy, 1996) and the Roland and Morris Back 
Pain Disability scale (Roland and Morris, 1983), for assessing physical 
functioning exist in the literature. The IMMPACT group recommends the use of 
a disease specific tool for assessing physical functioning in studies where a 
well-established and validated tool is available for that particular disease 
(Dworkin et al., 2005). However, disease-specific measures of physical 
functioning do not exist for all types of chronic pain. Therefore, generic 
measures should be used when the study population consists of patients with 
different types of chronic pain conditions (Dworkin et al., 2005).  
Since patients with a variety of chronic pain conditions were referred to the 
pain clinic, only generic measures were considered for selection. The IMMPACT 
group recommends either pain interference items of BPI (Cleeland and Ryan, 
1994) or MPI (Kerns et al., 1985). MPI is a 9-item questionnaire which assesses 
a number of dimensions of chronic pain experience, including pain intensity, 
emotional distress, cognitive and functional adaptation, and social support. On 
the other hand, BPI is a 7-item instrument and measures pain interference with 
seven daily life activities including general activity, walking, work, mood, 
enjoyment of life, relations with others and sleep (Cleeland and Ryan, 1994, 
Cleeland et al., 1996). The validity and reliability of both instruments have been 
documented in different settings and languages (Dworkin et al., 2005). Unlike 
BPI, MPI does not assess pain interference with sleep, an important outcome; 
therefore, a valid and reliable measure is required to assess the impact of pain 
on sleep if MPI is used (Dworkin et al., 2005).  
138  
 
BPI was chosen for the present study because it is shorter and unlike MPI 
it precludes the necessity of using another questionnaire to assess the impact of 
pain on sleep, preventing an undue burden on the patients. In the BPI, each of 
the seven interference items is scored on an 11-point (0-10) scale ranging from 
0 = does not interfere to 10 = completely interferes (Appendix XVII). BPI pain 
interference is calculated as the mean of the seven interference items. This 
mean can be used if more than 50%, or four of seven, of the total items have 
been completed on a given administration (Cleeland and Ryan, 1994).  
5.3.4.4 Emotional functioning 
Mood disturbances, anxiety, anger and depression are well reported 
consequences of chronic pain (Fernandez, 2002). Depression combined with 
physical illness has greater adverse outcomes than physical illness alone (Stein 
et al., 2006). However, assessment of emotional functioning in chronic pain 
patients is a challenge because some of the symptoms of depression such as 
fatigue, reduced libido and weight gain are also associated with chronic pain 
itself and medication used for its treatment (Gallagher and Verma, 2004).   
A number of instruments to measure emotional functioning exist in the 
literature such as the Hospital Anxiety and Depression Scale (HADS) (Zigmond 
and Snaith, 1983), Beck Depression Inventory (BDI) (Beck et al., 1961), the 
Patient Health Questionnaire (PHQ-9) (Spitzer et al., 1999), the General Health 
Questionnaire (GHQ-28) (Goldberg and Williams, 1988), the Centre of 
Epidemiology Studies-Depression (CES-D) (Radloff, 1977), the Geriatric 
Depression Scale (GDS) (Yesavage et al., 1983), and the Profile of Mood 
States (McNaire et al., 1971). Each of these instruments has their own 
advantages and disadvantages and explaining all these tools individually is 
beyond the scope of this thesis. The IMMPACT group recommends the use of 
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the BDI or the POMS (Dworkin et al., 2005), as both instruments are reliable, 
validated and widely used. BDI is a 21-item questionnaire that can be divided 
into two subscales: the cognitive-affective (items 1 to 13) and the somatic-
performance (items 14 to 21) (Beck and Steer, 1993). POMS assesses six 
mood states: tension-anxiety, depression-dejection, anger-hostility, vigor-
activity, fatigue-inertia, and confusion-bewilderment (McNaire et al., 1971). 
Limitations of the BDI include (Richter et al., 1998): high item difficulty, lack of 
representative norms leading to uncertainty in the objectivity of interpretation, 
debatable factorial validity and poor discriminant validity against anxiety. 
Nevertheless, BDI has high internal consistency, high content validity, high 
discriminant validity in differentiating between depressed and non-depressed 
individuals, and sensitivity to change (Richter et al., 1998). 
Since HADS (Zigmond and Snaith, 1983) was routinely used in the pain 
clinic to assess emotional functioning, it was decided to continue its use in the 
present study. Asking patients to fill in another questionnaire to assess the 
same outcome would have put patients under unnecessary burden. Substituting 
HADS with BDI or POMS would have affected the routine clinical practice which 
was undesirable. Furthermore, HADS is shorter as than BDI and has well 
documented validity and reliability (Bjelland et al., 2002). It was developed to 
identify possible cases of anxiety and depression among patients in non-
psychiatric clinics. It consists of two subscales; Anxiety subscale (HADS-A) and 
a Depression subscale (HADS-D). Each subscale consists of 7-items and each 
item has four numerical response options from 0 to 3 with a minimum score of 0 
and a maximum of 21 for each subscale. The mean cut-off score for HADS-A 
and HADS-D is 8 (Bjelland et al., 2002). A review by Bjelland and colleagues 
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(2002) concluded that HADS is a valid and reliable tool to detect anxiety and 
depression and assess their symptom severity in primary care.  
GL assessment holds exclusive copyright of HADS. An agreement with GL 
assessment was signed and license fees were paid to ensure lawful use of the 
questionnaire (Appendix XVIII).   
5.3.4.5 Quality of life 
Chronic pain adversely affects the quality of life of patients. The IMMPACT 
group has not identified Health-related quality of life (HRQoL) as an 
‘independent outcome domain’, but it recommends the use of a generic HRQoL 
measure (e.g. SF-36) in trials evaluating the effectiveness of an intervention in 
chronic pain (Dworkin et al., 2005). The use of a generic HRQoL measure has 
been recommended because: it allows a meaningful comparison with other 
disease conditions; and the data could be used in cost-effectiveness analyses. 
  HRQoL instruments can be divided into three categories with each type 
having its own specific clinical and research use: generic measures, condition-
specific measures, and preference-based measures (Vetter, 2007).  The ten 
most cited generic and preference based QoL measures include (Vetter, 2007): 
the SF-36 (Ware and Sherbourne, 1992), the EuroQol Scale (EQ-5D) (Rabin 
and de Charro, 2001), the Nottingham Health Profile (NHP) (McEwen and 
McKenna, 1993), the SF-12 (Ware Jr et al., 1996), the Sickness Impact Profile 
(SIP) (Bergner et al., 1981), the Health Utilities Index (HUI) (Furlong et al., 
2001), the World Health Organization Quality of Life Scales (WHOQOL) (The 
WHQOL Group, 1995), the Dartmouth COOP and Dartmouth COOP/WONCA 
Charts (Nelson et al., 1996), the Quality of Well-Being Scale (QWB) (Kaplan et 
al., 1993) and the SF-6D (Brazier et al., 2002).  
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In the present study, HRQoL of life was used as an independent 
outcome measure because, arguably the improvement in physical functioning 
and pain relief should also be reflected in the improvement in overall quality of 
life. The Medical Outcomes Study-Short Form version 2 (SF-36v2)® was used 
for  measuring the HRQoL (Ware and Sherbourne, 1992). Initially, while 
designing the research project, the length of the questionnaire was a source of 
concern and shorter alternatives such as SF-12 and SF-8 were considered. But 
unlike the SF-36, both the SF-12 and the SF-8 do not have pain items in the 
questionnaire therefore SF-36 was chosen. Furthermore, the IMMPACT group 
also recommends the use of SF-36 as a generic HRQoL tool. SF-36 consists of 
eight subscales: Physical Functioning (PF), Role-Physical (RP), Bodily Pain 
(BP), General Health (GH), Vitality (VT), Social Functioning (SF), Emotional 
Role (ER) and Mental Health (MH) (Appendix XIX). Scores for each variable are 
summed then transformed into a Likert scale ranging from 0 (worst) to 100 
(best) (Ware et al., 2005). Various studies have documented the validity and 
reliability of the SF-36 in different settings and languages (Sersic and Vuletic, 
2006, Leung et al., 2010, Chia et al., 2006, Almborg and Berg, 2009, Kosinski et 
al., 1999). It is suitable for adults ≥ 18 years of age and can be self, telephone 
or interviewer administered.  
Quality Metric Incorporated (QM), Lincoln RI, USA has the exclusive 
copyright for SF-36. A non-commercial license agreement was signed between 
the Office of Grants and Scholarly research (OGSR), Quality Metric 
Incorporated and the author to enable the use of SF-36 in this research project. 
Under the agreement 360 copies of SF-36v2 together with the e-manual and 
scoring software v4 were provided by QM free of cost.  
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5.3.4.6 Chronic Pain Grade questionnaire (CPG) 
  The Chronic Pain Grade (CPG) questionnaire was used, in addition to as 
an outcome measure, to assess pain severity among patients referred to the 
pain clinic. The World Health Organization’s International Classification of 
Functioning Disability and Health (ICF), provides a standard framework for the 
comparison and understanding of health outcomes, and has identified three 
main outcomes for chronic pain namely, impairment (I), activity limitation (A) 
and participation restrictions (P) (World Health Organization, 2001). The CPG 
measures all three of these ICF outcomes (Dixon et al., 2007) (Appendix XX). 
The CPG is a seven-item questionnaire and measures pain severity in 
three dimensions: persistence, intensity and disability (Von Korff et al., 1990). 
Three questions (questions 1 to 3) measure pain intensity, each item using an 
11-point numerical rating scale (NRS) ranging from 0 = no pain to 10 ‘worst pain 
you can imagine’. Another three (questions 5 to 7) measure pain related 
disability, each item using an11-point numerical rating scale (NRS) ranging from 
0 = no pain to 10 ‘worst pain you can imagine’. One question (question 4) gives  
disability points based on the number of days in the past six months the 
respondent was unable to do his/her regular work because of pain ( 0-6 days 0 
points; 7-14 days 1 point; 15-30 days 2 points; >= 31 days 3 points). Based on 
the pain intensity score, disability score and disability points, CPG classifies 
chronic pain patients into one of the five hierarchical categories according to 
pain severity: Grade 0, Pain free; Grade I, low disability-low intensity; Grade II, 
low disability-high intensity; Grade III, high disability-moderately limiting; and 
Grade IV high disability-severely limiting. The questionnaire was originally 
proposed by Von Korff et. Al. (1992) and has been validated in the UK general 
population (Smitha et al., 1997). The method proposed by Von Kroff et al. 
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(1992) was used for the scoring and classification of patients in the above 
mentioned chronic pain grades. 
5.4 Data analysis 
The Statistical Package for Social Sciences (SPSS) for Windows version 
20 (Chicago, IL, USA) was used for data analyses. All quantitative data were 
coded numerically (e.g. for gender; male was coded as 1 and female was coded 
as 2) and entered into SPSS. Subsequently a codebook was prepared. As 
mentioned earlier (section 4.3.4.5), quality of life (SF-36) data (both baseline 
and discharge) were entered into the scoring software provided by the Quality 
Metric Incorporated (QM), Lincoln RI, USA. Once scoring was completed the 
results were exported to SPSS for further analyses. For the Chronic Pain Grade 
(CPG), data were entered into Microsoft Excel and the scoring of the 
questionnaire was conducted based on the algorithm proposed by Von Korff et 
al. (1992). Data were then exported to SPSS for further analyses. Patients were 
then classified into IV groups, described above, based on the severity of chronic 
pain (Von Korff et al., 1992).  
Descriptive statistics such as measures of central tendency and spread 
were used to summarise and present data. Since parametric tests have more 
statistical power and produce more accurate and precise estimates, they were 
preferred over non-parametric tests if data were continuous and normally 
distributed (Siegel and Castellan, 1988). However, if the assumptions of 
parametric tests were not met, for example, if the data were skewed,  non-
parametric tests were used. Data were considered normally distributed if the 
skewness value was between +1 and -1, calculated using SPSS. (Altman, 
1991). Data are reported as mean and standard deviation, if normally distributed 
and as median and intra-quartile range (IQR), if not normally distributed. 
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Since data were paired (repeated measures; pretest-posttest study 
design), either the paired t-test (comparing means) or its non-parametric 
equivalent the Wilcoxon Signed-Rank test (comparing medians) was used 
based on the distribution of the data. The Wilcoxon Signed-rank test was used 
for comparing baseline and discharge scores of pain intensity, physical 
functioning, anxiety and depression, and pain intensity and disability (measured 
by CPG). The paired t-tests were used for comparing quality of life data. The 
Wilcoxon signed rank test was preferred over the Sign test, an alternative test 
for two related samples, because the Wilcoxon Signed-rank test is statistically 
more powerful. This is because in addition to assigning positive or negative 
ranks to the observations according to where they lie above or below some 
hypothesized value, it also takes magnitude of the observation into account 
unlike the sign test (Siegel and Castellan, 1988). In the results chapter (Chapter 
6), to enhance clarity, the name of the statistical test used to calculate the P-
value is also given at the bottom of each table, where applicable. A two-tailed P-
value of less than 0.05 was considered statistically significant.  
5.5 Descriptive qualitative study 
The primary objective of the qualitative phase was to explore patients' 
views around their experiences and satisfaction with the service provided by the 
nurse-pharmacist managed pain clinic.  The rationale for choosing a descriptive 
qualitative design has been explained in chapter 3. In the following sections, 
procedures for subject recruitment, sampling, data collection and data analysis 
are explained. Alternative approaches, where available, are also presented and 
the rationale for choosing a particular approach is justified. 
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5.5.1 Selection of patients 
As mentioned earlier, an embedded design was used for this study and 
therefore, the process of patient recruitment for the qualitative phase was 
nested within the process of recruitment for the quantitative phase (see section 
5.3.2). Within the consent form for the quasi-experimental study (quantitative 
phase), patients were also asked about their willingness to participate in the 
qualitative interview upon discharge from the service. Patients who indicated 
their willingness constituted the sampling frame for the descriptive qualitative 
study.  However, patients were allowed to withdraw their consent and refuse to 
participate in the interview at any stage before, or upon, discharge from the 
service. Whilst discharging patients, the clinical nurse specialist (KM) sought 
their willingness to take part in the interview. If willing, the contact details (name 
and telephone number) of the patient were communicated to the author. The 
author then arranged the time and date of the interview based on the patients’ 
preference. In addition to the inclusion and exclusion criteria for the quasi-
experimental phase, the following inclusion and exclusion criteria were applied 
for the qualitative descriptive study.  
5.5.1.1 Inclusion criteria 
 Discharged from the service within the study period. 
5.5.1.2 Exclusion criteria 
 Referred to secondary care after the first consultation. 
 Discharged from the service due to nonattendance at two consecutive 
consultations without informing the clinic staff. 
146  
 
 Patients deemed unsuitable for an interview due to communication or 
medical issues (e.g. speaking/listening disability, patients with psychiatric 
disorders) identified by the clinical nurse specialist.  
5.5.2 Sampling 
Like quantitative research, sample selection can profoundly affect the 
quality of qualitative research (Coyne, 1997). In the past, qualitative researchers 
had been criticized for not describing the sampling strategy adequately resulting 
in difficulties in interpretation and study replication (Kitson et al., 1982). Unlike 
quantitative research, the aim of sampling in qualitative research is not to recruit 
a statistically representative sample of respondents in order to generalize 
findings to the population (Pope et al., 2000). But instead, as Morse (1991b) 
pointed out, sampling in qualitative research is based on the principle of 
appropriateness that requires purposeful sampling and a ‘‘good’’ informant (i.e. 
one who is articulate, reﬂective, and willing to share with the interviewer)’ (p. 
127) (Morse, 1991b). The sample size for qualitative study is usually small as 
the focus of qualitative research is to provide an in-depth understanding of the 
phenomenon under study rather than statistical generalization (Crouch and 
Mckenzie, 2006). The principles of quantitative sampling are not applicable to 
qualitative studies for both practical and theoretical reasons (Marshall, 1996). 
Firstly, random sampling only produces a representative sample only if the 
study variables are normally distributed within the population. But qualitative 
studies explore attitudes, beliefs and values which are not normally distributed 
within the population (Marshall, 1996). Secondly, it is well known among the 
qualitative researchers that some participants are “richer” than others and such 
participants are more likely to provide an in-depth insight on the research 
question therefore choosing someone at random may be inappropriate 
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(Marshall, 1996). On the other hand, purposeful sampling may enable a 
researcher to find a rich-informant. It can also be argued that the qualitative 
researchers should not waste their time and resources in doing random 
sampling as the aim of qualitative sampling techniques is not to select a 
statistically representative sample, a desired characteristic of random sampling 
techniques.  
A number of sampling strategies are available in qualitative research and 
the selection is based on the type of qualitative design and research question 
(Miles and Huberman, 1994). According to Patton (1990), all sampling 
techniques in qualitative research can be encompassed under the umbrella of 
purposeful sampling. Purposive sampling refers to selecting individuals who are 
likely to generate ‘appropriate and meaningful data’ (Green and Thorogood, 
2009). The aim of purposive sampling is to recruit ‘information rich cases for in 
depth study’ (Patton, 1990) (Page 169). Patton (1990) identified 15 different 
sampling techniques within purposeful sampling including extreme or deviant 
case sampling, intensity sampling, maximum variation sampling, homogenous, 
typical case sampling, stratified purposeful sampling, critical case sampling, 
snow ball sampling, criterion sampling, theory based or operational based 
sampling, confirmation and disconfirmation cases, opportunistic sampling, 
sampling politically important cases and convenience sampling. Patton 
described theoretical sampling, described by Strauss and Corbin (1990) as a 
three stage process consisting of open sampling, relational and variation 
sampling and discriminate sampling associated with grounded theory studies, 
as a variant of purposeful sampling. Morse (1991b) and Sandelowski (1995) 
endorsed Patton’s view (1990) and also recognized theoretical sampling as a 
variant of purposeful sampling. Whether theoretical sampling is an independent 
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method or encompassed under purposeful sampling is a debated topic among 
qualitative researchers (Patton, 1990, Strauss and Corbin, 1990, Morse, 1991b, 
Sandelowski, 1995, Coyne, 1997).  However, this author believes that, whether 
a qualitative study aims to generate a theory or not, all qualitative researchers 
aim to recruit ‘information rich’ participants therefore all the sampling techniques 
can be broadly encompassed under purposeful sampling.  
In this study, a combination of two purposeful sampling techniques, 
namely convenience sampling and maximum variation sampling were used. In 
convenience sampling participants are selected because of their convenient 
accessibility and proximity to the researcher. Maximum variation sampling aims 
at “capturing and describing the central themes or principal outcomes that cut 
across a great deal of participant or program variation” (Page 172) (Patton, 
1990). Initially for the first five interviews, convenience sampling was used and 
patients meeting the inclusion/exclusion criteria and consenting for an interview 
were recruited. In order to ensure representation of different types of patients 
referred to the clinic, the remaining 14 interviewees were recruited using 
maximum variation sampling. Maximum variation sampling is the most 
frequently used technique (Sandelowski, 1995). 
A framework for maximum variation sampling was developed based on 
pain scores on discharge, duration of chronic pain and gender (Figure 4.2). In 
the first step, patients were classified into two groups based on pain scores on 
discharge: pain score < 7 (mild to moderate pain) and pain score ≥ 7 (severe 
pain). Following that, based on duration of chronic pain, the patients were 
stratified into two groups: pain duration ≤ 3 years; and pain duration > 3 years. 
Finally, each of these four groups was further stratified based on gender. 
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However, any patient meeting the inclusion criteria, who expressed interest in 
participating in the interview was recruited. 
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Figure 5.2. Framework of maximum variation sampling 
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5.5.3 Sample size 
Unlike quantitative research, in qualitative research there are neither rules 
nor a priori methods to calculate sample size. Sample size in most of the  
published qualitative research is often determined by data saturation 
(informational redundancy) (Lincoln and Guba, 1985) or theoretical saturation 
(Strauss and Corbin, 1990). However, reported sample sizes are often too small 
to support either informational redundancy or theoretical saturation 
(Sandelowski, 1995). The concepts of informational redundancy and theoretical 
saturation are, although related, different from each other. Informational 
redundancy is said to occur when no new information is obtainable from newly 
sampled units, and the information obtained therefore becomes redundant 
(Patton, 2002). Similarly, Sandelowski (1995) described informational 
redundancy as the point when a researcher feels that he has seen and heard 
the same thing repeatedly and collecting more data will add no further 
interpretive value to existing data.  On the other hand, theoretical saturation, 
associated with grounded theory inquiry, is said to occur when gathering more 
data adds no value to the properties of a theoretical category (Strauss and 
Corbin, 1990). It should be noted here that in contrast to informational 
redundancy, theoretical saturation is associated with the data interpretations 
rather than data collection and it is the endpoint of theoretical sampling and is 
achieved via constant comparison analytic technique.  
In general, sample sizes in qualitative research should neither be too 
small to achieve data saturation nor too large to limit in-depth case-oriented 
data analysis (Sandelowski, 1995). The principle of data saturation offers mainly 
conceptual guidance rather than practical guidance for sample size estimation 
before data collection (Guest et al., 2006) and judgment and experience of the 
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qualitative researcher eventually determines the number of participants in the 
majority of qualitative research. Several factors which influence saturation have 
been highlighted in the literature including the study aim, nature of topic, 
heterogeneity of the population, methods of data collection, groups of special 
interest requiring  intensive study, study design and quality of data (Morse, 
2000, Ritchie et al., 2003, Charmaz, 2006). Based on the type of qualitative 
research design, different guidelines on the sample size have been proposed by  
researchers ranging from 5 to 50 (Creswell, 2007, Morse, 2000, Ritchie et al., 
2003).  Morse (1994) suggested that at least six participants are required when 
the goal of the study is to understand the essence of experience. Green and 
Thorogood (2009) suggested that for an interview based study saturation 
usually occurs after 20 interviews.  
In this study, data saturation or informational redundancy was used to 
guide sample size. In total, 19 patients were interviewed. The author continued 
to interview patients until no new information was coming out during the 
interview. The author started to sense data saturation after 17 interviews but 
conducted two additional interviews to ensure data saturation. As mentioned 
earlier, unlike theoretical saturation, it is not necessary to analyse data 
concurrently with data collection to ascertain data saturation. The author 
listened to each interview afterwards and made notes of key points. In addition 
to listening to the same information repeatedly, this guided the researcher in 
establishing data saturation - when the author felt that there was repetition of 
the information and key points. 
5.5.4 Interviews 
Data for qualitative research is gathered through interviews (one to one and 
group interviews), observations and reviewing documentary sources (public 
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records, personal documents, mass-media outputs and research outputs). A 
researcher may choose one or a combination of two or more techniques (e.g. 
interviews + participant observation) for generating qualitative data. Each data 
collection technique has its unique advantages and disadvantages and the 
choice of a particular method is governed by the study aim and objectives. 
Interviews are the most widely used data collection method in qualitative 
research.  The purpose of a qualitative interview is to gather descriptions of the 
life-world of the interviewee (Kvale, 1983).  Interviews can be of different types: 
structured, semi-structured, in-depth, narrative and informal interviews (Green 
and Thorogood, 2009). Keeping in mind the aim of the qualitative phase, semi-
structured interviews were chosen because in semi-structured interviews, the 
interview agenda is determined by the researcher but the interviewee’s 
responses determine the nature and depth of information unlike the structured 
interviews where participants’ responses are fixed (Green and Thorogood, 
2009).  
Interviews can be conducted face to face, via telephone, internet (email, 
Skype and MSN Messenger) individually or in groups and each has its 
advantages and disadvantages (Opdenakker, 2006). There are different types 
of group interviews namely consensus panel, community interviews and 
participatory methods, focus groups and natural groups (Green and Thorogood, 
2009). For the present study, all interviews were conducted face-to-face. 
Individual face-to-face interviews were selected as they allow more 
confidentiality and freedom to express individual experience and feelings and 
are not influenced by group interaction and dynamics (Gibbs, 1997). Group 
interviews are often difficult to arrange, manage and the researcher has less 
control over the data produced (Morgan, 1988). Furthermore, focus groups were 
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not practical for this study due to the nature of the research design and working 
of the clinic. The author aimed to interview patients within two weeks of their 
discharge from the pain clinic and patients were discharged from the service 
from weeks to months apart, making arrangement of focus groups impossible. 
Conducting focus group interviews would have inconvenienced patients into 
travelling to the interview location from different parts of the city, which 
considering the physical disability associated with chronic pain, was not 
appropriate. It was also anticipated that recently discharged patients in the 
group would have a fresh memory of their experience compared to those 
patients discharged months ago; the former might tend to dominate and 
influence the group which was not desirable. The major limitation of using 
interviews as a data collection tool is that they only provide access to what 
people say but not to what they do in their lives (Green and Thorogood, 2009). 
However, the study aim was not to document participants’ behavior rather to 
explore their views about services at NPMPC for which interviews were best 
suited. 
As mentioned earlier, interviews were conducted either at the patients’ 
home or at the clinic based on the patients’ preferences as interview setting 
influences the nature and quality of data generated (Green and Hart, 1999). 
One interview was conducted at the patient’s work place during a lunch break, 
at her request. Patients were explained the purpose of the interview and 
measures (such as assigning pseudonyms, not using personal identifiable data 
in any publication, and keeping data on a password protected server) taken to 
ensure confidentiality. Following this, patients were explained the format of the 
interview and informed about the expected length of the interview. Once 
explained, patients were asked to sign the consent form. Permission was also 
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obtained to audio record the interview. Interviewees lasted between 15-45 
minutes and interviews were audio taped using two digital audio recorders 
A topic guide (Appendix XXI) was prepared to ensure uniformity, based 
on the literature review and study objectives. Topic guide, frequently used in 
semi-structured interviews, contains topics and questions that the interviewer 
can ask in different ways for different participants (Lindlof and Taylor, 2002). As 
mentioned earlier (Chapter 4, section 4.3), patient satisfaction is a 
multidimensional phenomenon therefore the topic guide was designed to cover 
the following areas: expectations from the service; efficacy of the service (did it 
help? How?); interaction with nurse and pharmacist (time given for consultation, 
engaging patient in discussion and designing of therapeutic plan, listening to 
and understanding the problem); understanding of chronic pain and self-
management; and overall satisfaction (experience compared to other services in 
past, aspects of the service which need improvement etc.) with the service. In 
addition, in the beginning of each interview, patients were asked about their 
history of chronic pain and its impact on daily life including physical functioning, 
emotional functioning and quality of life. Interviewees were given a chance to 
express any additional views at the end of the interview. Once prepared, the 
author discussed the topic guide with his supervisors, who have substantial 
experience of conducting qualitative research, and amended it in light of their 
recommendations. A trial interview was also conducted with another PhD 
student. 
5.5.5 Data management 
After each interview, data from both audio recorders were transferred to a 
password protected university server. All consent forms were kept under lock 
and key in the author’s office at the university. Once transferred, the audio 
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recordings were deleted from both recorders. All interviews were transcribed 
verbatim by a professional transcribing company registered with the University 
of Leeds. For the purpose of transcribing, the audio files were uploaded on a 
secure online server, which were only accessed by the assigned transcriber. All 
the interviews were transcribed by a single transcriber. Once transcriptions were 
received, the author listened to the audio recordings to check the transcriptions 
for accuracy.  
5.5.6 Data analysis 
A variety of qualitative data analysis methods are available and the 
selection of an appropriate method is guided by the study objectives. These 
methods can be broadly divided into three categories (Smith and Firth, 2011): 
Sociolinguistic methods (discourse and conversation analysis), grounded 
theory, and thematic analysis. 
Thematic analysis “is a method for identifying, analysing and reporting 
patterns (themes) within data” (page 78) (Braun and Clarke, 2006). Thematic 
analysis is often seen as a ‘tool’ or a process used within other qualitative data 
analysis techniques rather than a specific method on its own. This is because 
identifying themes is an integral component of most, if not all, qualitative data 
analysis techniques such as grounded theory and interpretative 
phenomenological analysis (IPA). However, Braun and Clarke (2006) have 
argued that thematic analysis is a definite method in its own right. This author 
believes that thematic analysis can be used for either of the above mentioned 
purposes, it can be used as a core component of other qualitative data analysis 
methods (e.g. grounded theory) and it can be an independent method, 
depending on the overall research objective. For this study, keeping in mind the 
research objectives, thematic analysis was used as an independent method. 
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Unlike IPA and grounded theory analysis, methods which are tied to a specific 
theoretical stance, thematic analysis offers flexibility as it is not tied to any 
particular theory and can be applied across different theoretical stances 
(Sandelowski, 2000). This is what made it the method of choice for the present 
study, keeping in view the pragmatic approach of the author. 
5.5.6.1 Process of data analysis 
Although thematic analysis is widely used, there is no consensus on how to 
undertake a thematic analysis rigorously (Braun and Clarke, 2006). One of the 
contributing reasons for the said problem is the fact that the process of data 
analysis is often not described in detail in the published qualitative reports. 
Braun and Clarke (2006) proposed a six step procedure in an attempt to give 
structure to thematic analysis and ensuring transparency. The same six steps, 
detailed below, were followed by the author to undertake thematic analysis. 
However, it should be noted here, as also highlighted by Braun and Clarke 
(2006), that these steps are not sequentially fixed and the researcher is 
allowed to move back and forth as needed.  
 Familiarising with data (Phase 1) - Familiarisation with the data is the 
first and the most important step of conducting thematic analysis. The 
author familiarised himself with the data through a number of ways: 
Firstly, the interviews were conducted by the author which gave slight 
flavour of the data; Secondly, each transcript was checked against the 
main interview recoding to check the accuracy of the transcription, 
providing more in-depth information about the data; and finally the 
author read and re-read interview transcripts before formally beginning 
the coding of data. 
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 Coding of data (Phase II) – A code is “the most basic segment, or 
element of the raw data or information that can be assessed in a 
meaningful way regarding the phenomenon” (page 63) (Boyatzis, 1998). 
Data were coded manually. Interview transcripts were printed using 
wide margins, allowing the author to write notes. “Post-it” notes were 
also used as required. All interview transcripts were coded line by line 
and segments of the transcripts against each code were highlighted 
using different color highlighters. The process of coding continued until 
all the transcripts were coded. A few examples of coding from an 
interview are shown in Table 6.4. The initial coding framework was 
checked by two senior qualitative researchers (MB, SJC) for accuracy 
and completeness by reviewing two coded interview transcripts.  
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Table 5.2. Example of coding 
Data extract Code 
Medication, that was it really, which seemed inadequate 
most of the time…I didn’t feel that it was doing a lot of 
good at the time but in retrospect and also now I 
wouldn’t like to be without it……..” 
Helpfulness of 
medication 
“I had undergone various physiotherapies to try and get 
rid of it none of which worked, it was still there, and has 
been.” 
Usefulness of 
physiotherapy 
Well our marriage has more or less broken and I think 
that’s a lot of it is to do with me becoming less and less 
able to cope with life in general” 
Inability to cope 
“I can’t ….I ‘m in enough pain not to be able to tolerate 
people who are telling me its not real, you know, 
because it is real” 
Frustration on 
disbelieving 
“Up to now, although the pain is still there, they have 
taken steps to help the emotional side, which that’s, you 
know sort of getting out and meeting people. And [the 
nurse] picked on that very quickly, very, very quickly…” 
Emotional support 
at the pain clinic 
“I have more ideas about what I can do to try and 
control it. So I do feel a little bit more positive because I 
don’t have to just sit and be in pain……” 
Self-management 
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 Searching for themes; Reviewing themes; Defining and naming themes 
(Phase III, IV, V) 
Although Braun and Clarke (2006), have described these as individual 
phases, in practice, these phases are interlinked and not independent, 
especially the later two.  Since these phases ran concurrently, for clarity 
and easy comprehension, the phases have been merged into a single 
phase in the following explanation.  
The process began with the searching for themes. Once all the 
interviews were coded, a list of all the codes was generated. The author 
read through the list of initial codes and removed any duplication. It 
should be noted that only duplicated codes were removed but not the 
data extracts. Following that, different codes were sorted into potential 
themes. The relevant data extracts were collated within these potential 
themes. As the new themes emerged, old ones were reviewed and 
sometimes renamed in the light of emergence of new themes. Mind 
maps were used for collating codes into themes. 
Once the initial set of potential themes was developed, then the 
process of reviewing and, if required, amending the themes began. 
Where deemed appropriate, two themes were collapsed to form a single 
theme and where there was not enough data to support a potential 
theme, that theme was abandoned. The concepts of internal 
homogeneity and external heterogeneity proposed by Patton (1990), for 
judging criteria for categories, guided this process. Internal homogeneity 
means that the data within each theme should be coherent with each 
other, while external heterogeneity means that each theme should be 
clearly different from each other.   
160  
 
This to-and-fro process continued until the set of themes was finalized 
and named. The research objectives guided the data analysis process. An 
example of the above mentioned process is shown in Figure 5.3. 
 
Figure 5.3. Mind map of “impact on life” theme 
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 Producing a report (Phase VI) - As with other forms of data analysis, the 
final step was writing qualitative results. The findings are presented in 
chapter 6 in detail. Data extracts have also been provided to 
demonstrate the prevalence of themes and sub-themes. 
5.5.6.2 Rigour in qualitative data analysis 
  In the past, qualitative research in general and qualitative data analysis 
in particular have been criticized for lacking rigor and transparency (Poses and 
Isen, 1998, Laubschagne, 2003). Like quantitative studies, although in a 
different context, rigour and validity are of key importance in qualitative studies. 
The appropriateness of using positivist terminologies such as validity and 
reliability in qualitative research has been debated among qualitative 
researchers (LeCompte and Goetz, 1982, Lincoln and Guba, 1985, Lather, 
1993, Sandelowski, 1993), some suggesting to abandon their use and use 
alternatives (Ely et al., 1991). Lincoln and Guba (1985) introduced the concept 
of trustworthiness in qualitative research and proposed the terms credibility, 
transferability, dependability and conformability as qualitative equivalents for 
internal validity, external validity, reliability and objectivity respectively. 
Whittemore et al. (2001) proposed 29 strategies to ensure ‘trustworthiness’ in a 
qualitative study, covering various aspects from study design to final report 
writing. Creswell and Miller (2000) outlined eight strategies frequently used by 
qualitative researchers including prolonged engagement, triangulation, peer 
review or debriefing, negative case analysis, researcher reflexivity, member 
checking, rich thick description, and external audits. Creswell (2007) suggested 
that at least two strategies should be used in a qualitative project.  
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For this qualitative study, peer review/debriefing and providing rich thick 
description  (Lincoln and Guba, 1985) were used to ensure credibility and 
transferability of the findings. Peer review/debriefing was carried out by the 
author’s supervisors (SJC and MB).  From study design to report writing, the 
author held regular meetings with his supervisors (SJC, MB, DPA) and 
discussed various aspects of data collection and analysis. A supervision 
meeting report was produced by the author, after each supervision meeting, 
detailing the matters arsing and decisions made during the meeting. All the 
reports were electronically signed by the main supervisor and where necessary 
comments were added. 
“Rich thick description” means that a detailed account of the study 
settings, participants, sampling technique, and data analysis method should be 
provided to ensure transferability of the findings. A detailed account of all 
aspects of data collection (sample size, inclusion/exclusion criteria, interview 
guide, and data analysis) has been made in the earlier sections of this chapter 
to ensure transparency and enabling reading to establish the transferability of 
findings to other settings. In addition to these steps, as mentioned earlier, two 
senior qualitative researchers (MB and SJC) independently reviewed the codes 
and themes against the transcripts.  
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CHAPTER 6 
RESULTS OF QUANTITATIVE PHASE 
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CHAPTER 6                                                                     
RESULTS OF QUANTITATIVE PHASE 
6.1 Introduction 
The results of the quasi-experimental phase (quantitative) are presented in this 
chapter. As mentioned in the previous chapter, both descriptive and inferential 
statistics have been used to analyse the data. Figures and tables have been 
used and embedded in the text to facilitate reading and comprehension. 
The chapter begins with the description of sociodemographic and clinical 
characteristics of participants included in the study. Following that, comparison 
of all outcome measures at baseline, discharge and 3-month follow-up are 
presented. Then, the recommendations, both medicine-related and non-
pharmacological, made to the patients and GPs are described. The chapter 
concludes with the summary of key findings. Where findings are statistically 
significant P-values are presented in bold text. In addition to reporting measures 
of central tendency and spread of data for the outcome variables, where 
appropriate, clinically important differences have also been reported, in line with 
the recommendations of the IMMPACT group (Dworkin et al., 2008). 
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6.2 Sociodemographic characteristics of the patients  
As per the calculated sample size, seventy nine patients were enrolled in the 
study. After completing baseline assessment, one patient withdrew from the 
study for personal reasons before discharge. The mean age of the patients was 
46.5 years SD ± 14.5 (range 22-86). Almost half of the patients were between 
36 to 50 years of age (Figure 6.1). Approximately two thirds of the patients were 
female (67.1%) and more than half of the participants were married or living with 
partner. About a quarter of the patients were working in the private sector 
(24.1%) and slightly more than a quarter (25.3%) was unemployed due to pain. 
Sixty-seven (84.6%) patients were white (British) while six (7.6%) were 
Asian/Asian British. Twenty-nine (36.7%) patients were educated up to 
secondary school level. Almost half of the patients, 48.1% and 44.3%, did not 
disclose their alcohol and smoking status respectively. Details of 
sociodemographic characteristics of patients are presented in Table 6.1 
 
Figure 6.1. Stratification of patients in various age groups 
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Table 6.1. Sociodemographics of patients 
Characteristic N (%) 
Age  
(Mean: 46.49 ; SD:14.5) Range (22-86) 
 
18-35 18 (22.8) 
36-50 37 (46.8) 
51-65 17 (21.5) 
>65 7 (8.9) 
Gender  
Male 26 (32.9) 
Female 53 (67.1) 
Marital Status  
Single 24 (30.4) 
Married/living with partner 45 (57.0)  
Divorced/separated 6 (7.6) 
Widowed 3 (3.8) 
Undisclosed 1 (1.3) 
Living arrangement  
Alone 21 (26.6) 
With partner/children 58 (73.4) 
Employment status  
Public 3 (3.8) 
Private 19 (24.1) 
Self-employed 3 (3.8) 
Retired 14 (17.7) 
Unemployed (pain) 20 (25.3) 
Unemployed (other reason) 14 (17.7) 
Student  2 (2.5) 
Undisclosed 4 (5.1) 
Ethnicity  
White 67 (84.8) 
White others 3 (3.8) 
Asian/Asian British 6 (7.6) 
Arab 2 (2.5) 
Undisclosed 1 (1.3) 
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Education level  
Undisclosed 10 (12.7) 
GCSE/O-Level 29 (36.7) 
A-level/NVQ 19 (24.1) 
Diploma 5 (6.3) 
Degree 10 (12.7) 
Postgraduate 6 (7.6) 
Alcohol status  
Yes 16 (20.3) 
No 25 (31.6) 
Unknown 38 (48.1) 
Smoking Status  
Yes 17 (21.5) 
No 27 (34.2) 
Unknown 35 (44.3) 
 
6.2 History of chronic pain and other medical problems 
More than a quarter of the patients (26.6%) reported suffering from chronic pain 
for one to three years while nine (11.4%) patients had chronic pain for more 
than 10 years (Figure 6.2). Low back (68.4%) followed by lower limb (58.2%) 
were the most commonly reported pain sites by the patients (Figure 6.3). It 
should be noted that patients were allowed to choose more than one pain site.  
The number of pre-existing co-morbidities ranged from zero to four among 
patients. Almost half, 34 (43.0%) of the patients, had no other pre-existing co-
morbidity while 19 (24.1%) had at least one comorbidity. Among the patients 
with pre-existing comorbidities, sixteen (20.3%) patients had asthma while nine 
(11.4%) had Diabetes Mellitus (DM). The majority of patients 56 (70.9%) 
reported to have never been referred to a pain clinic/ pain consultant in the past. 
In terms of source of referral to the pain clinic, as per the referral guidelines, all 
patients were referred by their GPs. However, for 12 patients (15.2%) a hospital 
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physician/consultant requested referral and nine (11.4%) of the patients were 
referred on the request of physiotherapists (Figure 6.4).  Thirty-five (44.3%) 
patients had their first consultation with both the nurse and the pharmacist while 
44 (55.7%) patients had their first consultation with the nurse only. 
  
Figure 6.2. Stratification of patients based on pain duration in years 
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Figure 6.3. Chronic pain sites in patients referred to the pain clinic 
  
Figure 6.4. Source of referral to the pain clinic 
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Table 6.2. Pain and other medical history of patients  
Item N (%) 
Pain Duration (Years)  
< 1 year 13 (16.5) 
1 to 3 21(26.6) 
3-5 19 (24.1) 
5-10 17 (21.5) 
>10 9 (11.4) 
Comorbidity  
Diabetes Mellitus 9 (11.4) 
Hypertension 8 (10.4) 
Asthma 16 (20.3) 
Hypothyroidism 6 (7.6) 
Ischemic Heart Disease 6 (7.6) 
Others 30 (38.0) 
Number of comorbidities  
None 34 (43.0) 
1 19 (24.1) 
2 15 (19.0) 
3 10 (12.7) 
4 1(1.3) 
Past visit of pain clinic/consultant  
No 56 (70.9) 
Yes 23 (29.1) 
Route of referral  
GP 57 (72.2) 
Hospital Doctor 12 (15.2) 
Physiotherapist 9 (11.4) 
Self 1 (1.3) 
Healthcare professional seen  
Nurse only 44 (55.7) 
Nurse and pharmacist 35 (44.3) 
 
171  
 
6.3 Outcome measures 
6.3.1 Pain intensity  
As mentioned in the methods chapter, pain intensity was measured using 
an 11-point NRS, administered as part of the BPI. Patients were asked to rank 
the worst pain, least pain and average pain that they had experienced in the 
past 24 hours.  Patients were also asked to rank “pain right now” as well using 
the same 11-point NRS. 
For baseline, pain intensity scores were available for all 79 patients. 
However, at discharge pain scores were available for 35 patients only. Since 
pain intensity data were not normally distributed therefore the data are 
expressed as medians with respective interquartile ranges (IQR). At baseline, 
the median values (IQR) of worst pain, least pain, average pain, and  pain right 
now  were 8 (7; 9), 5 (3;7), 7 (5; 8), and 7(5; 8) respectively. Upon discharge, 
there was a statistically significant reduction for worst pain (P = 0.02) and 
average pain (P = 0.02). However, for least pain and pain right now the 
reduction in pain intensity score was not statistically significant (P = 0.12) and 
P=0.06 respectively (Table 6.3). 
To improve clinical interpretation of the results, patients were classified 
into groups based on the recommendations of the IMMPACT group on 
benchmarks for interpreting clinically important changes (Dworkin et al., 2008).  
As per the recommendations of the IMMPACT group, a 10-20% decrease in 
pain intensity was considered minimally important, ≥ 30% decrease was 
considered moderately important and a reduction of ≥50% was considered 
substantially important (Dworkin et al., 2008). Additionally, patients achieving a 
reduction in “average pain” intensity score of less than 10% were grouped under 
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“no meaningful change” and patients for whom “average pain” intensity scores 
were more than the baseline scores were grouped under “deterioration in pain 
score”. Thirteen (37.1%) patients achieved a minimum clinically important 
difference while two (5.7%) each achieved moderately and substantially 
important differences (Figure 6.5). For 3-month follow-up, pain intensity scores 
were available for 9 patients only. The median (IQR) values for worst pain, least 
pain, average pain, and pain right now were 7 (5.50;8), 4 (3;6), 5 (4;6.5), 5 (2;7) 
The results of 3-month follow-up were not statistically compared with the 
baseline as the number of patients for 3-month follow-up was too small to make 
any meaningful comparison.  
Table 6.3. Comparison of pain intensity scores at the baseline and  
discharge 
 N N* Median (IQR) Z  **P value 
Worst Pain      
Baseline 79 35 8.00 (7.00;9.00) - 2.41 0.02 
Discharge 35  7.50 (5.00; 8.00) 
Least Pain      
Baseline 79 35 5.00 (3.00; 7.00) -1.56 0.12 
Discharge 35  4.00 (2.00; 6.00) 
Average pain      
Baseline 79 35 7.00 (5.00; 8.00) -.2.32 0.02 
Discharge 35  6.00 (4.00;7.00) 
Pain right now      
Baseline 79 35 7.00 (5.00; 8.00) -1.82 0.06 
Discharge 35  6.00 (2.00; 7.00) 
* Number of patients for whom pain scores were available both at the baseline 
and discharge. **Calculated from Wilcoxon-Signed rank test. 
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Figure 6.5. Stratification of patients based on clinically important changes 
in average pain intensity  
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was also a trend of reduced interference in the remaining five domains but this 
did not reach statistical significance (Table 6.4). 
BPI scores were available for only nine patients for the 3-month follow-
up. Statistical analyses were not performed as the numbers were too small to 
make any meaningful comparison between the baseline and 3-month follow-up 
results.  
Like pain intensity, patients were classified into groups as per the 
recommendations of IMMPACT group on benchmarks for interpreting clinically 
important changes for physical functioning (Dworkin et al., 2008). A reduction of 
one point in the overall interference of pain is considered minimum clinically 
important. But unlike pain intensity, criteria for defining a moderate and 
substantial change have not been described by the IMMPACT group (Dworkin 
et al., 2008). Patients not meeting criteria for the minimum clinically important 
difference were either  classified into “no clinically important reduction” if there 
was a reduction in the overall interference score upon discharge, or into 
“deterioration of physical activity” if the overall interference score was higher at 
the discharge compared to the baseline (Figure 6.6). Fourteen (40%) patients 
achieved minimum clinically important difference. 
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Table 6.4. Comparison of pain interference with physical functioning at 
baseline and discharge 
Item N N* Median (IQR) Z **P 
General Activity  
Baseline 79 35 7.00 (6.00;9.00) -1.58 0.11 
Discharge 35  7.00 (3.00; 9.00) 
Mood  
Baseline 79 35 7.00 (5.00;9.00) -1.25 0.21 
Discharge 35  5.00 (2.00; 8.00) 
Walking ability  
Baseline 79 35 8.00 (4.00;10.00) -1.43 0.15 
Discharge 35  7.00 (3.00;10.00) 
Normal work  
Baseline 79 35 8.00 (5.00;10.00) -1.93 0.05 
Discharge 35  7.00 (4.00;9.00) 
Relationship with other people 
Baseline 79 35 6.00 (2.00;8.00) -0.21 0.84 
Discharge 35  5.00 (1.00;8.00) 
Sleep  
Baseline 79 35 8.00 (6.00;10.00) -1.98 0.04 
Discharge 36  7.00 (4.00;10.00) 
Enjoyment of Life  
Baseline 79 35 7.00 (5.00;9.00) -2.60 0.01 
Discharge 36  6.00 (2.00;9.00) 
Over all Interference  
Baseline 79 35 7.14 (5.71;8.28) -2.31 0.02 
Discharge 36  6.14 (4.00; 8.71) 
*Number of patients for whom both baseline and discharge scores were 
available.** Calculated from Wilcoxon-Signed rank test. 
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Figure 6.6. Stratification of patients based on clinically important changes 
in overall pain interference with daily activities 
 
6.3.3 Anxiety and Depression 
Anxiety and depression were assessed by using the respective subscales of the 
Hospital Anxiety and Depression Scale (HADS). Both HADS-A and HADS-D 
were divided into four ranges: normal (0-7); mild (8-10); moderate (11-15); and 
severe (16-21). The median HADS-A score at baseline was 10 (7; 14), 
calculated for 76 patients (missing data for 3 patients).  Almost two-thirds of the 
patients (67.1%) had HADS-A scores more than 7, i.e. were likely to have an 
anxiety disorder. Twenty-four (31.6%) patients had moderate anxiety (Table 
6.5). The median HADS-A score upon discharge was 8.5 (5.75; 12.25), 
calculated for 34 patients. However, the reduction in the median HADS-A score 
was not statistically significant (P = 0.21). However, for 13 (38.2%) patients 
there was a reduction in the severity of anxiety by at least one category (e.g. 
moderate to mild or severe to moderate etc.). 
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Table 6.5. Categorisation of patients based on HADS-A scores at the 
baseline and discharge 
HADS-A Baseline 
N (%) 
N = 76 
Discharge 
N (%) 
N = 34 
Change in 
category  
N (%) 
N = 34 
Normal 25 (32.9) 14 (41.2) ≤ -1 13 (38.2) 
Mild 14 (18.4) 10 (29.4) 0 13 (38.2) 
Moderate 24 (31.6) 7 (20.6) ≥ 1 8 (23.5) 
Severe 13 (17.1) 3 (8.8)   
 
The depression scores (HADS-D) at baseline were calculated for 76 patients 
with a median score of 10.00 (5.00; 13.00). The majority of the patients (46 
[60.5%]) had HADS-D scores more than 7, likely to suffer from depression. 
Twenty-seven (35.5%) patients had moderate depression and eight (10.5%) 
had severe depression (Table 6.6). The HADS-D scores upon discharge were 
available for 34 patients with a median score of 8.00 (3.75; 12.25). Like anxiety, 
the reduction in the HADS-D score was not statistically significant (P = 0.22). 
However, a reduction in severity of depression by at least one category was 
noticed in 7 (20.6%) patients (Table 6.6). 
 For the 3-month follow-up HADS-A and HADS-D scores were available 
for nine patients. Of these nine patients, the majority of them (n=6) had their 
HADS-A scores less than 7, likely not to suffer from any anxiety disorder. The 
remaining three patients had mild (n=1), moderate (n=1) and severe (n=1) 
anxiety. Compared to the baseline, at the 3-month follow-up, there was 
reduction in the severity of anxiety by at least one category for three patients 
(33.3%). While, no change (improvement or worsening) was found for five 
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patients (55.6%) and increase in the severity of anxiety by at least one category 
was found in one patient (11.11%).  
 Similar to the HADS-A score, six patients had their HADS-D scores less 
than 7, likely not to suffer from any depression disorder. One each had mild, 
moderate and severe depression. Compared to the baseline, there was 
reduction in the severity of depression by at least one category for two patients 
(22.2%); no change in severity class for five patients (55.6%); and increase in 
severity by at least one category for 2 patients (22.2%) at the 3-month follow-up. 
Table 6.6. Categorisation of patients based on HADS-D scores at the 
baseline and discharge 
HADS-D Baseline 
N = 76 
N (%) 
Discharge 
N = 34 
N (%) 
Change in 
category  
N (%) 
N = 34 
Normal 30 (39.5) 16 (47.1) ≤ -1 7 (20.6) 
Mild 11(14.4) 5 (14.7) 0 21 (61.8) 
Moderate 27 (35.5) 10 (29.4) ≥ 1 6 (17.6) 
Severe 8 (10.5) 3 (8.8)   
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6.3.4 Chronic pain grade 
As mentioned in the previous chapter, the CPG questionnaire was scored using 
the method suggested by Von Korff et. al. (1992). Patients were classified into 
one of the four hierarchical categories according to pain severity:  
 Grade I, low disability-low intensity. 
 Grade II, low disability-high intensity. 
 Grade III, high disability-moderately limiting. 
 Grade IV high disability-severely limiting.  
At baseline, CPG scores were calculated for 76 patients. The median for 
pain intensity score was 76.66 (66.67; 83.33) and the median for disability score 
was 70 (60.00; 90.00) at baseline. Compared to the baseline, there was a 
statistically significant reduction in pain intensity (Median 73.33; IQR 55.00; 
83.33) at discharge (P = 0.02). However, no statistically significant improvement 
in disability score was found (P = 0.89) at the discharge (Median 73.33; IQR 
51.66; 91.67).   
At the baseline, a majority of the patients (50 [65.8%]) were categorised 
in grade IV. CPG scores at discharge were available for 34 patients. In terms of 
change in chronic pain grade, 7 (20.6%) patients reported improvement in 
chronic pain grade by at least one grade. However, the majority of the patients, 
21 (61.7%) did not report any improvement (Table 6.7). 
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Table 6.7 Comparison of chronic pain grade at the baseline and discharge 
Chronic Pain 
Grade 
Baseline 
N (%) 
N=76 
Discharge 
N (%) 
N=34 
Change in 
Grade 
(Outcome) 
N (%) 
N=34 
I 2 (2.6) 4 (11.8) ≤ - 1 7 (20.6) 
II 13 (17.1) 2 (5.9) 0 21 (61.7) 
III 11 (14.5) 7 (20.6) ≥ 1 6 (17.6) 
IV 50 (65.8) 21 (61.8)   
 
6.3.5 Quality of life 
As discussed in the methods chapter (section 5.3.4.5), quality of life was 
assessed using SF-36. It should be noted here that higher scores represent a 
better quality of life. Both the individual domain scores and summary scores 
(Physical and Mental) have been presented in Table 6.8. The comparison of 
QoL scores between baseline and discharge is shown in Figure 6.7. For 
individual domain scores, compared to the baseline score statistically significant 
improvements were found in physical role (RP) (P= 0.01), bodily pain (BP) 
(P=0.01) and social functioning (SF) (P=0.03) at discharge. However, there 
were no statistically significant differences in physical component summary 
(PCS) scores (P=0.15) and mental component summary (MCS) scores 
(P=0.08).  
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Figure 6.8. Comparison of QoL at the baseline and discharge. 
PF=Physical Functioning; RP= Physical Role; BP=Bodily Pain; GH=General 
health; VT=Vitality; SF=Social Functioning; RE=Emotional Role; 
MH=Mental Health; PCS= Physical Component Summary; MCS=Mental 
Component Summary 
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Table 6.8. Comparison of quality of life at baseline and discharge 
Domain N N
* 
Mean (SD) T  **P 
PF      
Baseline 78 36 28.84 (11.03) 1.11 0.27 
Discharge 36  30.82 (12.92)   
RP      
Baseline 78 35 24.64 (28.63) 2.89 0.01 
Discharge 36  36.66 (33.12)   
BP      
Baseline 78 36 14.22 (17.56) 3.28 0.01 
Discharge 36  28.63 (23.84)   
GH      
Baseline 77 35 38.97 (23.83) 1.26 0.21 
Discharge 35  42.68 (26.41)   
VT      
Baseline 79 36 26.04 (21.93) 1.73 0.09 
Discharge 36  31.30 (25.57)   
SF      
Baseline 78 36 33.33 (30.17) 2.16 0.03 
Discharge 36  42.01 (34.47)   
RE      
Baseline 77 34 Median 50.00 
IQR (20.83;83.33) 
 Z= -
1.654 
***0.098 
Discharge 36  Median 54.16 
IQR (25.00; 100.00) 
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MH 
Baseline 79 36 49.13 (24.63) 0.98 0.33 
Discharge 36  52.91 (23.34)   
PCS      
Baseline 74 33 28.84 (11.03) 1.49 0.15 
Discharge 35  30.82 (12.92)   
MCS      
Baseline 74 33 36.34 (15.17) 1.83 0.08 
Discharge 35  41.20 (14.63)   
*Based on the number of patients for whom both scores were available. 
**Calculated from paired t-test.***Calculated from Wilcoxon signed rank test. 
PF=Physical Functioning; RP=Role-Physical; BP=Bodily Pain; GH=General 
health; VT=Vitality; SF=Social Functioning; RE=Emotional Role; MH=Mental 
Health; PCS= Physical Component Summary; MCS=Mental Component 
Summary 
184  
 
6.4 Nature of intervention 
Data on the nature of the intervention were available for 35 patients. The 
mean number of visits made by each patient to the pain clinic was 3.05 
(S.D=0.97) (Range 2 to 6). Fourteen (40%) of the patients were discharged 
after 3 visits (Table 6.9). Recommendations were made to the GP for 34 
(97.1%) patients. In total, 101 medicine-related recommendations were made to 
the GP with a mean of 2.9 (range 1 to 6) recommendations per patient. For 
most of the patients [22 (62.8%)] 3 to 5 medicine-related recommendations 
were made to their GPs. In addition, 34 non-pharmacological recommendations 
were made in total with a mean of 1.3 (range 1 to 3) per patient. The different 
types of medicine-related interventions made at the clinic are shown in Figure 
6.7. Adding a new drug (n = 30) followed by titrating the dose (n = 29) were the 
most commonly made recommendations. Among non-pharmacological 
recommendations, pacing activities (n = 18) were the most common. Other non-
pharmacological interventions included referrals to: physiotherapy (n = 3); 
psychological therapy (n = 3); and a local pain support group (n = 6). Six 
(17.1%) patients were also referred for spinal injection. 
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Table 6.9. Care process at the pain clinic 
Item  N (%) 
Number of visits  
2 11 (31.4) 
3 14 (40.0) 
4 8 (22.9) 
5 1 (2.9) 
6 1 (2.9) 
Recommendation made to the GP  
Yes 34 (97.1) 
No 1 (2.9) 
Number of pharmacotherapeutic recommendations  
No recommendation 1 (2.9) 
Less than 3 9 (25.7) 
3-5 22 (62.8) 
More than 5 3 (8.5) 
Referrals   
Physiotherapy 3 (8.5) 
Spinal injection 6 (17.1) 
Psychological therapy 3 (8.5) 
Support group 6 (17.1) 
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Figure 6.9. Number of pharmacological recommendations made at the 
pain clinic 
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6.5 Summary of key findings 
 Seventy-nine patients were enrolled in the study. Data collection upon 
discharge was stopped as the service was decommissioned by the 
Leeds Primary Care Trust and was available for 36 patients. 30 patients 
were sent the 3-month follow-up questionnaires, only nine patients 
returned the questionnaires (BPI and HADS). 
 
  Almost half of the patients were between 36 to 50 years of age (range 
22-86). Approximately two thirds of the patients were female. 
 
 Slightly more than a quarter (25.3%) of patients was unemployed due to 
pain.  
 
 More than half (56.6%) of the patients had chronic pain for more than 3 
years and 56 (70.9%) patients had never been referred to a pain 
clinic/consultant in the past. 
 
 For pain intensity, statistically significant reduction was noted for worst 
pain (P = 0.02) and average pain (P = 0.02) but not for (P = 0.12) least 
pain and pain right now (P=0.06). Thirteen (37.1%) patients achieved a 
minimum clinically important difference while two (5.7%) each achieved 
moderately and substantially important differences. 
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 For physical functioning, overall interference of pain with physical activity 
was significantly reduced (P=0.02) at the discharge. Fourteen (40%) 
patients achieved minimum clinically important difference. 
 
 For anxiety and depression, no significant differences were found 
between baseline and discharge scores for HADS-A and HADS-D. 
However, a reduction in severity of anxiety and depression by at least 
one category was noticed in 13 (38.2%) and 7 (20.6%) patients 
respectively.  
 
 For chronic pain grade, 7 (20.6%) patients reported improvement in 
chronic pain grade by at least one grade. However, the majority of the 
patients, 21 (61.7%) did not report any improvement. 
 
 For quality of life (SF-36), among individual domains, there were 
significant improvements in physical role (RP) (P=0.01), bodily pain (BP) 
(P=0.01) and social functioning (SF) (P=0.03). However, for summary 
scores, there were no significant improvements in either physical 
component summary (PCS) (P=0.15) or mental component summary 
(MCS) (P=0.08).  
 
 For 35 patients, 101 medicine-related (2.9 per patient) and 34 non-
pharmacological (1.3 per patient) recommendations were made. Adding 
a new drug and titration of the dose were the most frequently made 
medicine-related recommendations.  
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CHAPTER 7                                                                     
FINDINGS OF THE QUALITATIVE PHASE 
7.1 Introduction 
This is the second of the two results chapters of this thesis. In the previous 
chapter the results of the quasi-experimental study, quantitative phase, have 
been presented. In this chapter findings of the descriptive qualitative study are 
presented. As mentioned earlier, the main objective of the qualitative study was 
to explore patients’ views about their satisfaction with the care received from the 
pain clinic. In addition, patients’ experiences of living with chronic pain and 
using other chronic pain services were also explored. The rationale and 
methods for the descriptive qualitative study have been presented earlier in 
chapters 4 and 5. 
The chapter begins with a description of the sociodemographic 
characteristics of the participants. Following that the key themes and subthemes 
which emerged from the data analysis are outlined. Anonymized quotes from 
the participants’ interviews have also been provided within each theme and 
subtheme, a measure to ensure the trustworthiness of the findings. A theme 
summary is also presented at the end of the each theme. 
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7.2 Sociodemographic characteristics of participants 
In total, 19 participants including eight males and eleven females were 
interviewed. The age of the participants ranged from 27 to 74 years. Ten 
interviews were conducted at patients’ homes, eight at the pain clinic and one at 
the patient’s office (during lunch break). Interviews lasted between 25 and 45 
minutes. The sociodemographic characteristics of the participants are given in 
Table 7.1. 
Table 7.1. Sociodemographic characteristics of participants  
 ID Age 
in 
Years 
Gender Employment 
status 
Marital 
status 
Chronic 
pain 
duratio
n 
in Years 
Pain 
intensity 
(baseline) 
Pt.1 36 Female Full-time Married 5-10 5 
Pt. 2 49 Male Full-time Married 5-10 5 
Pt. 3 63 Male Retired Married 5-10 5 
Pt. 4 30 Male Full-time Married 5-10 6 
Pt. 5 74 Female Retired Undisclosed < 1 0 
Pt. 6 58 Female Unemployed Divorced > 10 7 
Pt. 7 39 Male Unemployed Single 1- 3 7 
Pt. 8 40 Female Part-time Married < 1 7 
Pt. 9 51 Male Part-time Married 3-5  10 
Pt. 10 54 Female Undisclosed Divorced 3-5 7 
Pt. 11 44 Female Part-time Single 1-3  5 
Pt. 12 39 Female Full-time Married > 1  8 
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Pt. 13 54 Male Unemployed Widowed 5-10  10 
Pt. 14 64 Female Retired Married > 10 5 
Pt. 15 55 Male Full time Married 3-5 9 
Pt. 16 54 Female Part time Married  1-3 6 
Pt. 17 48 Female Unemployed Married >10  4 
Pt. 18 27 Female Unemployed Married 1-3 5 
Pt. 19 47 Male Full time Single >10 7 
7.3 Key themes 
Three major themes emerged from the data: impact on life; barriers to effective 
pain care; and satisfaction with the service provided at the pain clinic. The 
detailed description of each theme and its sub-themes is presented below. 
7.3.1 Impact on life 
The patients reflected on the multidimensional negative impact of chronic pain 
on their lives. From not being able to enjoy a television programme through to 
the inability to work full-time, chronic pain turned the lives of the patients upside 
down. The patients were unable to enjoy their lives, as chronic pain interfered 
with their sleep, mood, and physical functioning. Chronic pain even affected 
their relationships with their partners and/or children.  
“It’s hard to explain to people how you actually feel.  It’s like, walk 
in my shoes for a week and you will see exactly what my life is, you 
know.” [Pt. 6, 58 years old female] 
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“I can’t kneel down, I can’t squat, I can’t put my own socks on, he 
has to put my socks on for me.  So that shows how much the pain affects 
your life.” [Pt. 14, 64 years old female] 
Major sub-themes in the “impact on life” theme are outlined in Figure 7.1. The 
detailed description of each sub-theme is  given below.  
 
Figure 7.1. Sub-themes within the impact on life theme 
 
7.3.1.1 Interference with physical functioning 
The interference of chronic pain with their physical functioning was seen as the 
root cause of all the other problems in the lives of chronic pain patients. It 
restricted patients’ physical activity to an extent that they struggled to perform 
simple daily routine tasks like cooking, washing and hoovering.  
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“I can’t do things that I want to do physically, it just restricts me 
and it’s getting worse and worse and worse.” [Pt 4, 30 years old male] 
“Even things like bending down to the washing machine, maybe I 
can get down but then I can’t get back up again, [laughs] so I’ve got to 
physically drag myself up from the thing.” [Pt. 8, 40 years old female]. 
In addition to the increase in pain severity, another factor which contributed to 
patients’ restricted physical activity was their lack of energy. A few patients 
described chronic pain as an “energy drain”- depriving them of their energy, 
meaning that they had to adjust their lives accordingly. 
“I think it’s like a niggling injury or a niggling pain, it’s just there all 
the time and it’s just draining, a drain on your life.” [Pt. 1, 36 years old 
female] 
“Well basically it was like somebody had taken… zapped me of all 
my energy for one, and my life had to change because I couldn’t do 
things like I did before.” [Pt. 6, 58 years old female]  
7.3.1.2 Interference with employment 
The majority of the participants also described negative impacts on their 
professional life. The impact on employment was directly associated with the 
patients’ inability to be physically active. Since chronic pain restricted their 
physical activity, some patients had to stop working, switch jobs or work only on 
a part-time basis. Subsequently, the patients had to face financial problems as 
they were not able to work full-time. 
“It’s ruined it.  It’s totally ruined it, you know.  I can’t work in my 
job I‘ve done for 22 years, suddenly that’s it, it’s gone.” [Pt. 9, 51 years 
old male] 
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“When I started with this back pain and I went off sick that was it.  
They waited the statutory two years and got rid of me. So that was very 
difficult.” [Pt 15, 55 years old male] 
“I was earning 1,000 pound and now that’s cut our income down 
by half.”  [Pt. 10, 54 years old female] 
However, the impact of chronic pain was not significant for all patients and a 
couple of patients continued to work as before despite suffering from chronic 
pain. 
“I’m the kind of person that regardless of what I’m… if I’m ill or I’m 
in pain I still work.  I’ve been like that all through my life and I think the 
past 6-7 years I’ve had two days off ill.” [Pt. 4, 30 years old male] 
“Well it’s not massively affected me.  I mean… I can… I still do 
anything that I used to do it’s just that I put up with the pain.” [Pt 2, 49 
years old male] 
7.3.1.3 Interference with family life 
A number of the patients described the negative impact on their relationships 
primarily due to their inability to fulfill their partner’s expectations. The patients 
felt that they had become a burden on their partners/spouses as they were not 
able to perform their own daily routine tasks due to the pain. 
“Well it puts pressure on it because I can’t stand and iron, I can’t 
hoover or anything for too long because then the pain starts coming on.  
If the pain’s bad we won’t go out anywhere because I just can’t drive.  So 
yes it does affect that, it puts a strain on it.” [Pt. 4, 30 years old male] 
“Well, our marriage has more or less broken down and I think that 
a lot of it is to do with me becoming less and less able to cope with life in 
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general, which seems a bit harsh but there you go.  But yes, it’s heart 
breaking knowing what I used to be able to do.” [Pt 10, 54 years old 
female] 
However, patients also recognised the importance of support from family and 
friends in helping them overcome chronic pain. Family and friends provided 
patients with both physical and emotional support, enabling them to cope well 
with their difficulties. Family and friends were seen as giving patients a purpose 
to continue living and fighting their chronic pain.  
“Easily, I would have taken my life a long time ago if it weren’t for 
my children and my husband, I wouldn’t be here now, no way.” [Pt. 12, 
39 years old female] 
“If I get pain that bad I end up taking my frustrations out on my 
son and my daughter, which is wrong, which I shouldn’t do, but they’re 
the only people there that I can bounce off. Yes, yes, if it wasn’t for my 
son and my daughter I’d either be locked up or dead, one of the two.” [Pt. 
13, 54 years old male] 
“I’ve got my husband and he helps, well we work together you 
know.” [Pt. 14, 64 years old female] 
Chronic pain did not only negatively affect patients’ relationships with their 
partners but also relationships with their children/grandchildren. Quite a number 
reflected on their inability to actively engage in activities with their children. The 
patients were annoyed and displeased because they were not able to play with 
their children like other parents due to persistent pain.   
“I couldn’t take my daughter places where I’d do things, you 
know, like running round the park as other parents do, I couldn’t do any 
of that.” [Pt. 15, 55 years old male] 
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“He’s quite an active little boy so I can find it difficult to kind of 
keep up with him.” [Pt. 18, 27 years old female] 
“There’s nothing wrong with me, you know, it’s not chopped off, 
it’s not broken it just annoys me because you can’t do stuff with the kids, 
you know what I mean.” [Pt 7, 39 years old male] 
This did not only affected the patients but also their children as they were no 
longer able to play or go out with their parents.   
“They’re suffering as in we don’t go out on weekends anymore.  
We used to go walking everywhere and now they’re got getting out.”[Pt. 
8, 40 years old female] 
7.3.1.4 Interference with social life 
As with other aspects of life, the social life of the patients suffered as well. The 
patients had to give up their social lives and became socially isolated either 
because of the restricted physical activity associated with chronic pain or due to 
depression resulting from the pain. They became confined to their homes and 
were not able to go out and enjoy their lives like their peers.  
“It’s completely screwed my life up.  I can’t go back to work, I 
can’t work, I can’t go out.  I can’t remember the last time I was in a pub, 
and I’m stuck in four walls, I’m stuck in my house.” [Pt. 13, 54 years old 
male] 
“I just cut back on doing things socially and that changes you as a 
person really when you’re not sort of like getting the most out of things.” 
[Pt. 19, 47 years old male] 
Patients avoided engagement in social activities when in pain as a coping 
strategy. This reflects that, perhaps depression associated with chronic pain 
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may be a key contributing factor towards chronic pain’s interference with social 
activity.  
“I am a sociable person but when you’re in pain I go quiet and I 
don’t want to be talking because I'm concentrating on getting rid of this 
pain.” [Pt. 6, 58 years old female] 
Since the patients were not able to socially engage in activities outside their 
homes, they lost interest in getting dressed and looking good, another indication 
of depression being a contributing factor. 
“No I don’t bother getting dressed, I just think, well I’m not going 
out so what’s the point.  It’s affected my appearance, I can’t be bothered, 
I can’t drink anymore so we haven’t been out to the pub for over a year.” 
[Pt. 8, 40 years old female] 
 
Similarly, patients were unable to continue to play sports due to fitness 
problems, lack of energy and motivation, common consequences of chronic 
pain.  
“I used to play football and I can’t play football or golf.  I can’t play 
a full round of golf anymore.” [Pt 4. 30 years old male] 
“I was always very active, I couldn’t do the sport that I used to do, 
I was still only in my early 30s then, I was still playing football then.  I had 
to stop all that.” [Pt. 15, 55 years old male] 
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7.3.1.5 Interference with sleep 
Sleep deprivation was also reported by a number of patients. In addition to the 
problem with falling asleep, repeatedly waking up during the night because of 
pain was also seen as a major issue which prevented them enjoying a good 
night’s sleep. As a result, the patients were not able to perform their daily 
activities/work efficiently and felt tired all the time.  
“I think the biggest problem for me is sleep deprivation when I 
wake up in the night I find it very difficult to get back to sleep and I think 
when you’re tired everything is worse, the whole world is worse”. [Pt. 1 
36 years old female] 
“I’m always tired because yes you move about 10-15 times in a 
night but when you’re in pain you wake up and it’s hard to get back to 
sleep.” [Pt. 7, 39 years old male] 
Patients believed that their poor sleep affected their ability to cope well with 
chronic pain. 
“It keeps you awake; you’ve no energy to face the day. If you get 
a good night’s sleep it’s not so bad, you can cope during the day but 
during the night when you’re kept awake that is bad.” [Pt. 14, 64 years 
old female] 
7.3.1.6 Interference with mood 
Chronic pain not only affected patients physically but also mentally. A majority 
of the patients described negative impact of chronic pain on mental functioning. 
The impact of pain on mood was often very apparent. 
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“It affected my mood, of course it did, yes it does affect your 
mood, pain does.  You try and ignore it but you can’t sometimes.”[Pt. 16, 
54 years old female] 
Two important associations came up during the analysis. Firstly, the patients 
linked their anger and frustration with their inability to perform daily activities. As 
described above, the patients were unable to perform routine daily activities as 
their physical activity was limited by their pain.  
“You can’t do things that you want to do or if you do them it’s 
painful, it’s very frustrating and that can make you very sort of, not 
anxious but very kind of het up about things and very frustrated.” [Pt. 1, 
36 years old female] 
“I couldn’t do things like I did before, like taking the curtains down 
and putting them up, like moving objects too heavy, so it was very 
frustrating and I was so annoyed, really angry that I couldn’t do these 
things.” [Pt. 6, 58 years old female] 
Secondly, patients described a two-way association between pain and 
depression. Patients felt depressed due to pain and experienced more intense 
pain when depressed. 
“You know, if you’re a bit depressed it [pain] seems to be worse 
than it is.” [Pt. 3, 63 years old male] 
“It’s a bad combination, it’s a really, really bad combination.  It 
just… because when you get down you think about your pain more.” [Pt. 
12, 39 years old female] 
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Patients experienced low mood because of their pain but recognised the 
importance of keeping a positive attitude to avoid escalating the negative impact 
of chronic pain on their mood.  
“But I also feel it’s a vicious circle because the more depressed I 
get or the more down I feel then I believe that my body responds to the 
emotional thing as well.  And I believe that stuff gets worse if you can’t 
keep a positive attitude.” [Pt. 10, 54 years old female] 
Foreseeing little to no chance of improvement in their pain and fearing 
continuous suffering associated with pain for the rest of their lives also 
contributed to patients’ low mood. 
“…mentally I just thought, I don’t want to live like this, you know.  
And that’s when you think that it’s never going to go away.” [Pt. 5, 74 
years old female] 
“When the pain was really bad I’d often kind of feel quite low and 
feel like it was never going to improve.” [Pt. 18, 27 years old female] 
7.3.1.7 Theme summary 
Within this theme, the impact of chronic pain on various aspects of patients’ 
lives was explored. Chronic pain changed patients’ lives to a great extent, with 
limited physical activity being the root cause of the majority of the other 
problems. It restricted their physical activity, compromising their ability to work, 
play with their children, enjoy a good relationship with their spouses, perform 
routine tasks and enjoy a good night’s sleep. This led to anger, frustration and 
depression. When depressed, the patients felt more pain and lacked motivation 
to engage in any physical activity. This became a vicious circle which it was 
often difficult to break and come out from.  
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7.3.2 Barriers to effective pain care 
In general, the patients had predominantly negative experiences with healthcare 
professionals, and described dissatisfaction and displeasure with the service 
that they received in the past from various healthcare professionals especially 
from the GPs. During the interviews the patients highlighted a number of 
barriers which affected the quality of care that they received. These barriers 
have been classified into two categories: healthcare professional-related and 
healthcare system-related (Figure 7.2). 
 
Figure 7.2. Sub-themes within barriers to effective pain care theme 
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7.3.2.1 Healthcare professional-related barriers 
Healthcare professional-related barriers included: lack of interest and empathy; 
lack of GP’s specialised knowledge; short consultation time with GPs; and lack 
of communication between healthcare professionals. Since chronic pain is 
predominantly managed in primary care, a number of the barriers in this 
category were related to the GPs’ ability to assess and manage chronic pain. 
However, some of the issues identified by the patients were not only limited to 
GPs but also applied other healthcare professionals. These barriers have not 
been listed in any order of priority.  
a. Lack of interest and empathy  
A number of patients expressed concerns over the lack of interest shown by 
healthcare professionals in listening to their problems and managing their pain. 
The patients felt that, perhaps chronic pain was not a life-threatening disease 
(like, for example, cancer), healthcare professionals were not interested in 
identifying the cause of the pain. 
“I went to my GP and was just told it’s wear and tear, age, nothing 
we can do about it, left it at that.” [Pt. 9, 51 years old male] 
The patients were disappointed and felt that they were wasting their time in 
explaining their problem as no one was interested in listening to their problems.  
“I’m not getting anywhere and I thought, oh don’t bother saying 
anything, it’s a waste of time, nobody’s listening – that’s what I’m trying 
to say.” [Pt. 6, 58 years old female] 
The patients felt that the GPs did not understand pain well enough to appreciate 
its negative impact on their daily lives, and this lack of understanding was very 
frustrating for them (patients). 
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“They [GPs] don’t understand what the pain is.  They just look at 
you and think, well how you can have pain, you know, they don’t realise 
what pain is and what it does to you.  I mean at times it drives me mad.” 
[Pt. 13, 54 years old male] 
A few of the patients considered that rheumatologists on the other hand were 
only interested in listening to their initial problems, but not to their other ongoing 
problems, which sometimes might have been of more importance to the 
patients.  
“And then from rheumatology they don’t listen to you, they don’t… 
they listen to the initial problem and then they just do what they want to 
do and they don’t listen to the ongoing problems from thereon.” [Pt. 4, 30 
years old male] 
The patients found that physiotherapists were not different from the GPs and 
rheumatologists in terms of listening and understanding their medical problems. 
A few were told that there was nothing wrong with them and they were not 
suffering from chronic pain. 
“My last visit to physiotherapy at the hospital rheumatology, she 
just didn’t want to listen, she didn’t think that there was much wrong with 
me and pushed me straight out the door effectively.” [Pt. 4, 30 years old 
male] 
A number of the patients felt that they were disbelieved and judged by the 
healthcare professionals. They were annoyed by these attitudes and this led 
them to stop seeking any further treatment from that particular healthcare 
professional. 
“The second physiotherapist I saw basically told me that the pain 
was in my imagination.  So I had one appointment with him and he said 
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that I was imagining it, it wasn’t real and I didn’t go back because it is 
real to me. I’m in enough pain not to be able to tolerate people who are 
telling me it’s not real, you know, because it is real. [Pt. 10, 54 years old 
female] 
However, the patients also praised some GPs who listened to them and showed 
a duty of care towards them. 
“… I don’t feel as they’ve just been giving me anything just to get 
rid of me, no they’ve been good.”[Pt.16, 54 years old female] 
“My GP is superb.  He will say, what’s wrong with you, like blah-blah-
blah, right what do you want me to do.” [Pt. 7, 39 years old male] 
 
b. Lack of GPs’ specialised knowledge 
The main reason, highlighted by the patients, for GPs’ inability to effectively 
manage chronic pain was the lack of specialised knowledge in chronic pain 
management.  Patients expressed concerns over the competency of GPs to 
effectively deal with and mange chronic pain, and frequently did not find they 
received much help from them. 
“My GP she was absolutely useless and I kept telling her it’s not 
helping, it’s not doing me any good, it’s not…” [Pt. 12, 39 years old 
female] 
“I’m not saying my GP isn’t qualified but he is a general 
practitioner, he’s not a consultant and he’s not specified in that area.” [Pt. 
6, 58 years old female] 
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Since the GPs had no specialised chronic pain management knowledge, they 
had to rely on other services (e.g. pain clinics) to get the right information to 
develop an appropriate management plan. 
“I think the issue had been that because there’s been a diagnosis 
of fibromyalgia the doctor really didn’t know enough about fibromyalgia 
so she’s relied on this service… To help give her the knowledge..” [Pt.8, 
40 years old female] 
A few of the patients also felt that this lack of specialised knowledge was used 
as an excuse by the GPs to refer to the physiotherapist without establishing 
whether the patients actually needed physiotherapy or not. 
“I think the your GP finds it an easy… she doesn’t know…he or 
she doesn’t know what the problem is they just not specialised in 
anything, it’s the easy answer to shove you to the physio and let them 
have a look at you and then see what bounces back out of that.  That 
seems to be the way and a lot of people end up with that, oh I’ll send you 
to physio..” [Pt.4, 30 years old male ] 
Patients saw GPs as having limited therapeutic options, with their approach 
towards pain management being confined to prescribing a range of painkillers, 
irrespective of whether the patients were gaining any benefit or not.  
“The GP’s have been useless basically.  According to them all 
they could do was give me paracetamol, and the best was co-codamol.” 
[Pt.9, 51 years old male] 
“He’ll just keep giving me tablets.  He doesn’t feel there’s anywhere else 
to go as regards trying to find out what it is.” [Pt.3, 63 years old male] 
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c. Short consultation time with GPs 
Another problem frequently pointed out by the patients was the short 
consultation time with the GP. This meant that the GPs could not listen to the 
patient’s full story and therefore could not design an individualised therapeutic 
plan to meet their needs. 
“It’s the running of the GPs basically, we’re not getting heard, 
patients aren’t getting heard and listened to.  There’s not enough time 
[Pt.6, 58 years old female] 
The short consultation time was seen as insufficient, by the patients, to obtain 
full medical and medication history, perform any physical examination and to 
develop an appropriate therapeutic plan accordingly. The patients felt that the 
combination of the lack of sufficient consultation time and GPs’ lack of 
specialised knowledge often hindered the development of individualised 
therapeutic plans. 
“No sadly I don’t think the GPs have enough time to look at each 
individual and to go through their medical history to see if they can tweak 
it here and there to help that patient.  Sadly they haven’t” [Pt.6, 58 years 
old female] 
“The GP…again it goes back down to the amount of time that he 
has to work with an individual patient.  I mean he’s working on an 
average of about 13 minutes with a patient.  There’s not much he can do, 
you know, on a really, really personal level. [Pt.10, 54 years old female] 
In some cases, the patients felt that due to the limited consultation time, GPs 
just prescribed medicines as requested by them without obtaining a full history, 
putting them at high risk of experiencing an adverse or even life threatening 
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event. The patients felt that a careful review of medical and medication history 
was essential as it would enable GPs to recognise an ongoing and/or a potential 
drug-related problem (DRP), and to take appropriate measures to prevent any 
negative consequences. 
“I went to the doctors and asked if I could have a stronger 
painkiller…. she just prescribed it, she didn’t ask me any questions apart 
from how long had I had the pain, and she just prescribed me co-
codamol.” [Pt. 17, 48 years old female] 
“The GP was worried about the high blood pressure but didn’t take 
time to look at the medication she’d actually put me on, whereas the 
pharmacist pointed it out to her. Potentially according to the pharmacist, 
for three months, I was at high risk of having a stroke because of the 
GP.” [Pt. 9, 51 years old male] 
d. Lack of communication between healthcare professionals 
Since the patients were referred to various specialists, the patients were 
concerned about the lack of communication between the different healthcare 
professionals, which led to inconsistency in terms of the approach towards pain 
management. 
“I think you tend to see everybody in isolation so the physio will 
refer and they will write a little letter and they will refer to a podiatrist.  But 
then the podiatrist kind of sees the problem from such a different light 
that they’re not really communicating with each other, so the podiatrist 
when I go tends to focus on my ankle because I still limp, rather than my 
back……”.[Pt. 1, 36 years old female] 
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The patients felt that a number of unnecessary referrals were made due to the 
lack of effective communication between healthcare professionals, and 
considered that better communication would have ensured referral to the correct 
healthcare professional, saving both time and money.  
“I went to the doctors, it’s nothing.  Tennis elbow, then it was 
arthritis, then it wasn’t arthritis, then it was because of a previous injury.  
He sent me for an x-ray then referred me to physiotherapists here.  I 
came here, the physiotherapist looked at the x-ray and couldn’t 
understand why I’d been referred here, he said it’s arthritis, there’s 
nothing you can do with it and referred me back to the GP.” [Pt. 9, 51 
years old male] 
In some instances the lack of communication led to clash of opinions between 
the healthcare professionals and left the patient confused about their diagnosis.  
“I was caught up in a bit of a battle between them two because 
the rheumatologist was saying no it’s not a rheumatology problem and 
the orthopaedic guy was saying, well we believe it is.” [Pt. 15, 55 years 
old male] 
7.3.2.2 Healthcare system related barriers 
In addition to a number of healthcare professional related barriers, described 
above, a number of healthcare system related barriers were also identified. 
These barriers included long waiting time for appointments in secondary care 
and the lack of a holistic approach. In general, the patients were not satisfied 
with the quality of the care provided by the NHS and were willing to seek 
treatment from the private sector.  
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a. Long waiting time for appointments in secondary care 
The patients were concerned over the long waiting times not only for 
appointments with the consultants but also for scans, x-rays and other tests. 
The long waiting time delayed the whole care process. The patients considered 
that there were many unnecessary steps in the referral chain, and consequently 
expressed dissatisfaction with the service that they received from the NHS.  
“You’re going round the houses to get back to where you want to 
be.  It takes a long time, it does take a long time. And like even 
from being referred to having a scan can take time.” [Pt. 3, 63 
years old male] 
“I felt like I’d just had to jump through hoops really, and they’re 
just unnecessary steps in the chain.” [Pt. 19, 47 years old male] 
“I was brought up to think that the Health Service would provide 
everything, but it doesn’t, not quickly enough.”[Pt. 5, 74 years old female] 
In some instances, patients spent a long time under the care of the GP, without 
making any significant progress before being referred to the specialist, which 
also contributed to the overall waiting time.  
“I had to wait… I mean my doctor she took ages.  I think I had 7 
months because she referred me; 7 months I had to wait and she could 
see that nothing she was giving me was working at all.”  [Pt.12,  39 years 
old female] 
As described above, the patients felt that healthcare professionals, especially 
GPs, were not interested in listening to and understanding their problems, which 
in some instances led to referral to the wrong healthcare professionals, causing 
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delay in receiving correct treatment. Timely referral to the right healthcare 
professional was viewed as very important for effective pain management. 
“My GP sent me to [hospital] and they put it down as sciatica 
which I said to my GP, it doesn’t start in my spine, I said it starts at the 
bottom of my hips and it works its way round.  They said it’s sciatica.  So 
they sent me back to the [hospital] under the doctor, I can’t remember his 
name, he was a back specialist.  They scanned me and I went back to 
see him just before Christmas and he said, there’s nothing wrong with 
your spine.  I said well I’ve said that to my GP, I said, what about my 
hips.  He said that’s not my department, it’s a different department.  So I 
went back to my GP and told her what I thought.  I said I told you it 
wasn’t sciatica, I haven’t got sciatica, I said it’s my hips [13] 
Another patient had a similar experience.  
“I went for an x-ray and, it turned out it was osteoarthritis.  He was 
a rheumatoid arthritis specialist so he shouldn’t have been seeing me, 
although he’d been seeing me for 18 months.  He then referred me on to 
see another consultant.”[Pt. 9, 51 years old male] 
Since the patients were not happy with the long waiting time for the 
appointments in secondary care, they expressed their desire to go for private 
treatment, provided that they had the funds to meet the cost.  
“……if I could afford it I’d go private, put it that way.” [Pt. 4, 30 
years old male] 
Patients who were able to afford it went on to seek care from the private sector 
and felt that the service provided there was much better than the NHS.  
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“I find the private sector, you know, service is much better.  I do, 
I’ve found the NHS physio not very… [Pauses], if you are paying for 
treatment it is better, let’s face it.” [Pt.11, 44 years old female] 
Since the patients, being tax payers, had already paid into the NHS, they 
expected a good service from it. They were annoyed by the fact that the 
treatment was in fact better in the private sector and they had to pay again to 
obtain this good service.  
“You wait so long in the Health Service.  But I had no alternative really 
except pay to see somebody, and that really rankles me, I don’t want to do that.  
Because I’ve paid into it haven’t I, my husband all these years.” [Pt. 5, 74 years 
old female] 
b. Lack of holistic approach 
Since chronic pain has a multidimensional impact on patients’ lives, a uni-
dimensional approach towards its management based on the bio-medical model 
may not achieve optimum pain relief. The set-up and the working of chronic pain 
management services in the NHS was seen as a hindrance in delivering 
integrated holistic care to patients.  
“Within the NHS, every individual is great and they work really 
hard and they’re really supportive, but they seem to be very caught in 
their little boxes and can’t or aren’t allowed to step outside them to 
maybe provide a more effective solution sometimes.” [Pt. 1, 36 years old 
female] 
In addition to the lack of a holistic approach in terms of the working and 
integration of chronic pain services, there was also a lack of holistic approach in 
terms of management of chronic pain patients. The specialists tended to focus 
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on the initial problem only, but not on the ongoing problems. The patients felt 
that they were not managed as a whole, but that healthcare professionals 
instead focused on only one of the affected area or joint.  
“He was not interested in any other joints, just the left elbow and I 
wanted them to look at all.” [Pt. 9, 51 years old male] 
Patients felt that they were treated impersonally, being thrown from one 
healthcare professional to another. 
“Well certainly NHS, I believe that it does need a big shape up 
because there’s… the way that they treat you is absolutely disgusting 
from point to point, there’s no… you’re treated as a number, you’re not 
treated as a person.” [Pt. 4, 30 years old male] 
Since chronic pain interfered with both physical and mental functioning, patients 
believed that a holistic, interdisciplinary approach was required to effectively 
manage their pain. 
“Well the pain management, my doctor looks after really, and the 
physio did the exercise part of it and I think both of it together was 
needed, you know.”[Pt. 5, 74 years old female] 
“Especially for people who are dealing with kind of long term and 
chronic pain because it can kind of cause people, you know, as well as 
the physical pain it can cause emotional problems and I think it’s 
important to have a service where kind of all of that can be addressed 
together.” [Pt. 18, 27 years old female] 
The patients stressed the need for a collaborative holistic approach and were 
frustrated with the current situation feeling that perhaps the NHS was not willing 
to make necessary reforms in order to improve chronic pain management.  
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“I don’t know whether that’s a cost thing, whether arthritis is not a sexy 
disease like cancer or other things that the NHS want to throw money at.” [Pt. 9, 
51 years old male] 
The patients believed that structural reforms were needed within the NHS so 
that it could better serve the needs of chronic pain patient population.  
“I find that very frustrating because I think, you know, maybe if the 
NHS was set up in a slightly different way so that people worked together 
better, that maybe we could resolve the problem” [Pt.1, 36 years old 
female] 
7.3.2.3 Theme summary 
In this theme, various healthcare professional and health system-related 
barriers, hindering an effective delivery of quality pain management services, 
were explored.  In general, patients expressed their dissatisfaction with the 
quality of care provided by the NHS. A common perception existed among 
patients that GPs lacked interest and did not have specialised knowledge in 
managing chronic pain. The patients also felt that the lack of communication 
between the healthcare professions led to unnecessary referrals, adding to 
patients’ frustration.  This also partly contributed to the long waiting time for 
appointments in secondary care. Another key issue highlighted by the patients 
was the lack of interdisciplinary chronic pain services within the NHS.  A need to 
reform chronic pain services within the NHS was also emphasised in order to 
facilitate the effective delivery of quality services. 
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7.3.3 Experiences at the nurse-pharmacist managed pain clinic 
In general, the patients had good experiences of the services received at the 
nurse pharmacist managed pain clinic. Expectations of a particular service are 
major drivers of patient satisfaction and overall experience. Early recognition of 
these expectations can help healthcare professionals to tailor their approach 
accordingly. As reported in the previous chapter, patients of different 
sociodemographic and clinical characteristics were referred to the pain clinic. 
Therefore, their expectations from the nurse-pharmacist managed pain service 
varied and were influenced by the duration of their pain, past experiences of 
other pain services and information from their peers. Their expectations ranged 
from a probably unrealistic hope of cure from chronic pain to simply knowing 
what was wrong with them.  
“Miracles  [laughs];  I was expecting miracles.  No, in reality I was 
hoping to reduce the medications because I’m on such a lot.” [Pt.10, 54 
years old female] 
“My expectations… well my hopes were to end up painless 
[laughs].” [Pt. 2, 49 years old male] 
“I wanted to find out what was wrong with me.” [Pt.7, 39 years old 
male] 
Some patients had no clue about the service and had no clear expectations 
from it 
“I wasn’t entirely sure what it was about, no one explained that, 
you know, this was what was going to happen.  It was, this is chronic 
pain services, they’ll talk to you about your pain and that’s it, so I wasn’t 
sure if it was going to be, I don’t know, some kind of psychiatrist kind of 
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thing or if it was physiotherapy again or anything to be honest.” [Pt. 4, 30 
years old male] 
Some of the patients expected a negative attitude from the service, but were 
surprised to receive a listening and caring attitude from both the nurse and the 
pharmacist. 
“I thought I’d come here and they’d palm me off with something, 
you know, go for physiotherapy, like the GPs.” [Pt. 9, 51 years old male] 
The sub-themes identified are outlined below in Figure 7.3. 
 
Figure 7.3. Sub-themes within experiences at the pain clinic theme  
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7.3.3.1 Satisfaction with the service 
Overall, the patients were satisfied with the quality of care that they received at 
the pain clinic. Four factors were identified during the data analysis which 
contributed towards positive patient experience with the service: ample 
consultation time, in-depth specialised knowledge, listening and understanding 
individual patients’ needs, and a holistic approach. The patients recognised and 
appreciated the role of both the clinical nurse specialist and the pharmacist at 
the pain clinic.  
“I think it’s a good little service that they’ve got going on there; I 
really, really do.” [Pt. 12, 39 years old female] 
In the following sections, these factors are described in detail.  
a. Ample consultation time 
The patients felt that they were given full freedom and time to express their 
views. In contrast to the ten minute consultation slot with the GP, the patients 
had one hour for the initial consultation and 30 to 45 minutes for the follow-up 
appointments which allowed them to discuss their problems more openly and 
freely. 
“You’re very conscious of the amount of time you have with your 
GP and it was knowing that I was going to see somebody who actually is 
a pain specialist, you just feel more confident and that because you feel 
they will take time with you and listen to you and understand…” [Pt. 16, 
54 years old female] 
“When you come here you don’t feel that pressure, so you can be 
a bit more open and a bit more frank and you can be a bit more 
descriptive.” [Pt. 8, 40 years old female] 
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“I mean [the clinical nurse specialist] sits and listens and then she 
writes them[ GP] letters and it helps me when I go down to see them [GP].” 
[Pt. 13, 54 years old male] 
b. In-depth specialised knowledge 
The in-depth specialised knowledge of both the nurse and pharmacist in terms 
of chronic pain management was quickly recognised by the patients. Patients 
had the impact of pain on their lives, pacing activities, the impact of being active 
on pain, and the usefulness of light exercise explained by the clinical nurse 
specialist.  
“I think there’s also that knowledge base here.  They’re obviously 
treating or speaking with people that have got similar symptoms and 
therefore know what kind of route to take when it comes to pain 
management and so on.” [Pt. 8, 40 years old female] 
“I learnt quite a lot from them about pacing myself and timing 
[activities].” [Pt.10, 54 years old female] 
“[The clinical nurse specialist]  explained what’s going off, how it 
affects me, and then [Pharmacist]  we’ve been sat down and we’ve been 
balancing all my medications out, how much there is to take and how 
much… and what to take and what not to take, you know.  So it’s been a 
real…to me it has, it’s been a really good thing to have been coming up 
here to the pain clinic.”  [Pt. 13, 54 years old male] 
The pharmacist focused on optimising the use of analgesics and other 
medicines involved in pain management. The patients were informed about the 
side effects and negative impact of over/under dosing.  She also encouraged 
the patients to adhere to the therapeutic regimen. 
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“We [pharmacist and I] talk and they sort my medication out more 
than what… my GP hasn’t got a clue, you know, they haven’t got a clue 
what I’m doing.  I mean I could go and ask them for anything and I think 
they’d just give me it, you know. I was taking too much and they said, 
well you won’t get any benefits from taking extra MST [Morphine], so I 
cut it down, I stopped taking as much.” [Pt.13, 54 years old male] 
As a routine practice, the pharmacist reviewed patients’  medication history. In 
cases where the dosage was not right, the pharmacist recommended the right 
dose and medication was stopped if the medication was not required by the 
patient. 
“She [GP] was overdosing me as well on there and the 
pharmacist was absolutely mortified when she found out how much I was 
taking.  And I didn’t know, I’m no doctor, you know, I’ve just gone by my 
GP.” [Pt.12, 39 years old female] 
“I felt she was very professional and she knew what she was doing, 
which is comforting. I’ve seen the pharmacist on Tuesday and the way she sort 
of looked at my medication and she knows what everything’s doing, she knows 
what it should be doing, and she probably knows what I can do without, hence 
the tramadol [was taken off].” [Pt. 10, 54 years old female] 
c. Listening and understanding individual patients needs 
The patients found that both the nurse and the pharmacist expressed their 
interest in listening to patients’ views, in contrast to the GPs who the patients 
perceived as not being interested in obtaining a full medical and medication 
history. Based on thorough face-to-face interviews and careful consideration of 
individual patient’s needs, the nurse and pharmacist developed a therapeutic 
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plan in consultation with the patients. The patients felt that finally there was 
someone who was listening to their needs.  
“She [the clinical nurse specialist] was very good at listening.  She 
was, very good. It was lovely having somebody to talk to who understood 
what pain does to people and you could talk to her, she were a person 
that you could talk to, some you can’t can you, you know?  Some people, 
they just give off that aura, they don’t really care, you know.  But she 
were very good, she was yes.” [Pt. 14, 64 years old female] 
“I think it’s because there’s a sympathetic ear and people will 
listen.  And there seems as if this understanding and they’re offering 
advice that we’ll take on board, whereas we’ve not really had that… 
we’ve not felt that comfortable with the GP because she openly admitted 
that she didn’t really know anything about fibromyalgia and therefore she 
didn’t really know how to treat it.” [Pt. 8, 40 years old female] 
After each consultation, as per the routine clinical practice, a letter was sent to 
both the patient and his/her GP explaining the nature of and history of the 
present complaint with recommendations for a future therapeutic plan.  
“I can tell maybe because they sent me a copy of the letters that they 
send to the GP and everything I’ve said to them they’ve taken notice of and 
they’ve pointed out to the GP, you know.” [Pt. 9, 51 years old male] 
d. Holistic approach 
The clinic offered a more holistic approach towards pain management 
compared to the GP. The patients were given adequate time to explain their 
problem and both the clinical nurse specialist and the pharmacist listened to 
their problems, allowing carefully individualised therapeutic plans to be 
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designed.  Both pharmacological and non-pharmacological therapeutic options 
were explored for each patient.  
“Well really I suppose here they go through absolutely everything 
you know so it’s a lot more in-depth and looking at the whole picture 
rather than simply trying to give you medication for a problem like the GP 
does and then refer you to physio etc. It’s……..[Pauses].  Here it’s a 
much more holistic approach really and they try and cover absolutely 
everything for you and see what other services they may be able to refer 
you to or ask your GP to refer you to.  So I think really it’s a complete 
programme so it’s good in that way.” [Pt.11, 44 years old female] 
“Go to pilates, I did and that’s helped, yes, yes [Pt. 5, 74 years old 
female] 
The emotional needs of the patients were also assessed and appropriate 
referrals were made in order to help them in this respect.. 
“They have taken steps to help the emotional side, which that’s, 
you know, sort of getting out and meeting people.  And [the CNS] picked 
up on that very quickly, very, very quickly.”[Pt. 10, 54 years old female] 
After assessing individual patient’s needs, the patients were also referred to 
other services such as the expert patient groups, musculoskeletal services, and 
psychological services if required. The patients also found these referrals 
beneficial, contributing to an overall satisfaction with the service. 
“They [pain clinic] referred me to a physiotherapist who 
specialised in chronic pain.  And so through seeing that physiotherapist 
I’ve learnt different ways of managing the pain which I found to be more 
effective than the medication I was on.” [Pt. 18, 27 years old female] 
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“Because I’ve ended up if I hadn’t have come here I wouldn’t have 
had the injection, because that injection I don’t think would have been 
offered to me by my doctor.” [Pt. 2, 49 years old male] 
7.3.3.2 Issues with the pain clinic 
The patients also highlighted some negative issues with this service. They were 
not pleased by the fact that the pain clinic did not prescribe medicines to them 
and they had to go to their GPs to get the medicines. Patients felt that this 
caused unnecessary delay and had expected to get their medicines at the pain 
clinic. 
“When I found that I was going to have to go back to him for the 
prescription I was a bit in shock really.  I’m thinking what?  He’s referred 
me to you for you to... saying that you’ll be able to look at these things 
and I’ve come here hopefully to get these things and then you’re saying 
I’ve got to wait another two weeks while you send a letter to my doctor 
and then he’ll just write a prescription....[Pt. 19, 47 years old male] 
“I think the one thing we weren’t expecting is that there was going 
to be referrals from the pain management to the doctor.  We were 
thinking they were kind of independent bodies.” [Pt. 8, 40 years old 
female] 
Some of the patients also felt that they were not appropriate for this service and 
should not have been referred here. They considered that they had pain for 
quite a long time and knew about the various self-management strategies 
discussed at the pain clinic including being active, exercise and pacing 
activities. 
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“I think was more aimed at getting people re-motivated past their 
pain, so we did talk a little bit about painkillers and modified those a bit, 
but the main part of pain clinic to me seemed to be about getting people 
to get up and go and take additional steps that maybe they weren’t 
already doing, which really wasn’t kind of suitable for me I don’t think.  I 
don’t ever sit down; I don’t have time, so I think maybe I wasn’t really 
their target audience.” [Pt. 1, 36 years old female] 
“Well I just went through everything that I’d been through, you 
know discussing everything, going through every remedy and possible 
thing that may help but I’d heard it all and done it all, you know, it wasn’t 
anything new really.” [Pt. 11, 44 years old female] 
Although the patients appreciated the quality of care delivered at the nurse-
pharmacist managed pain clinic, not all the patients were able to achieve the 
desired pain relief. 
“I was expecting they might be able to do something different, but 
I’m quite happy with how it was conducted.  But I don’t feel as though 
I’ve made any progress.” [Pt. 3, 63 years old male] 
“I’m still in pain and what they’ve suggested so far it’s not helped 
the pain.” [Pt. 4, 30 years old male] 
7.3.3.3 Theme summary 
In this theme, the factors contributing towards patients’ good experiences and 
satisfaction have been explored. In addition, patients’ concerns about the 
service have been presented. The patients were generally satisfied with the 
service. The long consultation time and specialised pain management 
knowledge at the pain clinic enabled patients’ pharmacological and non-
224  
 
pharmacological needs to be explored and addressed. Individualised pain 
management plans were devised for patients after a careful review of their 
medical and medication history. In addition, the patients benefited from referrals 
to other services, where required. However, some of the patients were 
disappointed by the fact that they had to visit their GPs to get the prescribed 
medications. 
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CHAPTER 8                                                                         
DISCUSSION 
8.1 Introduction 
In this final chapter of the thesis, the results/findings of both the quantitative and 
qualitative phases are discussed in the context of the wider literature. In addition 
to studying the sociodemographic and clinical characteristics of the patients 
referred to the pain clinic, the aim of the quantitative phase was to evaluate the 
impact of nurse-pharmacist managed pain clinic on pain intensity, physical 
functioning, emotional functioning, quality of life and chronic pain grade. The 
aim of the qualitative phase was to explore patients’ views about their 
experiences at the pain clinic. The findings are discussed in the light of these 
objectives. Where possible, the findings of both the quantitative and qualitative 
phases are integrated to facilitate a better understanding of the results. Since 
the findings of the systematic review have already been discussed in detail in 
chapter 3, they are not discussed in detail here. However, reference to the 
findings of the systematic review is made where appropriate. 
The chapter begins with a general discussion on the use of the mixed-
methods methodology for this study and then the sociodemographic and clinical 
characteristics of the patients referred to the pain clinic are discussed. This is 
followed by the discussion on the effectiveness of the pain clinic. The limitations 
of the current study are then highlighted and recommendations for future 
research and policy are suggested. Finally, the dissemination plan for the 
research findings is outlined. 
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8.2 Discussion  
8.2.1. Learning experience during PhD:  A reflective account 
In my understanding, the overall aim of a PhD training is to facilitate 
transformation of the student into an independent researcher by equipping him 
with the necessary knowledge and skills required to undertake research. With 
the growing use of qualitative and mixed-methods research methodologies 
within practice disciplines, it has become increasingly important for practice 
researchers to understand the strengths and weaknesses of these methods as 
well.   
My PhD project which consisted of a systematic review and meta-analysis, 
and a mixed-methods study provided me with an excellent opportunity to learn 
and apply different research skills.  As I highlighted earlier (section 1.1), I had 
only a limited research training in the past, which was predominantly 
quantitative. During my PhD, I gained valuable knowledge and skills of 
designing and conducting systematic reviews, qualitative, quantitative and 
mixed-methods research. In addition, I learnt a lot about the art and science of 
publishing in a peer-reviewed journal, an important skill for an academic 
researcher. However, I do not consider myself as an expert qualitative and/or 
quantitative researcher but the PhD training has enabled me to become 
independent – I can find my way. I believe, because the research methods and 
issues keeps evolving, it is a life long journey which has just formally begun.  
8.2.2 A word on methodology 
This study used a mixed-methods methodology to evaluate the effectiveness of 
a community based nurse-pharmacist managed pain clinic. Over the past few 
years, there has been growing interest in the use of mixed-methods approaches 
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in health services evaluation (O'Cathain et al., 2008) as they allow the use of 
multiple methods to comprehensively answer different research questions in a 
single study (Creswell and Plano Clark, 2011). The rationale for using a mixed-
methods approach has been described in detail in the methodology chapter. 
Briefly, the use of mixed-methods methodology generated both effectiveness 
and satisfaction data within a single study, thus providing a holistic evaluation. 
Furthermore, the findings of the qualitative study not only identified the factors 
contributing to patients’ satisfaction but also enabled the author to overcome 
some of the threats to the internal validity of the quasi-experimental study 
(described in detail later in the limitations section). 
In the following sections the key findings of both quantitative and 
qualitative studies are discussed.  
8.2.3 Sociodemographic and clinical characteristics of the patients 
In general, the sociodemographic profile of the patients referred to the 
nurse-pharmacist managed pain clinic was similar to the profile of patients 
visiting outpatient pain clinics in Hong Kong and Toronto. In the present study, 
the mean age was 46.5 (SD 14.5) with almost half (46.8%) of the patients being 
middle aged (36-50 years). Similarly, the mean age of patients attending an 
outpatient pain clinic in Hong Kong (Chen et al., 2004) and a university hospital 
affiliated pain clinic in Toronto (Canada) (Mailis-Gagnon et al., 2007) were 48.7 
years (SD 15) and 48.5 years (SD 14.2) respectively, with the majority of the 
patients being middle aged (35-49 years age range) in both studies. The 
majority of the patients were female (67.1%). Chronic pain is more prevalent 
among women and they have been reported to use more healthcare resources 
compared to the men. The National Health Survey (Bridges, 2012) also reported 
a higher prevalence of chronic pain among females (37% females compared to 
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31% males). The high prevalence of chronic pain and higher utilisation of 
healthcare resources may explain the high number of female patients in the 
sample. More than a half (56.5%) of the patients had chronic pain for more than 
3 years and, more importantly, for 70% of the patients this was the first visit to a 
specialised pain service/clinic.  
The interplay of a number of factors including patients’ medical help 
seeking behavior, GPs’ lack of willingness to refer patients to a specialised pain 
service and, lack of awareness among the GPs and patients about the 
existence of such clinics may partly explain the delay in referral to a specialised 
pain service. In the present study, most of the patients were referred by the GP 
(72.2%), which suggests that the GPs were willing to refer the patients. 
However, how long the GPs kept the patients under their care before referring 
on to the clinic could not be established. Furthermore, during the qualitative 
interviews a few patients highlighted that they had to repeatedly ask their GPs 
for referral before they were referred. It will be interesting for future researchers 
to further explore this issue and its implications for the treatment outcomes.  
In the present study, 67.1 % of patients had HADS-A score of 8 (likely to 
suffer from anxiety) or above and 60.5% HADS-D score of 8 (likely to suffer 
from depression) or above. Anxiety and depression are common among chronic 
pain patients. The prevalence of depression, depending on the method of 
assessment, has been reported to vary from 1.5% to 87% (Worz, 2003). 
Chronic pain can cause and/or worsen symptoms of depression; on the other 
hand, depression is associated with increased pain intensity, reduced physical, 
social and occupational activity and a higher use of health services (Geisser et 
al., 1997, Worz, 2003).  Patients in the qualitative interviews also highlighted 
significant impact of chronic pain on their mental functioning and described a 2-
230  
 
way relationship between pain and depression. The patients felt depressed 
during the times when pain intensity was high and also felt that depression was 
contributing towards increased pain intensity. The National Health Survey 
(Bridges, 2012) also reported that participants in chronic pain grade IV (high 
disability-severely limiting) were more likely to be anxious and depressed than 
the participants with grade I (low disability-low intensity) and II (low disability-
high intensity) (Bridges, 2012). In the present study, more than 60% of the 
patients fell under Grade IV (high disability-severely limiting), explaining a high 
incidence of anxiety and depression among patients referred to the clinic. The 
high prevalence of anxiety and depression calls for integrating psychological 
services with chronic pain services to improve overall patient experience.  
In the present study, almost half of the patients (43%) were unemployed, 
of whom more than a quarter (25.3%) were unemployed due to pain. The 
negative impact of chronic pain on employment status was discussed frequently 
by the patients indicating its significance in their lives. The patients had to either 
stop working or switch jobs from full time to part time because of the pain. The 
negative impact of chronic pain on employment status, sickness absences, and 
loss of productivity is well documented in the literature (Steenstra et al., 2005). 
Studies have also documented an association between employment status and 
chronic pain intensity after adjusting for confounders. A systematic review by 
Patel et al. (2012), found that interference of chronic pain with employment 
affected 26% (Breivik et al., 2006) to 88% (Friessem et al., 2009) of patients 
with the loss of employment due to chronic pain reported to range from 18% to 
23% (Patel et al., 2012).  
The information on sociodemographic and clinical characteristics of the 
patients is valuable in a number of ways. Firstly, the clinical characteristics of 
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the sample represent a typical chronic pain population; therefore the findings of 
this study are potentially generalizable to the chronic pain population, keeping in 
view the limitation of inadequate sample size (issue further discussed in section 
8.5). Secondly, this information is important for identifying a suitable control 
group for future RCTs evaluating community-based pain clinics. Thirdly, for 
service commissioners, the high prevalence of psychiatric comorbidity among 
chronic pain patients calls for the integration of psychological services with 
chronic pain services as anxiety and depression can interfere with chronic pain 
management.  
8.2.4 Outcomes assessment 
The rationale for selecting the outcome measures and respective scales has 
been discussed in detail in chapter 5 (section 5.3.4). The recommendations 
made by the IMMPACT group guided the selection of outcome measures 
(Dworkin et al., 2005).  In terms of pain relief, statistically significant reductions 
in the “worst pain” and “average pain” were observed upon discharge. However, 
no significant differences were found for the “least pain” and “pain right now”. 
Due to the small sample size statistical analysis were not performed for 3-month 
follow-up. For physical functioning, there was a significant reduction in the 
overall interference of chronic pain with physical functioning (P=0.02).  As 
highlighted earlier (Chapter 3, section 3.5.1), it has been suggested that the 
population distribution of pain scores are usually not normally distributed and 
are ‘U-shaped’; therefore, reporting merely changes in the means/medians for 
continuous data (e.g. pain intensity) can be misleading (McQuay et al., 1996) as 
patients tend to have either very good or very poor pain relief. To avoid this 
limitation and to improve clinical interpretation of the results, percentages of 
patients responding to treatment have been reported as well, in addition to 
reporting medians/means, for two of the outcome measures: pain intensity and 
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physical functioning (IMMPACT group recommendations were available for 
these two outcomes measures only). For pain intensity, 17 out of 35 patients 
(48.6%) discharged from the clinic had achieved at least a minimum clinically 
important difference (10% of the baseline score) at the time of discharge. 
However, since the data were not available for all the patients, this figure 
(48.6%) may not be an accurate representation of the effectiveness of the clinic. 
For physical functioning, fourteen out of 35 (40%) patients had achieved 
minimum clinically important difference at the time of discharge from clinic. 
Again, the 40% could be an under or over representation of the effectiveness of 
the clinic. The findings of the systematic review reported in chapter 3 also found 
a significant reduction in pain intensity and a significant improvement in physical 
functioning among patients who had the intervention (i.e. pharmacist-led 
medication review) compared to the control. 
No statistically significant reductions were noted for anxiety (P=0.21) and 
depression scores (P=0.22). However, for anxiety, 13 out of 34 patients (38.2%) 
had improved at least by one category (e.g. from mild to normal or from 
moderate to mild etc). On the other hand, for depression, only 7 out of 34 
patients (20.6%) showed an improvement by at least one category. For quality 
of life, of the eight domains assessed, statistically significant improvements 
were noted for bodily pain (BP) and physical role (RP) only. There were no 
significant improvements in the physical component summary (PCS) score and 
the mental component summary (MCS) score. The lack of intervention effect in 
terms of anxiety, depression, and quality of life might be attributed to the small 
sample size. It is also possible that the intervention was not effective or the 
outcome measures were not sensitive enough to detect a difference.  
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For the chronic pain grade questionnaire, compared to the baseline, a 
significant reduction only in pain intensity subscale was found at discharge. No 
significant improvement was noted for disability sub-scale. Only seven (20.6%) 
patients showed improvement in terms of chronic pain grade while the majority 
of the patients showed neither improvement nor deterioration in their chronic 
pain grade. An alternative explanation for lack of intervention effect could be the 
nature of questions within the chronic pain grade questionnaire. All the 
questions except one (question 1) ask the patients to rank their pain intensity, 
and associated physical disability, over the past 6 months on a 0 to 10 NRS 
scale. Therefore, it may not necessarily detect a positive outcome in patients 
who are discharged less than 6 months of their baseline assessment, thus 
making it a less useful outcome measure for short to medium term evaluations. 
However, further research is required to explore this hypothesis.  
Patient satisfaction was another outcome, evaluated using face-to-face 
semi-structured interviews. The issues around patient satisfaction are discussed 
in the context of barriers to effective pain management, in the following section. 
8.2.5 Barriers to effective pain management 
In the previous chapter, while reporting the findings of qualitative phase, barriers 
to effective pain management were also highlighted. Although, the aim of the 
qualitative interviews was not to explore barriers to effective pain management, 
however, while exploring patients’ satisfaction with the service the patients 
volunteered a number of issues related to pain management. It is important to 
understand these issues in order to thoroughly appreciate the reasons for 
patient satisfaction.  
Both healthcare professionals and system-related barriers to effective 
pain management were identified during the qualitative interviews. The 
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healthcare professional-related barriers included: lack of interest and empathy, 
lack of GP’s specialised knowledge, short consultation time with the GPs, and 
lack of communication between healthcare professionals. The lack of interest 
among  healthcare professionals in managing pain has been well documented 
in the literature (Walker et al., 1999, Harding et al., 2005, Osborn and Smith, 
2008, de Vries et al., 2011). The lack of seriousness among the healthcare 
professionals in managing chronic pain may be partly attributed to their lack of 
belief in chronic pain patients. In addition to this study, patients in a number of 
qualitative studies have described a sense of “not being believed” and “being 
judged” by the healthcare professionals (Walker et al., 1999, Harding et al., 
2005, Osborn and Smith, 2008, de Vries et al., 2011). However, a large 
telephonic survey of primary care physicians (PCP) and chronic pain patients 
across eight European countries including the UK reported that about 90% 
(n=1,334) of physicians were interested in improving patients’ quality of life and 
offered all patients some sort of treatment. However, only 12–33% of patients 
were given written information about their condition (Woolf et al., 2004). 
Since chronic pain is predominantly managed within primary care and in 
the UK, referral to secondary care/pain service is made by the GPs based on 
their assessment, issues such as lack of specialised chronic pain management 
knowledge among GPs and short consultation time are of significant importance 
in the context of chronic pain management. A study from the US reported that, 
pain was discussed on average for only 2.3 minutes during consultations with 
primary care physicians (PCPs) (Tai-Sealea et al., 2012). The odds of having 
pain discussion were significantly associated with the level of pain, physician’s 
supportiveness, and gender concordance (physician and patient are of same 
gender) (Tai-Sealea et al., 2012).  GPs themselves have identified lack of 
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sufficient knowledge and skills in chronic pain management (Stannard and 
Johnson, 2003). In a survey more than two thirds (81%) of the GPs expressed 
an interest in receiving additional education and training in chronic pain 
management and more than a quarter of GPs surveyed desired more guidelines 
and local protocols to manage chronic pain (Stannard and Johnson, 2003). The 
survey further reported that the majority of the GPs (81%) believed that a 
substantial number of patients received suboptimal treatment for chronic pain. 
Similarly, 88% of the physicians in the US felt that their training in pain 
management was poor in medical school (Von Roenn et al., 1993).  This 
suggests that lack of specialised knowledge is not only the patients’ perceptions 
but also GPs/primary care physicians recognize this as a limitation as well. The 
patients felt that it was due to GPs’ lack of interest and specialised knowledge 
that they were referred from one healthcare professional to another. The 
interplay of all these factors contributed to patients’ dissatisfaction with the 
quality of care offered to them by various healthcare professionals especially 
the GPs. There is a need to improve GPs’ knowledge and skills in chronic pain 
management and to develop referral guidelines for chronic pain patients in order 
to improve chronic pain management in the community.  In addition, 
development of community-based pain clinics or setting up of pain clinics within 
GP practices managed by clinical specialist nurse and/or pharmacist can also 
improve chronic pain management in the community 
Long waiting times for appointments in secondary care and lack of a 
holistic approach were among the healthcare-system related barriers identified 
during the qualitative phase. Waiting time is an important issue in the context of 
effective pain management as a waiting times of 6-months or more is 
associated with an increase in pain intensity, depression and poorer quality of 
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life (Lynch et al., 2008). Unfortunately, no medically acceptable benchmarks for 
waiting time for chronic pain exist globally (Lynch et al., 2007), suggesting a 
need to develop evidence based waiting time standards for chronic pain 
patients. In the UK, no standard waiting-time specifically for chronic pain exist 
and, therefore the National Pain Audit used a generic 18-week standard waiting 
time for evaluating chronic pain services in the last audit (Price et al., 2012). 
However, the National Pain Audit recommended that the Royal College of 
Anaesthetists and the National Institute of Clinical Excellence (NICE) should 
develop guidance on waiting times for chronic pain patients (Price et al., 2012). 
In a survey, the GPs in the UK expressed concern for the long waiting times for 
appointments in the secondary care (Stannard and Johnson, 2003). On the 
other hand, primary care physicians in Canada considered long waiting times as 
a barrier to referral to secondary care (Lakha et al., 2011).  Patients were not 
only concerned about the waiting time for appointments with healthcare 
professionals in secondary care but also about the long waiting times for 
medical tests and scans (MRI, CT-scan, X-rays) as the later contributed to 
overall delay in treatment. In Canada, one third of patients had to wait for more 
than a year (over all mean 6 months; range 2-14 months) for appointments at 
publically-funded multidisciplinary clinics (Peng et al., 2007). However, the 
waiting time for private clinics was less than a month (mean 0.5 months; range 
1-4 weeks) (Peng et al., 2007). In the UK, the National Pain Audit reported that 
80% of clinics were meeting the 18-week generic waiting time standard (Price et 
al., 2012). Because of the long waiting time for consultation in secondary care in 
the NHS, patients during the qualitative interviews expressed an interest to opt 
for private treatment. However, “affordability” was a barrier. The patients also 
felt that the healthcare professionals’, especially the GPs’, approach towards 
pain management was unidirectional-medicine oriented and lacked holism. The 
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patients felt that a multidisciplinary approach would have benefited them more 
in terms of pain relief. Both the clinical effectiveness and cost effectiveness of 
multidisciplinary pain clinics have been demonstrated (Gatchel and Okifuji, 
2006, Scascighini et al., 2008). However, availability of and access to 
multidisciplinary clinics has been problematic. Only 40% of pain services 
audited during the National Pain Audit met the minimum criteria of 
multidisciplinary service (Price et al., 2012). The development of more 
community-based clinics jointly managed by a nurse and pharmacist can 
potentially overcome the issues related to availability and access. 
8.2.5.1 Patient satisfaction with service 
 Patient satisfaction was explored using face-to-face qualitative interviews. 
Patients were generally satisfied with the quality of care provided by the nurse 
and the pharmacist at the pain clinic. Ample consultation time, in-depth 
specialized knowledge, listening and understanding individual patient’s needs 
and, a holistic approach were identified as contributing factors toward patients’ 
satisfaction. It should be noted here that these factors are totally opposite to the 
barriers to effective pain relief  discussed earlier which suggests that a 
community-based pain clinic jointly managed by a nurse and a pharmacist can 
overcome the barriers to effective pain management. Furthermore, referrals to 
other services were made, where necessary, after a thorough assessment of 
individual patient’s needs. Non-pharmacological alternatives were suggested in 
instances where the patient: perceived not to take medicines; issues related to 
the side effects/tolerance; or non-pharmacological interventions were deemed 
necessary. The holistic approach was evident from the nature of 
recommendations made at the clinic. For 35 patients, 101 medicine-related 
(mean 2.9; range 1 to 6) and 42 non-pharmacological recommendations (mean 
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1.3; range 1 to 3) were made to the GPs and patients, suggesting that both 
pharmacological and non-pharmacological needs were assessed and 
addressed. Patients during the qualitative interviews appreciated the non-
pharmacological interventions as well including going to a support group   
8.3 Key findings from the three sections of the thesis:  Patients’ views 
and outcomes 
The key findings from the three sections of the thesis are summarised in table 
8.1. Although the aim of this research was not identify barriers to effective pain 
management but to emphasise the importance of research findings in relation to 
overcoming those barriers and facilitate a better understanding, the research 
findings are mapped, where applicable, to the barriers identified during 
qualitative interviews in Table 8.1.  
Table 8.1. Key findings from the three sections of the thesis 
Interview and questionnaire data  Systematic review of 
pharmacist-led 
medication review 
Barriers to effective 
pain relief 
Nurse-Pharmacist 
managed clinic 
Most of the patients 
were not pleased with 
the quality of care 
received.  
Patients were generally 
satisfied with the clinic. 
Patients were generally 
satisfied with 
pharmacists’ service 
(small to moderate effect 
size). 
  
Inadequate pain relief. On discharge patients 
reported a significant 
reduction in worst pain, 
average pain and an 
improvement in physical 
activity. 
Pharmacist-led 
medication review was 
effective in reducing 
pain intensity and 
improving physical 
functioning. 
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 Patients wanted their 
prescription there and 
then rather than having 
to return to their GP. 
 
Some weak evidence of 
reducing adverse drug 
effects 
Inappropriate referrals 
were made. 
Some patients felt it was 
too late to be attending 
the clinic and learned 
nothing new. 
 
Lack of a holistic 
approach. 
Holistic approach  
Lack of interest and 
empathy by healthcare 
professionals (HCPs) 
Listening and 
understanding of 
individual patients’ needs 
 
Short consultation times 
with GPs 
Ample consultation time  
GP lack of specialised 
knowledge. 
In-depth specialised 
knowledge. 
 
Lack of communication 
between HCPs 
Written communication 
with patients and GPs 
 
Long waiting times for 
appointments in 
secondary care. 
  
8.4 Conclusion 
Community based pain clinics jointly managed by nurses and pharmacists have 
the potential to improve chronic pain management in the community. In addition 
to reducing pain intensity and improving physical functioning, such community-
based clinics can not only improve access to specialised pain service but also 
reduce burden on the secondary care. The sufficient consultation time with 
patients allowed the nurse and the pharmacist to obtain full medication and 
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medical history and develop an individualised management plan addressing 
both pharmacological and non-pharmacological needs of the patients. In terms 
of the patients’ perspective, they felt that they were treated with respect and 
empathy and, were generally satisfied with the quality of service. There is a 
need to develop evidence-based referral guidelines for such community based 
clinics to ensure that the patients who are likely to benefit from such services 
are referred there. GPs should be encouraged to refer patients to such services 
early during the course of the treatment as GPs’ lack of specialised knowledge 
and short consultation time are barriers to effective pain management.  
Unfortunately, the service was decommissioned by the local PCT without 
taking all the stakeholders on board. This was in spite of the fact that the pilot 
study had documented positive outcomes and an in-depth evaluation from both 
clinical and patient perspective was in progress. Even though the patients highly 
appreciated and valued the role of the pharmacist in solving their medication- 
related problems and optimizing the use of medicines, the services of the 
pharmacist were dropped. The findings of the systematic review and meta-
analysis, reported in chapter 3, reported a significant impact of pharmacist-led 
medication review on various patient outcomes including pain intensity, physical 
functioning and patient satisfaction. This clinic provided a good practical 
example of public-private partnership in healthcare setting. Given the limited 
financial resources that the healthcare systems currently have, more avenues of 
public-private partnerships should be explored and evaluated.  
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8.5 Limitations 
The findings of this mixed-methods study should be carefully considered in 
context of its limitations. In terms of the design and conduct, there were three 
main limitations related to the quasi-experimental study. Firstly, in terms of 
study design, RCTs, not quasi-experimental studies, are considered the gold 
standard for evaluating the effectiveness of healthcare interventions (Bonnie 
and Martin, 1998). The reasons for not conducting a RCT for the present study 
have been discussed in detail in chapter 4 (section 4.4.1). Due to the lack of 
randomization and control group, several threats to the internal validity of 
before-and-after quasi-experimental studies have been reported in the literature 
including history, maturation, Hawthorne, instrumentation, regression-to-the-
mean, drop out and testing (Harris et al., 2004). In the context of this study, 
history, instrumentation and maturation were of significant concern. A “History 
threat” refers to the occurrence of other influential events, independent of the 
intervention, which could affect the outcome. Maturation threat to the internal 
validity refers to a natural processes (e.g. ageing) leading to physical or 
psychological changes in the participants, thus affecting the outcome measure. 
The triangulation of the findings of the quasi-experimental (before-and-after) 
and qualitative descriptive studies enabled the author to address these two 
threats to internal validity to some extent. The findings of the quasi-experimental 
study were supported by the findings of the qualitative descriptive study. During 
the qualitative interviews, the patients reflected on the usefulness of the clinic 
and attributed pain relief to various pharmacological and/or non-
pharmacological recommendations made at the pain clinic. An “instrumentation 
threat” refers to the change of the scale measuring the outcome between 
“before” and “after” measurements, which could affect the outcome. As 
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described in the methods chapter, (Chapter 5) all questionnaires/scales used in 
this study have well demonstrated validity and reliability. The same 
questionnaires were used for all outcomes during all assessments (baseline, 
discharge, 3-month follow-up) minimizing instrumentation threat to the internal 
validity of this study.  
The second major limitation of this study was the inability to achieve the 
required sample size. The required sample size, after accounting for a 15% 
dropout rate, to detect a minimum clinically important difference as 
recommended by the IMMPACT group (Dworkin et al., 2008) for pain intensity 
was 79. However, discharge data were available for 36 patients only as the 
service was decommissioned whilst data were being collected.  Subsequently, 
the services of the clinical nurse specialist were absorbed into a 
musculoskeletal service at the same community health centre and the services 
of the pharmacist were discontinued. Since there were structural changes in the 
provision of service, collecting further follow-up data would not have been 
appropriate. The inability to achieve the required sample size (i.e. 
underpowered) could lead to Type II error, failure to find a difference in 
presence of a real difference (Altman, 1991). This could explain a lack of 
intervention effect on the quality of life, anxiety and depression in the present 
study. On the other hand, the significant intervention effect on two of the 
outcome measures, pain intensity and physical functioning, might be due to 
Type I error, a false positive. Therefore, the results should be interpreted with 
care. However, as discussed above, patients during the qualitative interviews 
highlighted positive impact of the clinic on their lives in general.  
The third limitation, although linked to the second one, was the low 
response rate of the postal questionnaire. Traditionally, postal questionnaires 
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suffer a low response rate and a response rate of 50% or above is considered 
good {(Babbie, 1973, Kidder, 1981) cited in (Richardson, 2005)}. Sending the 
questionnaires in the post was the best possible approach for the 3-month 
follow-up as it would have been unethical to ask the patients to come to the 
clinic just to complete questionnaires without at least reimbursing their travel 
expenses. Furthermore, travelling to the pain clinic might have been 
inconvenient for patients in pain. The decision to drop SF-36 for the 3-month 
follow-up was made primarily to increase the response rate as shorter 
questionnaires have been reported to have a better response rate than longer 
questionnaires (OR1.86; CI 1.55 to 2.24) (Edwards et al., 2002). In addition, 
personalized letters were also sent together with the questionnaires in an effort 
to improve response rates as personalized letters improve response rates as 
well (OR 1.16; CI 1.06 to 1.28)  (Edwards et al., 2002).  Monetary incentives 
have also been reported to improve the response rate (OR 2.02; 95% CI 1.79 to 
2.27) (Edwards et al., 2002), but unfortunately, due to lack of funding giving 
patients monetary reward was not possible.   
For the qualitative descriptive study, there were two main limitations as 
well. Firstly, the patients were interviewed upon discharge from the service; 
theoretically, patients were discharged once the patients had made desired 
progress, which may explain their satisfaction from the service. However, as 
described earlier in chapter 5, a framework for maximum variation sampling was 
developed and baseline pain-intensity scores rather than discharge scores were 
considered in developing the framework. Despite that, patients in pain might not 
have consented for interviews, limiting the pool of potential participants. 
Secondly, the author/researcher being a pharmacist himself could have 
introduced researcher bias. However, the author clearly described his position 
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in the study in the very beginning. In addition, various measures were used 
such as peer debriefing and providing rich thick description, as  described in 
chapter 5, to ensure transparency, trustworthiness and, to minimize researcher 
bias. In addition, in-depth description of all the aspects of data collection 
(sampling, sample size, settings, topic guide)  and analysis (data management, 
method of analysis, methods to ensure rigour) has been provided to ensure 
transferability of qualitative findings.   
8.6 Recommendations for future research 
 Further research is required to establish the long-term effectiveness and 
sustainability of such community-based nurse-pharmacist managed pain 
clinics. The IMMPACT guidance should be followed in designing and 
reporting studies evaluating the effectiveness of interventions in chronic 
pain management.  
 The types of patients that are more likely to obtain benefits from such 
community based services are still not well known. Further research is 
required to determine the predictors of successful treatment outcomes. 
This information is crucial and should be used for developing evidence 
based referral guidelines. Such guidelines could ensure referral to the 
right healthcare professional at the right time thus minimizing cost to the 
healthcare system. Additionally, what factors encourage GPs to refer 
patients to pain clinics/secondary care/physiotherapy should be 
investigated.  
 As described in the literature review chapter, there is only weak evidence 
to support the cost effectiveness of nurse-led interventions in chronic 
pain management. However, no cost-effectiveness data are available for 
such pain clinics jointly managed by the nurse and the pharmacist. Cost 
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effectiveness data are important to advocate for the wider development 
of such pain services. 
8.7 Recommendations for policy and practice 
 The views of all stakeholders, including patients, should be considered 
especially before decommissioning of service as it may have negative 
consequences on their health. Service commissioners should rely on 
best available research evidence for commissioning and/or 
decommissioning of services. Had the service commissioners waited for 
this study to be completed, it may have guided them to make a well 
informed decision.  
 Pharmacists working in community pharmacies can play an important 
role in the management of chronic pain by ensuring the safe and 
effective use of medicines. Therefore, service commissioners while 
planning chronic pain services should think of ways of incorporating 
community pharmacists’ services in pain service. 
 Employing specialised pain nurses in GP practices can potentially 
facilitate effective pain management in the community. 
 Since anxiety and depression frequently co-exists with chronic pain, 
there is a need to assess mental functioning of chronic pain patients 
regularly in primary care. Help from psychological services should be 
sought when necessary, as anxiety and depression can also interfere 
with the management of chronic pain.  
 Since chronic pain is primarily managed in primary care, there is a need 
to train GPs in chronic pain management. GPs need to be informed 
about the existence of such clinics and should be encouraged to refer 
patients to community-based pain clinics, if available, early during the 
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course of the disease for a thorough assessment. Further referrals to 
other services and/or secondary care should only be made based on the 
recommendations of the pain clinic. This will potentially reduce burden 
on secondary care.  
 Since nurses and pharmacists have the potential to contribute to 
effective chronic pain management, structured and specialised training 
programmes in chronic pain management should be developed for them 
to further improve their knowledge and skills in chronic pain 
management. The nurses and pharmacists working in such clinics 
should be encouraged to become independent prescribers as it can 
improve patients’ access to medicines. This will also reduce the number 
of visits to the GPs to obtain prescription analgesics as well, reducing 
overall cost and time.  
8.8 Dissemination plan 
To disseminate the findings of research work is an ethical and professional 
responsibility. To date, as indicated in the beginning of this thesis, the author 
has published six peer reviewed papers in addition to two non-peer reviewed 
papers highlighting various aspects of the work presented in this thesis. The 
findings have also been presented in various conferences. The future 
dissemination plan is outlined in Table 8.1. 
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Table 8.1. Dissemination plan 
Proposed title Potential journal  Submission 
date 
An evaluation of nurse-
pharmacist managed pain clinic: 
A mixed-methods study 
The Clinical Journal of 
Pain/ Health Services 
Research 
June 2014 
Patients’ experiences of living 
with chronic pain: a qualitative 
study 
Pain/ The Clinical 
Journal of Pain 
July 2014 
Quality of life and clinical 
characteristics of the patients 
referred to a nurse-pharmacist 
managed pain clinic 
International Journal of 
Clinical Pharmacy 
July 2014 
“No one is listening here”- 
Chronic pain patients and the 
NHS: Barriers to effective pain 
management 
The British Medical 
Journal/ The Journal of 
Pain 
August 2014 
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Appendices 
Appendix I 
Search strategy for Medline 
 
 
269  
 
Appendix II 
Risk of bias assessment form for the systematic review 
Item Low/High/ 
Unclear 
risk 
Justification 
 
Random Allocation 
 
  
Allocation Concealment 
 
  
Blinding of Participants 
 
  
Blinding of Personnel 
(delivering intervention) 
  
Blinding of outcome 
assessor 
  
Incomplete outcome data   
Selective reporting of 
outcomes 
  
Baseline differences   
Use of Invalid 
questionnaires 
  
Notes:  
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Appendix III 
Letter of invitation to participate in the study  
 
 
Dear Sir/Madam, 
 
Invitation to participate in a research study entitled “Evaluation of  
Nurse-Pharmacist managed pain clinic” 
 
I am a PhD student at the School of Healthcare, University of Leeds. I am 
conducting research looking at the effectiveness of the nurse-pharmacist led 
pain clinic. As part of this research we want to find out how well the pain 
clinic works for the patients in terms of pain management and relief. In 
particular, we would like your views on the care provided by the clinic. You 
are receiving this letter because you have been referred to the pain clinic. 
However, please note that I have not been given access to any personal 
information about you to maintain confidentiality. 
The enclosed information sheet gives further details of the research and will 
hopefully answer any questions you have. However, please feel free to 
contact me by phone (0113 3433202) or email (hcmah@leeds.ac.uk), if you 
would like to know more about the project. 
Thank you for taking the time to read this letter. 
 
Yours sincerely, 
 
Muhammad Hadi 
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Appendix IV 
Invitation to take part in a follow-up assessment 
 
 
 
 
Dear Sir/Madam, 
Thank you very much for taking part in our study of the Nurse-Pharmacist 
managed pain clinic. You are receiving this letter because it has been three 
months since you were discharged from the clinic and we would like to know 
how you are coping with your pain now.  
I would be grateful if you could complete the accompanying questionnaires 
and return by post in the enclosed pre-paid envelope. The questionnaires 
are the same as the ones you filled in on your first and last visit to the clinic. 
The “yellow questionnaire” is about pain intensity and the “blue 
questionnaire” is about mood. If possible, please could you return the 
questionnaires within one week of receiving them.  
Should you have any questions, please feel free to contact me by phone 
(0113 343 3202) or email (hcmah@leeds.ac.uk). On the behalf of the 
research team, I would like to sincerely thank you once again for your 
continued support and participation in our research project. 
 
Yours sincerely, 
 
Muhammad A. Hadi 
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Appendix V 
GP information Sheet 
 
 
 
Dear Dr. 
 
 
THE EVALUATION OF A NURSE/PHARMACIST MANAGED PAIN CLINIC: A 
MIXED METHODS STUDY 
 
Your patient ........................................................................., has given their consent 
to be entered into this study. Your patient would not be given any new medicinal 
product or treatment as part of this research. The patient will receive usual care 
from the pain clinic. The aim of the present study is to evaluate the effectiveness of 
Nurse-Pharmacist managed pain clinic (NPMPC). It is an observational study. Upon 
discharge, patients will be interviewed about their satisfaction with the service 
provided by the clinic. 
The research study will take place entirely at the pain clinic and should have no 
ongoing consequences for you. The study is being sponsored and organized by 
School of Healthcare, Faculty of Medicine and Health, University of Leeds. Should 
you have any questions, please do not hesitate to contact the undersigned. 
 
Yours sincerely, 
 
 
Muhammad A. Hadi, 
School of Healthcare, 
University of Leeds. 
Email: hcmah@leeds.ac.uk 
Tel: 0113-343-3202 
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Appendix VI 
Patient information sheet 
 
 
 
Evaluation of Nurse-Pharmacist Managed Pain Clinic 
We would like to invite you to take part in a research study. Before you 
decide, you need to understand the purpose of research and what it would 
involve for you. Please take time to read the following information carefully. If 
you wish, you can discuss it with your friends and family. Should you need 
any further information, please feel free to contact us. 
1. What is the purpose of the study? 
The study will evaluate the effectiveness of nurse-pharmacist led pain clinic. 
We want to find out how well the pain clinic works for the patients. In 
particular, we would like your views on the care provided by the clinic. No 
new treatment will be given specifically as part of this study, but we will 
collect information from people receiving care at the clinic. 
2. Who is doing the study? 
The study is funded and organized by School of Healthcare, University of 
Leeds. The lead researcher is Muhammad Hadi, a PhD student at the 
School of Healthcare, under the supervision of Dr. Michelle Briggs, Prof. 
José Closs and Dr. David Alldred. 
3. Why have I been invited? 
You have been approached because your General practitioner (GP) has 
referred you to the pain clinic. We aim to include 105 adult patients who 
have chronic pain and have been referred to the clinic. 
4. Do I have to take part? 
It is totally up to you to decide. We will provide you with all the necessary 
information and answer all your questions related to this study. We will then 
ask you to sign a consent form to show that you have agreed to take part. 
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You can withdraw from the study at any time without giving a reason. This 
would not affect the care you receive. 
5. What will happen to me if I take part? 
You will receive the usual care from the clinic. There are two phases of the 
study. Participation in both phases is not compulsory and you can choose to 
participate only in one phase of the study if you wish. 
Phase 1: In the first phase, in addition to the routine questionnaires used at 
the clinic, you will be asked to fill in two questionnaires. One questionnaire is 
about your quality of life and the other is about severity of chronic pain. 
These questionnaires will take about 15-20 minutes to complete. You will be 
asked to fill in these questionnaires three times; 1) during your first visit; 2) 
upon your discharge from the clinic; 3) three months after discharge. For the 
first two times you will be asked to fill in the questionnaires at the clinic while 
waiting for your appointment. For the third time, we will send you the 
questionnaires by mail together with a pre-paid self addressed envelope. We 
would like you to return the questionnaires within two weeks. We will also 
gather information on your age, gender, employment, history of pain, other 
illnesses, your mood and the intensity and impact of pain on your life, from 
your clinical record. 
Phase 2: The second phase consists of a face to face interview. This will be 
conducted either at the clinic or your home, whichever you prefer. We would 
like to interview you within two weeks of your discharge from the clinic. The 
interview will be about your experience and satisfaction with the care 
provided by the clinic. We will send you the questions to be asked in the 
interview in advance, so that you can think about them. There are no right or 
wrong answers; we just want to hear about your experience of the pain 
clinic. The interview is expected to last for 20-30 minutes and if you agree, it 
will be audio taped. You will be asked to sign a separate consent form for 
the interview. You can choose to stop the interview at any time without 
giving any reason. We will still include the information you have already 
given us, unless you ask us not to. Your decision to participate in the 
interview will not affect the care you receive. 
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6. Will I be paid to participate in the study? 
You will not be paid for taking part in the research.  
7. What will I have to do? 
You just fill in the additional questionnaires, as explained above. 
8. What is the drug, device or procedure that is being tested? 
No drug or device is being in particular tested in this research.  You will 
receive usual care from the clinic.  
9. What are the possible disadvantages and risks of taking part? 
There are no risks specifically associated with participation in the study. You 
don’t have to visit the clinic or have any tests. The only possible 
disadvantage is the time taken to complete the questionnaires and interview 
(optional). 
10. What are the potential benefits of taking part?  
We cannot promise the study will help you but the information we get from 
this study should help improve the care provided by the clinic for other 
people with chronic pain. It will help us understand the working of the clinic 
and patient satisfaction with the care provided by the clinic. 
11.  What happens when the research stops? 
You will continue to receive usual care from your GP. You can be referred 
back to the clinic if desired by your GP. 
12. Will my personal data collected during the study be kept 
confidential? 
Yes. We will follow ethical and legal practice and all information about you 
will be handled in confidence. All data obtained will be anonymised and kept 
in a password protected personal computer. Only the research staff will have 
access to your data. However, if you tell us something that gives us cause of 
concern about your health or care, with your permission, we will share this 
information with relevant healthcare professionals. Your identity will not be 
revealed in any report and publication. Your GP will be informed about your 
participation in the research.  
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13. What will happen to the results of the study? 
This project is a key part of the researcher’s PhD thesis. We will be happy to 
share the information about the findings when it is completed in 2013. 
Findings from the study will be presented at conferences and submitted to 
relevant journals. Your identity will not be revealed in any publication. 
14. What if there is a problem? 
If you have any complaints or concerns about the study you can speak to 
your nurse/researcher who will do their best to answer your questions. 
Should you have a complaint about the way it is being conducted, please 
contact his supervisor Dr. Michelle Briggs (Tel: 0113 343 6885; email: 
m.briggs@leeds.ac.uk) or the Faculty Head of Research Support Ms. Clare 
Skinner (Tel: 0113 343 4897; email: c.e.skinner@leeds.ac.uk). You can 
withdraw from the study at any time without giving a reason. 
15. Contact for further information 
If you require further information, please feel free to ask any questions you 
wish.  
Investigator:    Clinical Nurse Specialist: 
Muhammad A. Hadi    Kathryn Marczewski  
PhD student     Clinical Nurse Specialist  
School of Healthcare,    Leeds Community Healthcare  
Baines Wing, University of Leeds  NHS Trust 
LS2 9UT Leeds, UK    Tel: 0113 392 9819  
Tel: 0113 343 3202                              Email: kathryn.marczewski@nhs.net   
Email: hcmah@leeds.ac.uk 
 
Thank you for your time for reading this information 
Please keep this copy. 
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Appendix VII 
Patient information sheet - phase 2 
 
 
 
Evaluation of Nurse-Pharmacist Managed Pain Clinic 
Thank you very much for your participation in Phase 1 of the study. We 
would like to invite you to take part in the Phase 2 of the study. Before you 
decide, you need to understand the purpose of research and what it would 
involve for you. Please take time to read the following information carefully. If 
you wish, you can discuss it with your friends and family. Should you need 
any further information, please feel free to contact us. Thank you for taking 
the time to read this. 
1. What is the purpose of the study? 
The purpose of phase 2 is to evaluate patient satisfaction with the service 
provided by the pain clinic.  
2. Who is doing the study? 
The research team is the same as of Phase 1. The lead researcher is 
Muhammad Hadi, a PhD student at the School of Healthcare, under the 
supervision of Dr. Michelle Briggs, Prof. José Closs and Dr. David Alldred. 
3. Why have I been invited? 
You have been approached because you indicated earlier in your consent 
form that you were interested in participating in an interview as well. We aim 
to include 15-25 adult chronic pain patients referred to the clinic. 
4. Do I have to take part? 
It is totally up to you to decide. We will provide you with all the necessary 
information and answer any questions you may have about this study. We 
will then ask you to sign a consent form to show that you have agreed to 
take part.  
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5. What will happen to me if I take part? 
You will be asked to participate in a face-to-face interview. This will take 
about 30-40 minutes. The interview can take place at the pain clinic or at 
your home, whichever you prefer. We would like to interview you within two 
weeks of your discharge from the clinic and you will be contacted by 
telephone to arrange a time and venue.  You will be interviewed by Mr. 
Muhammad Hadi (lead researcher, PhD student) who will audio-record the 
conversation. You will be asked to sign a separate consent form for the 
interview. Your decision to participate in the interview will neither affect the 
standard of care nor the participation in the research 
6. Will I be paid to participate in the study? 
You will not be paid any money for participation in the research.  
7. What will I have to do? 
You will be asked to participate in the interview as explained above.  You will 
be asked about your expectations of the pain clinic; 2) things that you liked 
and disliked in the clinic; 3) satisfaction with the service provided; 4) impact 
(positive or negative) of the  clinic on your pain. At the end of the interview, 
there will be additional time to discuss any other aspects of the clinic, if they 
have not been covered during the interview.  
8. What is the drug, device or procedure that is being tested? 
No drug or device is being tested in this research.  You will receive usual 
care from the clinic.  
9. What are the possible disadvantages and risks of taking part? 
There are no risks specifically associated with participation in the study. The 
only disadvantage is that it will take 30-40 minutes of your time and you may 
have to travel to the clinic, should you decide to be interviewed there. 
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10. What are the potential benefits of taking part?  
We cannot promise the study will help you, but we hope that the information 
we get from this study will help improve the service provided by the pain 
clinic for future patients. It will help us understand the working of the clinic 
from the patient’s point of view. 
11. What happens when the research stops? 
You will continue to receive usual care from your GP. You can be referred 
back to the clinic if desired by your GP. 
12. Will my personal data collected during the study be kept 
confidential? 
Yes. We will follow ethical and legal practice and all information about you 
will be handled in confidence. The interview will be audio recorded and then 
transcribed onto a computer. All data obtained will be anonymised and kept 
in a password protected computer. Your response will be treated with full 
confidentiality and anyone who takes part in the research will be identified 
only by code numbers. Only the research staff will have access to your data. 
However, if you tell us something that gives us cause of concern about your 
health or care, with your permission, we will share this information with 
relevant healthcare professionals. Your identity will not be revealed in any 
report or publication. Your GP will be informed about your participation in the 
research. If the interview upsets you and you feel you would like some 
additional help after the interview I will be able to advise you who to contact, 
for example GP, or Community Nurse,  You can choose to stop the interview 
at any time without giving any reason. We will still include the part of the 
interview you have already completed, unless you ask us not to.  
13. What will happen to the results of the study? 
This project is a key part of the researcher’s PhD thesis, which will be 
published by the end of 2013. We will be happy to share the information 
about the findings when it is completed. Findings from the study will be 
presented at conferences and submitted to relevant journals. Your identity 
will not be revealed in any materials made public from the study. 
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14. Who has reviewed this study? 
The study has been reviewed and approved by Leeds Research Ethics 
Committee. 
15. What if there is a problem? 
If you have any complaints or concerns about the study you can speak to 
your clinical nurse specialist or the lead researcher who will do their best to 
answer your questions. Should you have a complaint about the way it is 
being conducted, please contact his supervisor Dr. Michelle Briggs (Tel: 
0113 343 6885; email: m.briggs@leeds.ac.uk) or the Faculty Head of 
Research Support Ms. Clare Skinner (Tel: 0113 343 4897; email: 
c.e.skinner@leeds.ac.uk). You can withdraw from the study at any time 
without giving a reason. 
Contact for further information 
If you require further information, please feel free to contact the following 
people.  
Lead researcher    Clinical nurse specialist 
Muhammad A. Hadi    Kathryn Marczewski  
PhD student     Clinical Nurse Specialist  
School of Healthcare,    Leeds community Healthcare  
Baines wing, University of Leeds  NHS Trust 
LS2 9UT Leeds, UK    Tel: 0113 3929819  
Tel: 0113 3433202                             Email:kathryn.marczewski@nhs.net 
Email: hcmah@leeds.ac.uk 
 
Thank you for your time for reading this information 
Please keep this copy. 
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Appendix VIII 
Patient Consent Form - Phase 1 
 
Project title: Evaluation of Nurse-Pharmacist managed pain clinic 
Research Team: Muhammad Hadi, Dr. Michelle Briggs, Prof. Jose Closs,  
Dr. David Alldred, Kathryn Marczewski 
 
Note: Please read each statement carefully and initial each statement in the 
box provided 
 
 
1. I confirm that I have read and understood the 
information sheet. 
 
 
2. I understand that my participation is voluntary and that I 
am free to withdraw at any time, without giving any 
reason. In this case my medical care or legal rights will 
not be affected in any way. 
 
 
3. I give permission for my GP to be informed of my 
participation in the study. 
 
4. I agree to take part in the above study. 
5. I give permission to regulatory authorities to access the 
research data for auditing purposes. 
6. I would like to be considered for interview as well. 
 
 
_________________  ___________  
Name of patient   Date    Signature 
 
_________________  ___________  
Researcher   Date    Signature  
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Appendix IX 
Patient Consent Form - Phase 2 
 
 
Project title: Evaluation of Nurse-Pharmacist managed pain clinic 
Research Team: Muhammad Hadi, Dr. Michelle Briggs, Prof. Jose Closs,  
Dr. David Alldred, Kathryn Marczewski 
 
Note: Please read each statement carefully and initial each statement in the 
box provided 
 
 
1. I confirm that I have read and understood the 
information sheet. 
 
 
2. I understand that my participation is voluntary and that I 
am free to withdraw at any time, without giving any 
reason. In this case my medical care or legal rights will 
not be affected in any way. 
 
 
3. I agree to take part in the interview. 
 
4. I give permission to use anonymised quotes from my 
interviews in relevant publications, and I understand 
that my identity will not be revealed and such 
information will not be traced back to me. 
5. I give permission to regulatory authorities to access the 
research data for auditing purposes. 
 
6. I give permission to audiotape my interview.  
 
 
_________________  ___________  _______________ 
Name of patient   Date    Signature 
 
 
_________________  ___________  _______________ 
Researcher   Date    Signature 
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Appendix X 
Patient sociodemographic and clinical questionnaire 
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Appendix XI 
Clinical data collection form (Baseline) 
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Appendix XII                                                                                              
Clinical data collection form (Discharge) 
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Appendix XIII 
Ethical approval 
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APPENDIX XIV 
NHS research governance approval 
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Appendix XV 
Letter of access for research 
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Appendix XVI                                                                          
NHS ethics approval - substantial amendment 
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Appendix XVII 
Brief Pain Inventory (BPI) 
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Appendix XVIII 
Hospital Anxiety and Depression Scale (HADS) 
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Appendix XIX 
SF-36 
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Appendix XX 
Chronic Pain Grade Questionnaire (CPG) 
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Appendix XXI 
Topic guide for qualitative interviews 
Expectations 
What were your expectations from the pain clinic? 
Have these changed now? 
Has the care provided by NPMPC met your expectations? Disappointed? 
Expectations of prognosis 
Is this different from before? 
Efficacy 
Did it help? 
What was the most helpful part? 
How did it help? 
Did they help you to manage problems with your pain medication? 
Understanding and Self-management 
Did it help you to understand your problem? 
Was the information provided adequate? 
Do you feel you have control over problem? 
Do you think you can now manage your problem better on your own? 
Interaction with Nurse and Pharmacist 
Did they communicate well? Listened to your problem? 
Did they encourage you to be active and self manage? 
Did they give you enough time? 
Have you had any problems in following their instructions? 
Could they have done any better? 
Anything particularly good or bad about the service? 
Do you agree with their pain management approach?
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Overall Satisfaction 
Any other issues? 
How do you think care could have been improved? 
How do you compare it with other treatments? 
 
Note: In the beginning of each interview, patients were also asked about 
their history of chronic pain, its impact on their lives and their experiences of 
dealing with various healthcare professionals in relation with its 
management. 
